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Long thought to be irreversible, it is now clear that liver fibrogenesis is a dynamic process, 
with scar tissue capable of being remodelled as well as deposited. Macrophages have been 
shown to have a critical role in both liver fibrogenesis and fibrosis resolution. Whilst 
previous work has identified a Ly-6C
hi
 hepatic macrophage population, derived from 
recruitment of inflammatory monocytes, as being the main pro-fibrogenic population, the 
nature and phenotype of the pro-resolution macrophage subset is unknown. In this thesis, I 
sought to identify and characterise this restorative hepatic macrophage. I established a 







 hepatic macrophages represented the most numerous 
macrophage population and the principal expresser of matrix degrading MMP enzymes. 
Depletion of this population in CD11b-diphtheria toxin (DTR) mice prevented fibrosis 
resolution. Subsequent, adoptive transfer and in situ labelling experiments, demonstrated that 
this restorative macrophage population derives from inflammatory monocytes, a common 
origin to the pro-fibrotic Ly-6C
hi
 hepatic macrophage subset, indicating a switch in 
macrophage phenotype in situ to form the restorative phenotype. Characterisation of FACS-
sorted restorative and pro-fibrogenic liver macrophage subsets using gene expression 
profiling demonstrated higher expression of pro-resolution genes and lower expression of 
pro-fibrotic genes in restorative macrophages, which also upregulated a number of genes 
involved in phagocytosis. Confocal microscopy confirmed that restorative macrophages 
showed evidence of prior phagocytosis. This could be replicated in vitro, where feeding 
macrophages with cellular debris resulted in matrix-degrading properties analogous to those 
seen in vivo, which was dependent on activation of the ERK signalling cascade. This effect 
was also demonstrated with the phagocytosis of liposomes in vitro. Finally, the 
administration of liposomes to CCl4-injured mice in vivo induced phagocytosis, causing an 
increase in hepatic restorative macrophage number and accelerating fibrosis regression. 
Hence, I have been able to identify and characterise the restorative hepatic macrophage and 
have utilised these data to develop a novel method to alter macrophage phenotype in vivo 








The Clinical Burden of Liver Disease 
Chronic liver disease results from a range of conditions including chronic alcohol excess, 
chronic viral infection with hepatitis C or B, non-alcoholic fatty liver disease (NAFLD) in 
association with obesity and the metabolic syndrome, parasitic infection and numerous other 
immune and metabolic conditions. Ultimately, if left untreated, these diseases cause chronic 
liver damage resulting liver cirrhosis with the pathological hallmarks of advanced fibrosis, 
nodular hepatocyte regeneration and significant liver architectural disruption. Patients with 
chronic liver disease are then at risk of a number of clinical sequelae including portal 
hypertension, hepatocellular carcinoma and liver failure, all of which are major causes of 
morbidity and mortality worldwide. In the UK, chronic liver disease ranks as the 5
th
 
commonest cause of death, and unlike the other members of the top 5, the incidence is 
increasing (Leon and McCambridge, 2006). This worrying trend most likely represents the 
growing burden of alcohol problems in addition to the epidemic of obesity and the metabolic 
syndrome in the Western world. 
Despite this concerning epidemiological data, our treatment options remain limited. Clearly, 
removal of the causative agent or management of the underlying disease can be an effective 
strategy if done at an early stage. However, this is not always possible and due to the lack of 
preceding symptoms, many patients present with cirrhosis-related complications, at which 
juncture our therapeutic options are often restricted to management of these or potentially 
liver transplantation for a select few. With an already severe shortage of donor organs and an 
increasing demand predicted in forthcoming years, this is clearly not the optimum long-term 
solution. What are badly needed are disease modifying therapies, which can prevent liver 
disease progression or indeed induce regression of established liver disease.  
Central to the development of such therapies is an in depth understanding of the pathogenic 
mechanisms of liver disease. Given, that hepatic fibrosis is the key hallmark of all chronic 
liver disease and precedes the other clinical features of cirrhosis, knowledge of the molecular 
and cellular processes underlying this could be fruitful in yielding novel therapeutic 
strategies. Indeed, tissue fibrosis in all organs has been associated with up to 45% of deaths 
in the Western World (Hayden, 2011), and therefore anti-fibrotic strategies used in the liver 
may have a more generic role in other organ disease, whilst we can potentially utilise 





Liver Architecture in Health 
In order to understand the key mechanisms in the pathogenesis of liver fibrosis it is first 
important to have knowledge of the basic anatomy of the liver in health. The liver is the 
largest internal organ in the adult body and has a number of key functions including 
carbohydrate, lipid and protein metabolism, synthesis of proteins such as coagulation factors, 
drug metabolism, storage of a range of compounds and immunoregulation. The main 
metabolic factory of the liver is the parenchymal hepatocytes. These pallisades of 
hepatocytes are surrounded by a heavily fenestrated endothelial layer, called the hepatic 
sinusoidal endothelium (Fig 1.1). Separating the hepatocyte sheets and the hepatic sinusoidal 
endothelium is the Space of Disse, which normally contains extracellular matrix (ECM) 
components and vitamin A-containing hepatic stellate cells (HSCs). On the other side of the 
sinusoidal endothelial cells, within the hepatic sinusoid, are numerous tissue-resident 
macrophages, innate immune cells of the mononuclear-phagocyte system, which in the liver 
are called Kupffer cells (Fig 1.1). The other principal parenchymal cell type in the 
undamaged liver is the cholangiocyte. Cholangiocytes are polarised epithelial cells which 
line the large network of bile ducts. These networks begin at small vessels between sheets of 
hepatocytes known as bile canaliculi, which filter into canals of Herring and ultimately into 
larger bile ducts for drainage into the duodenum. This biliary epithelium mediates both bile 
salt and water transport and is responsible for the flow of bile in the biliary tree. 
Functionally, the liver is divided into acini, containing a central hepatic vein surrounded by 
pallisades of hepatocytes and portal triads. These portal triads contain branches of the portal 
vein (which drains blood from the GI tract, spleen and pancreas and is responsible for around 
75% of blood inflow to the normal liver), branches of the hepatic artery (responsible for 25% 
of blood flow to the normal liver) and terminal branches of the biliary tree. Incoming blood 
is then filtered from the portal vein and hepatic artery via hepatic sinusoids to the central 
vein. Conversely, bile secreted by the hepatocytes drains in the opposite direction via bile 
canaliculi to bile ducts. As the blood inflow is to the portal triad there is an oxygen and 
nutrient gradient across the sheets of parenchymal hepatocytes from the periportal area to the 
central vein. This creates the functional zonation of hepatocytes in the normal liver: zone 1 
representing the periportal areas, zone 2 is the midlobular portion whilst zone 3 is around the 
central vein. These different zones of hepatocytes have specialised functions for example 
gluconeogenesis occurring mainly in zone 1 whilst drug metabolism occurs predominantly in 
zone 3 (Colnot and Perret, 2011). Different zones are susceptible to different modes of injury 
and can result in differing histological disease patterns. 
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Figure 1.1 –Hepatic Sinusoidal Structure in Health and Liver Fibrosis 
(A) Schematic representation of the structure of the hepatic sinusoid in healthy liver. The 
sinusoid is surrounded by linear sheets of hepatocytes and is lined by hepatic sinusoidal 
endothelial cells. The space of Disse lies between the sinusoidal endothelial cells and 
hepatocytes and contains hepatic stellate cells. Blood flows into the sinusoid from the portal 
vein and hepatic artery and leaves the liver via the central vein. Kupffer cells (hepatic 
resident macrophages) lie within the sinusoidal space. Hepatocytes produce bile which 
drains via bile canaliculi in the opposite direction to sinusoidal blood flow, to the bile ducts. 
Bile ducts are lined with biliary epithelial cells known as cholangiocytes. Together the bile 
duct, portal vein and hepatic artery make up the portal triad. (B) In disease, chronic injury to 
the liver results in hepatocyte death. Hepatic stellate cells (HSCs) within the Space of Disse 
become activated and differentiate into extracellular matrix (ECM) producing hepatic 
myofibroblasts, which secrete scar tissue. Kupffer cells can become activated and there is 
recruitment of other inflammatory cells from the circulation including monocytes, 
lymphocytes, NK cells and neutrophils. Note the close proximity of activated myofibroblasts 
to the recruited immune cells. Also note that the activated myofibroblasts surround the 
hepatic sinusoid, meaning contraction can result in narrowing of the sinusoidal space and 







It has long been recognised that hepatic injury results in parenchymal cell damage/death and 
consequent inflammation mediated by a range of resident and recruited inflammatory cells 
(Iredale, 2008) (Fig 1.1B). In the acute setting this is rapidly followed by activation of 
regenerative pathways which can quickly restore the liver to normal architecture and 
function. Injury also results in the initiation of innate wound healing responses which, 
similar to most other tissues and organs, can result in scar deposition. In the acute setting, 
this ECM deposition is transient (Inuzuka et al., 1994) and far from being detrimental, this 
wound healing response is likely to be a key part of maintaining hepatic structure and 
functionality in the face of significant cell damage and death and is likely to facilitate the 
rapid regeneration we commonly observe. Similarly, there is a rapid hepatic fibrotic response 
in response to infection from liver parasites such as schistosomiasis, which serves to wall off 
the parasite and restrict growth (Anthony et al., 2010), and is hence protective to the host.  
However, in the face of chronic and iterative injury, as observed with all causes of chronic 
liver disease, hepatic wound healing responses are recurrently and persistently activated. 
Over a period of years in human disease, this ultimately results in liver fibrosis and 
eventually dense scar deposition, encircling nodules of hepatocytes and causing significant 
architectural disturbance – changes characteristic of cirrhosis (Anthony et al., 1977). 
Generally the scar tissue is made up of the main fibrillar collagens I and III (Rojkind and 
Martinez-Palomo, 1976, Yamamoto et al., 1984), but as fibrosis progresses the composition 
of scars can also evolve, incorporating a range of other extracellular matrix (ECM) proteins 
including fibronectin, laminin, hyaluronan, proteoglycans and elastin (Bataller and Brenner, 
2005). Indeed, the presence of increased amounts of elastin is associated with more advanced 
liver fibrosis (Shikata and Skai, 1974).   
What is becoming increasingly clear is that even within the category that is pathologically 
described as cirrhosis, this is not a static process and there are differing degrees of cirrhosis 
which correlate with differing clinical consequences for the patients (Garcia-Tsao et al., 
2010). Hence, closer correlation between specific pathological findings and clinical 
outcomes will be required moving forward. Furthermore, whilst often classified together as 
cirrhosis, differing modes of injury result in differing patterns of liver damage and fibrosis. 
For example, biliary injury (e.g. PBC or PSC) tends to follow a portal to portal pattern 
leading to porto-portal fibrotic septa surrounding nodules with preserved architecture 
between central vein and portal triads until a late stage. Conversely, chronic viral hepatitis is 
thought to cause both portal to central vein necrosis and interface hepatitis resulting in 
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portal-central fibrotic septa in addition to portal-portal scars. This causes an earlier 
derangement in vascular connections in the portal system, resulting in earlier portal 
hypertension. Liver disease due to alcohol or NAFLD, on the other hand, results in 
significant peri-sinusoidal ECM deposition in the space of Disse and around hepatocytes 
leading to the characteristic “Chicken wire” pattern (Hernandez-Gea and Friedman, 2011, 
Pinzani and Rombouts, 2004). Thus, whilst the clinical presentation may be common, it is 
important to bear in mind that cirrhosis can be heterogeneous, with differing patterns of 
fibrosis to differing degrees; hence caution should be observed in extrapolating data from 
one study or model to cirrhosis as a whole. 
However, despite this it is also apparent that a number of common mechanisms exist for 
wound healing responses in the liver irrespective of the nature of injury and indeed a 
commonality of mechanism probably exists with fibrosis in other organs (Wynn, 2008). 
Hence, a greater knowledge of these processes is likely to be informative for the 
development of badly needed anti-fibrotic therapeutic strategies. 
The Role of the Hepatic Myofibroblast in Fibrogenesis 
A major step forward in our understanding of the biology of liver fibrosis has stemmed from 
the development of techniques to isolate individual cell populations from the liver around 25 
years ago (Otto and Veech, 1980). Specifically, the isolation of pure populations of hepatic 
stellate cells (HSCs) identified them as the principal collagen producing population in the 
liver (Maher et al., 1988, Maher and McGuire, 1990, Friedman et al., 1985). Further work 
determined that these cells, in response to inflammatory signals or plating on tissue culture 
plastic in vitro, rapidly transdifferentiate into a myofibroblast-like population, losing their 
vitamin A content and expressing the intermediate filament alpha smooth muscle actin (α-
SMA) (Friedman and Arthur, 1989, Friedman et al., 1992, Iredale, 2007). These changes 
recapitulate those observed in experimental liver injury and in human pathological samples 
(Iredale, 2008). These critical findings have heralded a plethora of studies into the biology of 
HSCs. Whilst this field is ever evolving it is now clear that these activated HSCs adopt a 
number of potentially pro-fibrotic properties (Friedman, 2008). These include: 
1. Synthesis of ECM: Primarily in response to autocrine and paracrine TGF-β 
signalling but other factors such as Connective tissue growth factor (CTGF) also 
play a role 
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2. Proliferation: Increase in HSC number is also seen in liver injury, principally in 
response to platelet-derived growth factor (PDGF) which also acts in an autocrine 
and paracrine fashion 
3. Contractility: Activation of HSCs also confers them with a contractile phenotype, 
partially related to α-SMA but also in association with other factors such as nitric 
oxide and enodthelin-1. This phenotypic change could be clinically relevant, as it 
may contribute to the portal hypertension commonly seen in human liver disease 
which is a major source of morbidity and mortality  (Fig 1.1B) 
4. Release of Pro-inflammatory mediators: HSCs can release mediators that 
modulate the inflammatory response (Marra, 1999, Friedman, 2000). For example, 
MCP-1 (CCL2), a potent chemokine for monocytes, has been shown to be 
expressed by activated HSCs in the in vitro and in vivo settings. 
5. Regulation of Matrix Degradation: Activated HSCs are a major source of matrix 
metalloproteinases (MMPs) and the tissue inhibitors of metalloproteinases (TIMPs) 
which are involved in the dynamic balance regulating matrix deposition and 
degradation (see below) (Iredale, 2008). 
Whilst HSC activation is now a well defined source of hepatic myofibroblasts, other 
potential cellular sources have also been identified. Portal myofibroblasts have been defined 
as a distinct population, located at each portal tract, which may have enhanced significance 
in chronic cholestatic disease or periportal fibrosis (Kinnman and Housset, 2002, Knittel et 
al., 1999, Tuchweber et al., 1996, Beaussier et al., 2007). Indeed, these cells have potentially 
been shown to have a different phenotype to activated hepatic stellate cells (Bosselut et al., 
2010). Additionally, robust data from both human disease and animal models have defined a 
contribution from the bone marrow to the hepatic myofibroblast pool (Forbes et al., 2004, 
Russo et al., 2006). Furthermore, these bone marrow-derived cells have been shown to have 
a clear functional role in collagen expression in vivo (Russo et al., 2006, Kisseleva et al., 
2006). Whether these cells represent a population derived from circulating haematopoietic 
fibrocytes or mesenchymal stem cells or both remains to be fully defined (Kisseleva and 
Brenner, 2012). A further source of myofibroblasts in liver fibrosis has been postulated to 
derive from epithelial-mesenchymal transition (EMT), where hepatic myofibroblasts arise 
from differentiation of hepatocytes or cholangiocytes under specific conditions (Ikegami et 
al., 2007, Kaimori et al., 2007, Rygiel et al., 2008). However, many of these studies rely on 
identification of cellular markers to define different populations. What has now become clear 
is that these markers, such as FSP-1, are not necessarily specific (Osterreicher et al., 2011) 
and no functional role for EMT in liver fibrosis has yet been demonstrated.  
24 
 
Overall, however, it seems likely that in liver fibrosis the hepatic myofibroblast pool will be 
heterogeneous. The relative contributions of different populations are likely to vary 
depending on the nature and response to injury, and this may well alter the biology of liver 
fibrosis. 
Liver Fibrosis Progression – A balance of MMPs and TIMPs 
Matrix metalloproteinases (MMPs) are a group of 25 zinc-dependent enzymes which 
together are capable of degrading a wide spectrum of ECM components including fibrillar 
collagens. MMPs are generally divided into 5 categories largely on the basis of their 
substrate specificity and location. Those which have been associated with liver fibrosis 
include collagenases (MMP-1, -8 and -13), stromelysins (MMP-3, -10 and -11), gelatinases 
(MMP-2, -9 and -7), metalloelastase (MMP-12) in addition to a number of membrane-type 
MMPs (Hernandez-Gea and Friedman, 2011). Regulation of MMP activity and hence ECM 
turnover in vivo is complex and variably dependent on transcriptional control, activation of 
inactive pro-MMPs and by inhibition of MMP activity by a family of 4 Tissue Inhibitor of 
Metalloproteinases (TIMPs), which can reversibly bind the active domain of all of the 
known MMPs, preventing matrix degradation. 
Studies in fibrotic liver of both animal models and human cirrhosis have demonstrated an 
increase in expression of a range of MMPs (Arthur et al., 1999, Arthur et al., 1998, Benyon 
and Arthur, 2001, Iredale, 2008). Additionally, studies of isolated HSCs in vitro demonstrate 
that when activated they can express a plethora of these MMPs. Early during activation, 
there is transient upregulation of MMP-13 (collagenase-3) and MMP-3 (stromelysin), 
followed by increases in MMP-2 (gelatinase A), MMP-9 (gelatinase B) and MMP-14 (MT-
MMP) (Iredale, 2007). Some of these enzymes may in fact serve to further enhance HSC 
activation via basement membrane degradation. However, it is clear that there is already 
significant matrix degrading potential within the fibrotic liver.  
The key factor explaining the paradigm of progressive liver fibrosis in the face of increased 
amounts of ECM degrading MMPs are the aforementioned TIMPs. Even before upregulation 
of collagen 1 expression, HSCs express significantly increased amounts of TIMP-1 and 
TIMP-2, with an associated 20-fold gelatinase inhibition (Benyon et al., 1996, Iredale et al., 
1996, Iredale et al., 1992). This increase has been confirmed in human and animal fibrotic 
liver tissue (Iredale, 2007, Hemmann et al., 2007). The robustness and reproducibility of 
these findings has even lead to the proposed use of TIMP-1 as a serum marker of fibrosis 
(Patel et al., 2004). Cogent evidence for a functional role for TIMP-1 in hepatic fibrogenesis 
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was shown by Yoshiji et al. They developed a transgenic mouse model with hepatic 
overexpression of TIMP-1. Whilst these mice did not show any differences compared to wild 
type mice in de novo liver fibrosis, following hepatic injury with CCl4 the TIMP-
overexpressing mice showed accelerated liver fibrogenesis (Yoshiji et al., 2000). 
Thus, it is the balance between MMPs and TIMPs that determine the progression of hepatic 
fibrosis (Fig 1.2). This is emphasised by attempts to alter this balance with an anti-fibrotic 
aim. Hepatic overexpression of MMP-8 (neutrophil collagenase) using an adenoviral vector 
enhanced liver matrix degrading ability and resulted in reduced hepatic fibrosis following 
bile duct ligation in rats (Siller-Lopez et al., 2004). Attempts have also been made to inhibit 
TIMP activity in vivo. The use of a TIMP-1 neutralising antibody resulted in reduced 
progression of liver fibrosis in a rat CCl4 model (Parsons et al., 2004). A particularly 
intriguing method for TIMP inhibition was developed by Roeb and colleagues. They 
developed a series of MMP-9 mutants which lacked gelatinolytic activity but had preserved 
TIMP binding properties. These mutant proteins were able to inhibit TIMP-1 activity in vitro 
and in vivo and resulted in reduced liver fibrosis in a murine model (Roderfeld et al., 2006, 
Roeb et al., 2000). This is potentially an attractive strategy as it is less likely to have any off 
target effects. 
Is Human Liver Fibrosis Reversible? 
As discussed above, our knowledge and understanding about the mechanisms involved in 
hepatic fibrogenesis have evolved greatly in the past 20 years. However, it was still widely 
viewed that the progression of liver fibrosis was an inexorable one way process. In recent 
years this dogma is being challenged (Ramachandran and Iredale, 2009, Ramachandran and 
Iredale, 2012a). 
Anecdotal evidence has existed for many years to suggest that liver fibrosis is potentially 
reversible. However, it was only with the advent of effective anti-viral treatments for chronic 
hepatitis B and C and the resultant large scale clinical trials with pre- and post-treatment 
biopsies, that liver fibrosis reversibility was definitively demonstrated in large cohorts of 
patients (Dienstag et al., 2003, Iredale, 2001, Poynard et al., 2002, Marcellin et al., 2013). 
Now, evidence of liver fibrosis reversibility has been demonstrated in virtually every cause 
of chronic liver disease including alcohol (Pares et al., 1986), autoimmune hepatitis (Dufour 
et al., 1997, Serpaggi et al., 2006), chronic biliary obstruction (Hammel et al., 2001), 
hereditary haemochromatosis (Falize et al., 2006) and NAFLD (Dixon et al., 2006). Given 
the wide spectrum of hepatic diseases in which fibrosis regression can be observed, it seems 
26 
 
likely that generic rather than disease-specific mechanisms are at play. Furthermore, 
reversibility has been demonstrated in human tissue fibrosis in other organs including heart 
(Brilla et al., 2000, Diez et al., 2002), kidney (Fioretto et al., 1998), lung (Wallace et al., 
2007) and bone marrow (Beham-Schmid et al., 2002). Thus, it seems clear that tissue 
fibrosis is at least partially reversible, highlighting the dynamic nature of this process. Given 
the array of data and the reproducible experimental models of fibrosis, the liver provides an 
excellent paradigm to study the process of fibrosis regression (Ramachandran and Iredale, 
2012a). 
Loss of Hepatic Myofibroblasts in Fibrosis Resolution 
Rodent studies of bile duct ligation (BDL) followed by bilio-jejunal anastamosis or chronic 
carbon tetrachloride (CCl4) administration followed by cessation of dosing are both excellent 
models to study the dynamics of hepatic fibrogenesis and spontaneous resolution. In both of 
these models, established hepatic fibrosis resolves to near normal liver architecture within 4-
6 weeks (Iredale et al., 1998, Issa et al., 2001). During this resolution phase there is a striking 
and dramatic loss of the scar producing activated HSC/myofibroblast population. Closer 
analysis indicates that the activated HSCs are mainly lost by the process of programmed cell 
death, or apoptosis (Iredale et al., 1998, Issa et al., 2001).  
This important finding has led to numerous studies assessing signals which regulate HSC 
apoptosis (Elsharkawy et al., 2005). Activation of NF-κB signalling regulates a range of 
inflammatory, immune, wound healing and cell survival responses. In HSCs NF-κB 
signalling results in expression of pro-inflammatory and pro-fibrotic genes and promotes 
resistance to apoptosis (Hernandez-Gea and Friedman, 2011, Watson et al., 2008). 
Conversely, a variety of molecules and pathways have been shown to promote HSC 
apoptosis. These include farsenoid X receptor (FXR or bile acid receptor), CEBP/β 
signalling, cannabinoid receptor 2 (CB2), adiponectin, or TRAIL (Hernandez-Gea and 
Friedman, 2011). Nerve growth factor (NGF) can be released from infiltrating inflammatory 
cells or regenerating hepatocytes and is pro-apoptotic for activated HSCs (Oakley et al., 
2003, Trim et al., 2000, Kendall et al., 2009). Furthermore, direct cellular contact between 
macrophages and activated HSCs has been demonstrated to promote HSC death (Fischer et 
al., 2002). The exact contribution of these various mediators in determining HSC apoptosis 
in vivo remains to be elucidated, but it is likely that a complex cellular cross-talk exists 
which is impossible to recapitulate in vitro. 
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In addition to soluble mediators, interactions between the ECM itself and HSCs can 
modulate apoptosis. Binding between collagen-1 and HSCs promotes activation whereas loss 
of integrin-mediated contact can lead to the HSCs entering the apoptotic pathway (Zhou et 
al., 2004). Similar findings have been demonstrated in vivo, where a transgenic mouse 
expressing a non-degradable form of collagen-1 showed a failure of spontaneous fibrosis 
resolution and a persistence of activated HSCs in the scar following chronic CCl4 (Issa et al., 
2003). Hence, the myofibroblast-matrix interaction is critical in fibrosis resolution. 
More recently, other potential fates for activated HSCs have been defined. Senescence, a 
stable form of cell cycle arrest, of activated HSCs has been implicated in reducing scar 
production and upregulating ECM-degrading enzyme expression following the cessation of 
injury (Krizhanovsky et al., 2008). Additionally, 2 recent studies have identified that a 
proportion of activated HSCs can revert back to a quiescent phenotype after removal of the 
injurious stimulus (Kisseleva et al., 2012, Troeger et al., 2012). Interestingly, in both studies 
the quiescent HSCs derived from previously activated HSCs were not identical to quiescent 
HSCs from uninjured livers, but rather appeared to be primed and responded to repeat 
hepatic injury with a more profound pro-fibrotic phenotype. These findings may have 
clinical relevance in explaining fibrosis progression in humans following iterative injury 
over many years. 
Matrix Degradation in Fibrosis Resolution 
Whilst the loss of the scar producing cells is an important factor in fibrosis resolution, clearly 
there also has to be significant remodelling of already deposited ECM in order to restore 
normal tissue architecture. As discussed above, fibrotic livers show a significant increase in 
MMP expression and hence scar degrading capability, which is held in check by high levels 
of TIMP expression. However, by studying a series of timepoints during fibrosis resolution 
authors identified a rapid reduction in the levels of TIMP-1 and TIMP-2 (Iredale et al., 1998, 
Issa et al., 2004) with an associated increase in overall collagenase activity due to a switch in 
the MMP-TIMP balance, resulting in net ECM degradation (Issa et al., 2004). Furthermore, 
hepatic overexpression of TIMP-1 inhibited scar resolution following the cessation of injury 
(Yoshiji et al., 2002). In addition, TIMP-1 in itself is an anti-apoptotic signal for HSCs 
(Murphy et al., 2004). Thus, a reduction in hepatic TIMP levels is a critical step during 
fibrosis resolution, releasing the ECM degrading ability of hepatic MMPs and potentially 




What Renders Liver Fibrosis Irreversible? 
Whilst it is clear that there is a significant potential for hepatic fibrosis to regress, it is still 
uncertain whether advanced cirrhosis can return to normal architecture or whether a “point of 
no return” is eventually reached. Experimental hepatic fibrosis models have given us insight 
into this point. Issa and colleagues induced advanced micronodular cirrhosis in rats by 12 
weeks of CCl4 administration , and then allowed them to recovery for protracted periods of 
up to 1 year (Issa et al., 2004). 12 weeks of injury resulted in dense fibrotic septa. As 
anticipated during recovery, significant fibrosis remodelling was observed, particularly in the 
fresh scar adjacent to the nodules. However, strikingly the more mature scars failed to 
completely regress even after 1 year of recovery. This enabled more detailed study of the 
persistent scars, to identify features which could confer irreversibility. The authors identified 
3 key features of irreversible scars: 
1. Matrix crosslinking by tissue transglutaminase, which can render the ECM tissue 
more resistant to proteolytic degradation. However, the functional role of this 
mechanism has subsequently been challenged in murine liver fibrosis models (Popov 
et al., 2011) 
2. Change in ECM composition containing more elastin, which may be more resistant 
to degradation 
3. Hypocellularity in vicinity of irreversible scars, with a lack of scar associated 
activated myofibroblasts and macrophages compared to reversible scars. This could 
result in reduced local delivery of ECM degrading enzymes contributing to 
persistent scar tissue. 
These histological findings were strikingly similar to those observed in regressing human 
liver cirrhosis (Wanless et al., 2000), suggesting a commonality of mechanism. 
These data would suggest certain features of mature hepatic scars render them irreversible. 
However, a significant amount of remodelling did still occur in these livers, transforming 
micronodular cirrhosis into macronodular cirrhosis at least. Whilst this could suggest that 
normal liver architecture may never be fully restored, this degree of recovery may well be 
sufficient to abrogate a number of the clinical consequences observed and thus could still be 





The Role of the Immune System in Liver Fibrogenesis and Fibrosis Resolution 
Hepatic inflammation is a key feature following injury and there is now good evidence that 
the immune system can regulate the fibrotic response. The roles of individual cellular 
components of the immune system have therefore been studied in models of liver fibrosis. 
The majority of data exists for the role of cells of the monocyte/macrophage lineage in 
fibrogenesis and fibrosis resolution (see below). Other components of the innate immune 
response are also likely to have a role. Neutrophils, the early responders to tissue injury, are 
quickly recruited to sites of inflammation, have a high phagocytic capacity and possess a 
number of preformed antimicrobial molecules which can be rapidly released. Indeed hepatic 
neutrophil infiltration has been associated with worsening of a number of liver diseases 
including sepsis, ischaemia-reperfusion, alcoholic hepatitis, viral hepatitis and autoimmune 
hepatitis (Kubes and Mehal, 2012). However, evidence for the role of neutrophils in driving 
fibrogenesis is still limited. Specifically, in studies using either neutrophil anti-serum in BDL 
treated rats (Saito et al., 2003) or the administration of α-naphthylisothiocyanate (ANIT), a 
hepatotoxin causing periportal inflammation, to mice deficient in the key neutrophil 
chemokine receptor CXCR2 (Xu et al., 2004), a reduction in hepatic neutrophils was 
observed but no effect on liver fibrosis was seen. Conversely, by depleting neutrophils 
during recovery from biliary obstruction some authors have suggested that neutrophil MMP 
expression may have a role in collagen degradation during fibrosis resolution (Harty et al., 
2008, Harty et al., 2010). Whether neutrophils are present in the liver in sufficient number 
during the resolution phase for this to be a meaningful finding remains to be defined. 
Mast cells, another component of the innate immune response, have been shown to be 
increased in the liver in both animal models (Jeong et al., 2002) and human liver disease 
(Franceschini et al., 2007). These cells are a potential source of pro-fibrotic mediators such 
as TGF-β and PDGF (Li and Baek, 2002). However, studies in mast cell deficient rats and 
mice did not demonstrate any role in hepatic fibrogenesis using different experimental 
models (Sugihara et al., 1999, Okazaki et al., 1998). 
Natural Killer (NK) Cells are large granular lymphocytes, which are another key component 
of the innate immune response. NK cells have a key role in immune defence and surveillance 
responding rapidly to pathogens, in particular quickly being activated in response to virally 
infected cells. NK cells can then produce a range of cytokines and kill target cells if exposed 
to the correct combination of receptors. NK cells represent the most numerous lymphocyte 
population in the liver and are altered in various liver diseases (Gao and Radaeva, 2012). 
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Initial studies in murine models demonstrated that NK cells can induce killing of activated 
hepatic stellate cells and hence act in an anti-fibrotic manner (Melhem et al., 2006, Radaeva 
et al., 2006). These findings have been replicated in several further studies (Gao and 
Radaeva, 2012). In addition to direct cell killing, NK cells also produce cytokines such as 
IFN-γ, which induces HSC apoptosis and cell cycle arrest, further contributing to the anti-
fibrotic effect (Gao and Radaeva, 2012). 
Researchers have also focussed on the role of the adaptive immune system in hepatic 
fibrosis. T cells play a central role in the adaptive immune response, with a variety of 
subtypes having differing immunomodulatory roles. T helper cells (CD4
+ 
T cells; TH cells) 
become activated by interactions with antigen presenting cells (APCs) and secrete cytokines 
that influence other immune cells. The cytokine profile expressed by the TH cells is 
dependent on the nature of the signalling from the APC. In liver fibrosis, the TH2 subtype, 
expressing IL-4, IL-5, IL-13 and IL-21, has been shown to be strongly pro-fibrogenic, 
particularly in experimental models involving parasitic infection with schistosome eggs 
(Wynn, 2008). Conversely, a TH1 immune response is associated with IFN-γ and IL-12 
expression, which have been shown to be anti-fibrotic (Wynn, 2008). Thus, the relative 
balance of TH1 and TH2 cells may influence the degree of fibrosis progression (Shi et al., 
1997). Cytotoxic T cells (CD8
+
 T cells) destroy virally infected cells and adoptive transfer 
experiments have suggested they may have a pro-fibrogenic role in the liver (Safadi et al., 
2004). However, in other studies mice deficient in CD4 or CD8 T cells showed no difference 
in liver fibrosis in response to CCl4 when compared to control animals (Novobrantseva et al., 
2005). Thus, the exact role of different T cell populations in hepatic fibrosis remains to be 
fully defined, and is likely to be dependent on the nature of the injury driving the fibrotic 
process.  
B cells have also recently been examined as having a potential role in hepatic fibrogenesis. B 
cell deficient mice, whilst having a similar acute inflammatory response, were protected 
from the development of liver fibrosis in response to CCl4 or the toxin ANIT. This effect was 
independent of B cell immunoglobulin production or interactions with T cells 
(Novobrantseva et al., 2005). Whilst the exact mechanisms responsible for this effect remain 
undefined, it may reflect local cytokine production or direct cell-cell interactions. 
Overall, there is a clear and close relationship between the immune response and hepatic 
fibrogenesis. Whilst this is somewhat unsurprising given that fibrosis follows tissue injury 
and resultant inflammation, what is now becoming clear is that the multiple facets of the 
immune system are capable of fine tuning the fibrotic response and in fact promoting fibrosis 
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resolution. This may have important implications for the development of anti-fibrotic 
therapies. 
Macrophages as Part of the Mononuclear Phagocyte System 
Perhaps the most widely studied immune population in hepatic fibrosis is the macrophage. In 
order to understand the complex role of macrophages in liver injury and scarring it is 
important to understand basic macrophage biology.  
Macrophages were first identified by Elie Metchnikoff in 1884. His pioneering work, for 
which he was awarded the Nobel prize along with Paul Ehrlich in 1908, was the first to 
define the process of phagocytosis and he went on to classify phagocytic cells as 
macrophages (“large eaters”) and microphages (“small eaters”; now known as granulocytes). 
This discovery led to a plethora of work, identifying these highly phagocytic mononuclear 
cells and their precursors in numerous organs, in their entirety referred to as the mononuclear 
phagocyte system (MPS). Whilst this is obviously useful conceptual definition, it is now 
becoming clear that within the MPS there is vast heterogeneity in cell type, function and 
origin. This heterogeneity is critical to understanding the diverse range of biological 
functions served by this population. 
Macrophages are now recognised as haematopoietic cells that are present in every tissue in 
the body. Most tissue macrophages are now felt to have several common functions including 
the clearance of foreign and damaged cells, the induction of innate immune responses and 
the killing of micro-organisms during tissue infection, antigen presentation to effector T cells 
and remodelling and repair of tissues after inflammation (Gordon and Taylor, 2005). Despite 
these common properties, these tissue macrophage populations have diverse names, often 
dependent on their expression of specific cell surface markers, the name of the scientist who 
discovered them or their location within the tissue in question (Hashimoto et al., 2011). 
Specific examples include red pulp, marginal zone and tingible body macrophages in the 
spleen, subcapsular sinus and medullary macrophages in lymph nodes, alveolar and 
interstitial macrophages in the lung, microglia in the brain and Kupffer cells in the liver. 
However, these distinctions provide limited information on the cells’ origin and function. 
In order to start to dissect the heterogeneity of these tissue macrophage populations in vivo, 
the identification of macrophage cell surface markers has been invaluable. The use of F4/80 
in mice and CD68 in mice and humans, as “pan macrophage” markers has enabled more 
detailed study of the functionally distinct macrophage populations in different tissues. For 
example, in the lung, in addition to F4/80 and CD68, alveolar macrophages express high 
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levels of CD11c and CD169 and low levels of CD11b with high expression of pattern 
recognition receptors (such as mannose receptor and toll-like receptors which are responsible 
for rapidly recognising and binding conserved molecular structures on pathogens) and 
scavenger receptors (responsible for rapid internalisation of selected ligands). These findings 
likely represent the specialised role of alveolar macrophages in being the first line of defence 
in clearing inhaled microorganisms, viruses and particles from the lungs (Gordon and 
Taylor, 2005, Hashimoto et al., 2011). Conversely, the other main population of lung 
macrophages, the interstitial macrophage, which is likely to have a more immunomodulatory 






 and MHC II
+
 (Hashimoto et 
al., 2011). Similarly, in the spleen distinct patterns of expression of various scavenger 
receptors and lectins can be used to define different macrophage populations (Taylor et al., 











 cells (Hashimoto et al., 2011). Given the expanding and 
seemingly endless range of macrophage markers, and the additional heterogeneity which will 
be introduced by tissue injury, there are an almost infinite number of phenotypic 
possibilities, which will be critically dependent on the tissue microenvironment. Whilst this 
is likely to be inherently useful given the diverse range of pathogens and injurious stimuli to 
which the body exposed, it provides an ongoing challenge for macrophage biologists in 
determining which populations are responsible for which functional effects. 
Development of Tissue Macrophages 
Another important factor to consider in the heterogeneity of tissue macrophages is their 
origin. During early development, macrophage-like cells are seen to develop from the yolk 
sac and then migrate to the head mesenchyme and its circulation. This so called primitive 
haematopoiesis, leads to brain tissue macrophages or microglia, which can persist into adult 
life via local self-renewal (Ginhoux et al., 2010). Later on in the development process, the 
foetal liver becomes a principal site of haematopoiesis and generates large populations of 
macrophages which then become present in most organs. In the adult, haematopoiesis occurs 
principally in the bone marrow. The currently favoured model is that haematopoietic stem 
cells give rise to the CMP (common myeloid precursor) which then differentiates into the 
bipotent GMP (granulocyte macrophage progenitor) cells which can give rise to a neutrophil 
differentiation pathway or MDP (macrophage dendritic cell progenitor). This myeloid 
differentiation program is critically dependent on the transcription factor PU.1 (Auffray et 
al., 2009). Within the bone marrow these MDPs differentiate into monocytes or the CDP 
(common dendritic cell precursor). The CDPs are potentially capable of generating lymphoid 
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conventional dendritic cells (cDCs) without a monocyte precursor (Auffray et al., 2009). The 
monocytes generated from the MDP are released into the circulation. The generation of 
monocytes and macrophages is dependent on the growth factor receptor Csf1r (CD-115, c-
fms, M-CSFR), which is expressed on monocytes, macrophages and their precursors, and for 
which the natural ligands are Csf1 and IL-34. Op/op mice, which are constitutively deficient 
in Csf1, and Csf1r knockout mice both show profound deficiencies in both circulating 
monocytes and tissue macrophages in keeping with a key role for this system in MPS 
development (Dai et al., 2002). 
The longstanding dogma is that these circulating monocytes populate and replenish tissue 
macrophages, in addition to dendritic cells and osteoclasts (Gordon and Taylor, 2005). 
Whilst this undoubtedly plays a role in certain organs and under certain conditions, studies 
have also demonstrated the capacity of tissue macrophages to proliferate locally and hence 
replenish their population without recruitment. There is now cogent evidence that local 
macrophage proliferation at least partially contributes to renewal of tissue macrophage 
populations in the spleen, skin, lung and brain, particularly during steady state conditions 
without injury (Gordon and Taylor, 2005). Indeed a recent study has also highlighted a role 
for local macrophage proliferation in generating the tissue inflammatory response in 
response to specific types of injury (Jenkins et al., 2011). Under steady state conditions in 
the liver, a low basal level of Kupffer cell proliferation can be detected (Crofton et al., 1978) 
and indeed rat Kupffer cells have been shown to be potentially long-lived (Bouwens et al., 
1986). However, whole body irradiation, and presumably associated injury to existing 
Kupffer cells, results in repopulation of liver resident macrophages from the bone marrow 
(Crofton et al., 1978). Thus, Kupffer cells, like many other tissue macrophages, have the 
capacity to develop from either local proliferation or recruitment of circulating monocytes, 
depending on the circumstances to which they are exposed. 
More definitive evidence for the origin and dynamics of monocytes and tissue macrophages 
under steady state came from a series of fate mapping experiments (Yona et al., 2013). This 
study was based on the widespread expression of the chemokine receptor CX3CR1 in the 
mononuclear phagocyte system. The authors utilised transgenic mice constitutively 
expressing GFP (Cx3cr1
gfp
) or Cre recombinase (Cx3cr1
cre
) or conditionally Cre 
recombinase (Cx3cr1
creER
) under the control of the CX3CR1 promoter. This study 
demonstrated that in steady state, Kupffer cells, in addition to lung, peritoneal and splenic 
macrophages, are established before birth and remain independent of the monocyte pool in 
adulthood and are maintained by longevity and local self renewal (Yona et al., 2013). 
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Monocytes as Precursors of Tissue Macrophages 
Recruitment of circulating monocytes and consequent differentiation into macrophages (or 
dendritic cells) is a key feature of the inflammatory response to tissue injury. Monocytes are 
effector cells in themselves, expressing a number of scavenger receptors capable of 
recognising microorganisms and are able to produce a range of inflammatory mediators and 
are hence vital for defence from pathogens (Auffray et al., 2009). Monocytes also show 
significant heterogeneity. In mice, 2 distinct populations of mature monocytes found in the 
bone marrow, blood and spleen have been defined, which can be distinguished on the basis 
of cell surface marker expression. Murine monocytes are generally identified by flow 
cytometry on the basis of their size (forward scatter; FSC), complexity (side scatter; SSC) 
and expression of antigens CD115, CD11b and F4/80. Differential expression of the cell 







 monocytes show high levels of expression of the chemokine receptor CCR2, 
the adhesion molecule CD62L (L-selectin) and low levels of expression of the chemokine 
receptor CX3CR1 (Auffray et al., 2009, Gordon and Taylor, 2005). This population has been 
termed the “inflammatory monocyte” as they are rapidly and selectively recruited to sites of 
tissue inflammation, primarily in response to the chemokine CCL2 (monocyte chemotactic 
protein-1; MCP-1), and are capable of producing inflammatory cytokines such as TNF-α and 
IL-1 (Auffray et al., 2009). This Ly-6C
hi
 murine monocyte population has been shown to be 




, albeit not identical (Ingersoll et al., 2009). 
Following recruitment, they are capable of forming tissue macrophages and potentially 
inflammatory DCs (Auffray et al., 2009, Gordon and Taylor, 2005, Ingersoll et al., 2011). 
An example, has been shown in elegant work by Arnold and colleagues, where following 
muscle injury in mice, Ly-6C
hi
 (and not Ly-6C
lo
) monocytes are recruited from the 
circulation, initially forming Ly-6C
hi
 muscle macrophages with a pro-inflammatory 
phenotype which then change phenotype to anti-inflammatory Ly-6C
lo 
muscle macrophages 
which promote muscle regeneration (Arnold et al., 2007). Similarly, following spinal cord 
injury Ly-6C
hi
 monocytes are recruited and form an anti-inflammatory macrophage 
population which is important for recovery (Shechter et al., 2009). A further study on 
mammary tumours in mice, demonstrated that Ly-6C
hi
 monocyte recruitment contributes to 
the heterogeneous population of tumour associated macrophages, which can have important 
roles in tumour suppression and progression (Movahedi et al., 2010). Thus, Ly-6C
hi
 
monocyte recruitment can lead to the formation of macrophages and dendritic cells with a 













and have been termed “resident” or “patrolling” monocytes. This population is felt to be 




 monocytes (Ingersoll et al., 2009). Originally thought to 
be responsible for the replenishment of resident tissue macrophages, the exact function of 
this population remains poorly defined. Ly-6C
lo
 monocytes have been shown to crawl on the 
endothelial surface of blood vessels but rarely extravasate in the absence of inflammation, 
suggesting a role in scavenging lipids and dead cells from the endothelium during steady 
state conditions (Auffray et al., 2009). This population is also potentially capable of a very 
early response to inflammation. For example, irritants, aseptic wounding and peritoneal 
infection with Listeria monocytogenes result in CX3CR1-dependent rapid extravasation of 
Ly-6C
lo
 monocytes within 1-2 hours. In this context these cells can express inflammatory 
cytokines, pattern-recognition receptors, scavenger receptors, tissue remodelling genes and 
importantly genes involved in a macrophage differentiation programme (Auffray et al., 
2007). However, this extravasation is very short lived and is rapidly overtaken by a more 
conventional recruitment of neutrophils and Ly-6C
hi
 monocytes. The ability of Ly-6C
lo
 
monocytes to form tissue macrophages following injury has also been demonstrated in other 
studies. In response to experimental myocardial injury in mice, there is an early recruitment 
of Ly-6C
hi
 monocytes resulting in inflammation, proteolysis and clearance of debris by 
phagocytosis, with a second late phase recruitment of Ly-6C
lo
 monocytes results in 
myofibroblast accumulation, collagen deposition and angiogenesis resulting in wound 
healing (Nahrendorf et al., 2007). Additionally, Ly-6C
lo
 monocytes can give rise to lung 





 monocytes are recruited, forming plaque macrophages with 
seemingly different phenotypes (Tacke et al., 2007). Thus, dependent on the tissue and the 
nature of injury, both monocyte subsets have the capacity to form macrophages. 
An additional level of complexity to the relative roles of monocyte subsets in inflammation 




 monocyte populations. Previous 
data has suggested that Ly-6C
lo
 monocytes are derived from differentiation of Ly-6C
hi
 
monocytes (Sunderkotter et al., 2004). This has recently been confirmed in transgenic fate 
mapping experiments, which demonstrated that in a steady state, Ly-6C
hi
 monocytes are 
obligatory precursors of Ly-6C
lo





 monocytes must be released from the bone marrow into the circulation 
in a CCR2 dependent manner. Intriguingly, Ly-6C
hi
 monocytes also restrict the lifespan of 
their Ly-6C
lo
 progeny, potentially by acting as a sump for CSF-1 (Yona et al., 2013). The 
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exact role of these mechanisms during inflammatory responses remains unclear, but shown 
be borne in mind when considering lineage tracing data. 
Dendritic Cells – a Distinct Entity? 
The discovery, by Steinman and Cohn in the early 1970s, of a population of haematopoietic 
cells in the mouse spleen which excelled at antigen presentation and T cell activation, termed 
dendritic cells (DCs) has added further complexity to the study of the mononuclear 
phagocyte system. DCs, similar to macrophages, were subsequently found to populate 
virtually all lymphoid and non-lymphoid tissues. DCs were initially felt to be poorly 
phagocytic but accumulating evidence now shows that they also have potent phagocytic 
capacity, leading to a paradigm where DCs sample tissue antigens, migrate to draining 
lymph nodes, present extracellular antigens and initiate tissue specific T-cell immunity 
(Hashimoto et al., 2011). Given the difficulties of studying antigen presentation in vivo, 
progress in the field of DC biology has been dependent on the identification of cell surface 
markers such as CD11c (Integrin αx) and the development of culture systems to produce pure 
populations of DCs in vitro (Hume, 2008).  
The heterogeneity of DCs is now being widely studied and numerous subtypes have now 
been defined. Classical DCs (cDCs) are initially equipped with a high phagocytic capacity 
followed by the capacity to produce a large array of cytokines to elicit and regulate T cell 
responses. They are short lived and highly migratory, rapidly transiting from tissues to 
lymphatic organs, being replaced by blood borne precursors (Geissmann et al., 2010). 
Plasmacytoid DCs (pDCs) are found in all organs, are longer lived than cDCs and have 
adapted to respond to viral infections in addition to antigen presentation and control of T cell 
responses (Geissmann et al., 2010). Both cDCs and pDCs are thought to derive from the 
bone marrow from common DC precursors (CDPs), independent of monocytes. This process 
is thought to be driven by signalling via the cytokine receptor fms-related tyrosine kinase 3 
(FLT3) (Geissmann et al., 2010, Hashimoto et al., 2011).  
Once again this DC development paradigm applies during steady state conditions, but will be 
significantly different in response to inflammation. Specifically, there is now evidence that 
in response to inflammation, Ly-6C
hi
 monocytes can differentiate into DCs which can 
express TNF-α, iNOS and reactive oxygen species, known as TipDCs (Serbina et al., 2003, 
Cheong et al., 2010, Ingersoll et al., 2011). However, this raises an important point – how to 
differentiate between these DCs and macrophage populations within tissue? This has thus far 
been done on the basis the expression of cell surface markers such as CD11c, and functions 
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such as antigen presentation. However, it is now apparent that macrophage subpopulations 
can also express similar cell surface markers and perform similar functions to DCs. This is 
particularly apparent in response to inflammation, where the features attributed to TipDCs 
are also characteristic of macrophages. Furthermore, depletion of the monocyte/macrophage 
differentiation factor CSF1R also results in reduced numbers of DCs (Hume, 2008). Thus, 
whilst in steady state separate differentiation pathways may well exist, in response to 
inflammation the distinction between macrophages and DCs becomes blurred and it would 
be better to view both as part of a heterogeneous spectrum of mononuclear phagocytes rather 
than separate populations. 
The Spectrum of Macrophage Activation 
As described, significant heterogeneity exists in macrophages on the basis of their 
localisation and origin. Macrophages are also well known to be multifunctional and plastic 
cells which can adopt distinct activation states depending on the signals to which they are 
exposed. These macrophage activation states have broadly been classified as M1 (classically 
activated) and M2 (alternatively activated) in a manner analogous to TH1 and TH2 responses 
for T cells. The classically activated M1 phenotype is said to be the adopted by macrophages 
in response to IFN-γ alone or in combination with bacterial products such as 
lipopolysaccharide (LPS) or cytokines such as TNF-α. Indeed, ligation of TLR ligands on 
monocytes/macrophages can lead to self production of TNF-α which can act in an autocrine 
manner (Mosser and Edwards, 2008). This results in a macrophage phenotype which 
produces large quantities of pro-inflammatory cytokines, chemokines and free radicals. This 
phenotype is critical for host defences from micro-organisms (Mosser and Edwards, 2008). 











population, which also expresses high levels of chemokines such as CXCL9 and CXCL10 
attracting TH1 cells (Mantovani et al., 2004, Mantovani et al., 2013). Importantly, the 
mediators produced by M1 macrophages are also capable of producing host tissue damage 
and therefore this population must be tightly regulated (Mosser and Edwards, 2008). 
M2 alternatively activated macrophage phenotype was originally described in response to 







phenotype, with low expression of other inflammatory cytokines and high expression of 
chemokines such as CCL17 and CCL22 which are important in TH2 immune responses. 
These M2 cells also upregulate genes such as arginase-1, YM-1 and multiple other scavenger 
receptors and they are generally felt to take part in parasite clearance, immunomodulation, 
angiogenesis and wound healing (Mantovani et al., 2013). What is now becoming clear is 
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that numerous other signals can induce an “M2 like” macrophage phenotype, with some but 
not all of the features of the traditional IL-4/IL-13 polarized macrophage. Examples of such 
signals include immune complexes in combination with LPS or IL-1, glucocorticoids, TGF-β 
or IL-10 (Mantovani et al., 2013). Each of these results in a slightly different macrophage 
phenotype, highlighting the vast complexity and the range of potential macrophage 
activation states. When considering that these phenotypes are largely defined in vitro, in the 
presence of 1 or 2 signals, the range of signals to which macrophages are exposed in vivo 
will result in an almost infinite number of potential macrophage phenotypes. Thus the 
traditional paradigm of M1 and M2 polarization is generally inadequate to define 
populations in vivo and macrophages should be considered on a spectrum of activation 
states.  This consideration has resulted in experts aiming to classify macrophage phenotypes 
more on the basis of function such as classically activated, regulatory and wound healing 
macrophages (Mosser and Edwards, 2008). A good example of this in practice is the 
identification and characterisation of a macrophage population responsible for the resolution 
of peritoneal inflammation in mice, which shows features of both classical and alternatively 
activated macrophages (Bystrom et al., 2008). 
Macrophages are also plastic cells capable of ongoing changes in phenotype according to 
their microenvironment (Stout et al., 2005). This principle of macrophage plasticity has also 
been demonstrated in vivo in diverse pathologies such as cancer and tumour associated 
macrophages, obesity and adipose tissue macrophages, macrophages in skin wounding, 
macrophages in chronic venous ulceration, renal macrophages following kidney injury and 
monocyte-derived macrophages following muscle injury (Lucas et al., 2010, Mantovani et 
al., 2013, Mosser and Edwards, 2008, Arnold et al., 2007, Alikhan and Ricardo, 2013). This 
plasticity and constantly evolving phenotype provides challenges in defining distinct 
functional macrophage populations in vivo. 
Phagocytosis as a Modulator of Macrophage Function 
One of the key functions of macrophages is the rapid and efficient removal of a variety of 
particulate matter. This includes microorganisms, environmental material and of course dead 
cells. The clearance of dead or dying cells occurs in both health and disease, with an 
estimated 1 million apoptotic deaths per second occurring in health. Clearly, in 
diseased/damaged tissue this will increase, with epithelial and immune cell death both key 
features of acute and chronic inflammation. Importantly, in addition to the removal of 
potentially harmful cell debris, phagocytosis itself modulates the phenotype of the 
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phagocyte, which can have important implications for the inflammatory response (Henson, 
2005). 
The process of phagocytosis is itself complex, potentially involving numerous receptors and 
soluble mediators with a large amount of redundancy to ensure adequate clearance even in 
the face of inhibition of one pathway. These multiple mediators of phagocytic clearance may 
act together, forming the so called “phagocytic synapse”. In the first stage in the process in 
vivo, phagocytes must find the apoptotic cells. Data now exists that apoptotic cells release 
“find me” signals which leads to phagocyte recruitment. Examples of such signals include 
CX3CL1 (Fractalkine) which acts on CX3CR1 on mononuclear phagocytes, 
lysophosphatidylcholine (LPC) acting on the G2A receptor, sphingosine-1-phosphate (S1P), 
and the nucleotides ATP and UTP which are sensed by the P2Y2 receptor on monocytes 
(Hochreiter-Hufford and Ravichandran, 2013). Intriguingly, apoptotic cells secrete 
lactoferrin, which can act as a “stay away” signal to neutrophils but not mononuclear 
phagocytes and may thus determine the type of phagocyte engulfing them and hence the 
post-phagocytic response (Bournazou et al., 2009). Having come into proximity with the 
apoptotic cells, the phagocyte then encounters “eat me” signals on the surface of the dying 
cell. These include phosphatidylserine (PS), ICAM3, oxidised low density lipoprotein 
(LDL)-like moiety or bound opsonins such as thrombospondin or complement C1q. These 
“eat me” signals are recognised by a wide range of engulfment receptors on the surface of 
the phagocyte (Hochreiter-Hufford and Ravichandran, 2013). Examples of these receptors 
include: 
 Lectins which bind altered sugars on apoptotic cells 
 Integrins αvβ3 and αvβ5 in conjunction with CD36 which binds thrombospondin 
  LRP1/CD91 which binds C1q 
 CD14 which binds ICAM3 
 Scavenger receptors which bind oxidised LDL 
 Integrins αvβ3 and αvβ5 which bind the secreted molecule MFG-E8, which can bind 
PS 
 TAM receptor family (Tyro-3-Axl-Mer) which bind bridging molecules Growth-
arrest-specific 6 (Gas6) and Protein S, which are in turn bound to PS 
 Direct PS receptors including Brain-specific angiogenesis inhibitor 1 (BAI1), T-cell 
immunoglobulin and mucin-domain-containing molecule 4 (TIM-4), Stabilin-2 and 
the Receptor for advanced glycation end products (RAGE) 
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Following engagement of the apoptotic cell with the phagocyte synapse, a number of 
signalling pathways are activated leading to cytoskeletal rearrangement and engulfment. 
Following internalisation the phagosomes become progressively more acidic, eventually 
fusing with lysosomes, which contain the digestive enzymes for degradation. The phagocyte 
must process the degradation products efficiently in order to maintain homeostasis and 
molecules such as mitochondrial UCP2 for energy balance, DNase II to prevent 
accumulation of DNA fragments within phagocytes and ABCA1 to increase cholesterol 
efflux (Hochreiter-Hufford and Ravichandran, 2013). 
At all stages in the phagocytic process including post-ingestion, complex signalling cascades 
are activated within the phagocyte, ultimately leading to a change in phenotype. The method 
of death, the location and the means by which the cells are cleared will ultimately determine 
the response of the phagocyte. Generally organs such as the spleen and liver are thought to 
be tolerogenic and apoptotic cells cleared by resident macrophages in these organs are likely 
to be immunologically silent. Conversely, apoptotic cells cleared by incoming monocyte-
derived macrophages in an inflamed environment are likely to induce an immunomodulatory 
phenotype (Geissmann et al., 2010, Hochreiter-Hufford and Ravichandran, 2013). 
Specifically, in this context phagocytes can secrete increased amounts of anti-inflammatory 
cytokines such as IL-10 and TGF-β and pro-resolution lipid mediators whilst the production 
of pro-inflammatory cytokines is inhibited (Erwig and Henson, 2007). Indeed, the 
administration of apoptotic cells to inflamed peritoneum or lung shows an anti-inflammatory 
effect in vivo (Huynh et al., 2002). This is in contrast to the clearance of pathogens and 
necrotic cells, which despite being recognised by similar receptors to apoptotic cells, result 
in a pro-inflammatory macrophage phenotype, potentially due to activation of pattern 
recognition molecules such as TLRs (Erwig and Henson, 2007). Overall, it is clear that 
macrophage phagocytosis has significant effects on the cellular phenotype. The precise 
phenotypic effects are likely to be dependent on the exact micro-environmental cues which 
are impossible to recreate in vitro.   
Macrophages can Promote Hepatic Fibrosis 
Having discussed the complexity of macrophage heterogeneity, it is important to consider 
the current evidence suggesting a potential role in hepatic fibrosis. There is now an evolving 
tranche of evidence that macrophages play a key role in this process. On the morphological 
level it is clear that in the fibrotic liver, hepatic macrophages localise in close proximity to 
activated myofibroblasts and the scar tissue, leading to the term scar-associated macrophage 
(SAM) and suggesting a potential role in the fibrotic process (Duffield et al., 2005, 
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Fallowfield et al., 2007). The major functional evidence has come from in vivo macrophage 
depletion and blockade strategies. One group utilised gadolinium chloride (GdCl3) to deplete 
hepatic macrophages in rats and demonstrated reduced myofibroblast activation and fibrosis 
in response to thioacetamide injury (Ide et al., 2005). Furthermore, inhibition of principal 
monocyte chemokine CCL2 in rats or knockout of its receptor CCR2 in mice reduced 
hepatic macrophage infiltration in response to injury and significantly inhibited liver fibrosis 
(Imamura et al., 2005, Mitchell et al., 2009). However, both these approaches can potentially 
have “off target” effects on hepatic stellate cells. The seminal work in this field came from 
the use of a conditional macrophage depletion strategy using CD11b-DTR transgenic mice, 
which express the human diphtheria toxin receptor under the control of the CD11b promoter, 
enabling selective depletion of monocytes/macrophages by administration of diphtheria toxin 
(DT). Using this strategy the authors clearly demonstrated that macrophage depletion during 
ongoing hepatic injury with CCl4 resulted in inhibited liver fibrogenesis, hence confirming 
the pro-fibrogenic role of macrophages in this setting (Duffield et al., 2005). A similar pro-
fibrotic role for liver macrophages during injury has been demonstrated using a liposomal 
clodronate depletion strategy in both a transgenic model of hepatic injury and in response to 
CCl4 or BDL (Sunami et al., 2012, Pradere et al., 2013). 
Given the aforementioned heterogeneity in tissue macrophages, work has subsequently 
focussed on which liver macrophage population might mediate this pro-fibrotic effect. In 
response to hepatic injury, resident Kupffer cells and recruited monocyte-derived 
macrophages can be differentiated by flow cytometry (Holt et al., 2008). In an excellent 
study by Karlmark et al., the authors defined that a Ly-6C
hi
  hepatic macrophage population 
derived from CCR2-dependent recruitment of Ly-6C
hi
 inflammatory monocytes were the 
main pro-fibrogenic population in a murine CCl4 fibrosis model (Karlmark et al., 2009).  
Similarly, macrophages have now been identified as potentially pro-fibrotic cells in tissue 
fibrosis in other organs including the kidney (Conway and Hughes, 2012, Vernon et al., 
2010, Ricardo et al., 2008, Lin et al., 2009), heart (Hayashidani et al., 2003, Rickard et al., 
2009), lung (Osterholzer et al., 2013, Gibbons et al., 2011) and skin (Mahdavian Delavary et 
al., 2011, Lucas et al., 2010). Indeed, in several circumstances, similar to the liver, Ly-6C
hi
 
monocyte-derived macrophages are the main pro-fibrogenic macrophage population (Lin et 
al., 2009, Gibbons et al., 2011, Osterholzer et al., 2013). 
Focus has then turned to the mechanism of the pro-fibrogenic activity of macrophages in 
liver fibrosis. Macrophages can be potent producers of a wide variety cytokines, chemokines 
and other soluble mediators which could potentially have direct effects on hepatic stellate 
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cells and myofibroblast populations. Specifically, macrophages have been shown to express 
TGF-β, the archetypal pro-fibrotic cytokine which can promote myofibroblast activation and 
matrix synthesis (Karlmark et al., 2009, Wynn and Barron, 2010). Furthermore, 
macrophages have been shown to express PDGF, a potent myofibroblast mitogen, and TH2 
cytokines IL-4 and IL-13 which can directly stimulate collagen synthesis in fibroblasts. 
Macrophages have also been associated with the production of a range of chemokines which 
can recruit myofibroblasts and further inflammatory cells to the site of inflammation thereby 
perpetuating the response (Wynn and Barron, 2010). Galectin-3 is a lectin that has been 
shown to promote myofibroblast activation in both liver and kidney fibrosis models and is 
secreted by macrophages (Henderson et al., 2008, Henderson et al., 2006). More recently, 
hepatic macrophage derived pro-inflammatory cytokines TNF-α and IL-1β have been shown 
to act on activated hepatic stellate cells to induce NF-κB activity, promote stellate cell 
survival and increase liver fibrosis (Pradere et al., 2013). Indeed, macrophage subsets 
isolated from cirrhotic human liver also express high levels of pro-inflammatory mediators 
(Zimmermann et al., 2010). These pro-fibrogenic activities of hepatic macrophages are 
summarised in Fig 1.2 (adapted from (Ramachandran and Iredale, 2012b)). 
Thus, there is clear evidence of a pro-fibrotic role of macrophages in liver and other organs. 
The traditional view was that this “wound healing” fibrotic response was dependent on M2 
alternatively activated macrophages. However, as discussed previously, this binary 
classification is limited in an in vivo context, and in fact features of both M1 and M2 
macrophages can potentially be pro-fibrogenic. Thus, a functional characterisation of 
macrophages is likely to be more useful. 
Macrophages are Critical for Fibrosis Resolution 
Whilst the role of macrophages in promoting fibrosis is well established, there is emerging 
data which also indicates that macrophages are critical for liver fibrosis regression 
(Ramachandran and Iredale, 2012b). Principally, using the CD11b-DTR transgenic system, 
macrophage depletion by DT administration during the recovery phase following CCl4 injury 
resulted in a striking failure of scar resolution (Duffield et al., 2005). Additionally, in mice 
deficient in CCR2, a failure to recruit monocytes to the liver in response to CCl4 injury 
results not only in reduced fibrogenesis but also impaired fibrosis regression (Mitchell et al., 
2009). Similar findings have also been demonstrated in the lung, where macrophage 
depletion using liposomal clodronate during the recovery phase following bleomycin injury 
prevents the resolution from fibrosis (Gibbons et al., 2011). 
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So how do macrophages mediate this pro-resolution effect? Scar associated macrophages lie 
in close proximity to the fibrotic tissue and are hence ideally placed to mediate fibrosis 
degradation. Our group has previously demonstrated that hepatic macrophages are a key 
source of matrix degrading MMP enzymes, including MMP-13 (Fallowfield et al., 2007) and 
MMP-12 (Pellicoro et al., 2011), both of which are important for ECM degradation. 
Macrophages are also capable of expressing genes such as MMP-9 or TRAIL which have 
been shown to promote myofibroblast apoptosis. As described, another key feature of 
macrophages during inflammation is the clearance of cellular debris. Whilst, it had been felt 
that the process of phagocytosis may be pro-fibrogenic via the induction of TGF-β 
expression in macrophages, the phagocytic clearance of cellular debris will remove signals 
that can potentiate the inflammatory response. Indeed, macrophage phagocytosis has been 
associated with an upregulation of MMP expression (Popov et al., 2010).  
In addition to pro-resolution properties, the loss of some of the described pro-inflammatory 
and/or pro-fibrotic macrophage properties may result in a change in the local milieu to 
favour fibrosis regression. Specific signals such as CX3CL1 acting on CX3CR1 on 
macrophages (Karlmark et al., 2010) or the opsonin serum amyloid P (SAP) protein acting 
via Fcγ receptors (Castano et al., 2009) have been shown to promote an anti-inflammatory 
macrophage phenotype and consequent protection from tissue fibrosis. Current 
understanding of the pro-resolution macrophage and its mechanism of formation and action 
is summarised in Fig 1.2 (adapted from (Ramachandran and Iredale, 2012b)) 
Another proposed indirect mechanism for the role of macrophages in fibrosis resolution is 
via recruitment of other effector cell types. One group, for example, has proposed that in the 
repairing liver, hepatic macrophages cause the recruitment of neutrophils which express 
matrix degrading enzymes and result in scar resolution (Harty et al., 2008). Whilst, as 
discussed previously, the exact role of neutrophils in this process remains unclear, 
macrophages have the capacity to alter other cellular components of the immune response. 
Indeed, adoptive transfer of exogenous macrophages to mice during CCl4 liver injury has 
been shown to recruit host effector cells to mediate an anti-fibrotic effect (Thomas et al., 
2011).  
Dendritic cells have also been explored in the context of liver fibrosis resolution. Using 
CD11cC-DTR transgenic mice to deplete hepatic dendritic cells during the recovery phase 
following CCl4 injury, supplemented by adoptive transfer data and in vivo DC expansion 
using FLT3 Ligand, the authors demonstrated that DCs may also have a role in matrix 
degradation, potentially via MMP-9 expression (Jiao et al., 2012). Similarly, CD11c positive 
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DCs have been shown to have a role in the recovery from hepatic ischaemia/reperfusion 
injury (Bamboat et al., 2010). Whilst this needs to be proven in other studies, given the 
overlap between monocyte, macrophage and dendritic cell identity and function, particularly 
in the context of inflammation, caution needs to be adopted in ascribing specific functions to 
DCs. 
Overall, these data highlight an emerging understanding of the potential role of macrophages 
in the resolution of tissue fibrosis and the restoration of normal tissue architecture. However, 
a number of questions remained unanswered (Friedman, 2005, Wynn and Barron, 2010). Are 
the pro-resolution effects mediated by a specific restorative macrophage subset? Does this 
population derive from recruited or resident macrophages? Is there a contribution of local 
macrophage proliferation? Are they formed as a distinct population or do they form from 
pro-fibrotic macrophages via a change in phenotype in situ? What signals cause the 
formation of the pro-resolution phenotype? What genes do restorative macrophages express? 
It is only by trying to identify the pro-resolution macrophage and characterising it that we 
can hope to address some of these important questions. Ultimately, a greater understanding 
of the macrophage biology of fibrosis regression could lead to the development of badly 





Figure 1.2 – Macrophages can Promote Liver Fibrogenesis and Fibrosis Resolution 
Schematic representation of the role of macrophages in hepatic fibrogenesis and fibrosis 
regression (adapted from (Ramachandran and Iredale, 2012b)). During fibrogenesis Ly-6C
hi
 





) macrophages. These cells potentially have a range of potential pro-
fibrogenic features. Specifically they can express pro-inflammatory cytokines such as TNF-α 
and IL-1β which can perpetuate the inflammatory response and hepatocellular damage and 
also promote survival of hepatic myofibroblasts. They can also express chemokines which 
promote recruitment of monocytes, other inflammatory cells and hepatic stellate cells. Direct 
effects of pro-fibrogenic macrophages on hepatic myofibroblasts may be mediated by TGF-β 
or galectin-3 expression to promote activation or PDGF production to stimulate proliferation. 
Myofibroblasts themselves express TIMP-1 which inhibit MMPs and promote scar 
deposition. In contrast less is known about the pro-resolution macrophage population. They 
may derive from separate recruitment of monocytes or a change in macrophage phenotype, 
potentially via hepatic expression of anti-inflammatory signals such as CX3CL1. Pro-
resolution macrophages are likely to remove cellular debris and consequent pro-fibrogenic 
signals by phagocytosis. They may also express signals such as TRAIL or MMP-9 which 
promote myofibroblast apoptosis. This apoptosis removes the source of scar production and 
TIMP-1 expression, enabling endogenous MMPs to degrade ECM. Finally, pro-resolution 
macrophages are likely to be a source of MMPs such as MMP-13 and MMP-12 which 
directly breakdown scar tissue. Hepatic dendritic cells may also express MMP-9 and 







A distinct hepatic macrophage population, derived from circulating cells, mediates matrix 
remodelling in the reversal of liver fibrosis 
 
Aims and Objectives 
The overall aim of this thesis is that is to identify and characterise the hepatic macrophage 
population responsible for the resolution of liver fibrosis, the so called restorative 
macrophage. 
I will address this aim in several ways: 
 Establishing and characterising a robust and reproducible model of reversible murine 
liver fibrosis 
 In depth study of changes in hepatic macrophage populations during fibrosis 
resolution 
 Use of macrophage depletion during fibrosis resolution to identify the functionally 
relevant populations 
 Defining the origin and dynamics of the liver macrophage populations involved in 
fibrosis regression 
 Detailed characterisation of the phenotype of the pro-resolution hepatic macrophage 
and the signals involved in generating it 
 To use the above data to develop strategies to alter macrophage phenotype in vivo 













) were purchased from Harlan, UK and were utilised for the 
majority of experiments presented in this thesis unless otherwise stated. CD11b-DTR mice 
were used for macrophage depletion studies and have been previously described by our 
group (Duffield et al., 2005). This mouse strain was originally obtained from R. Lang 
(Children’s Hospital Research Foundation, Cincinnati) and was maintained as heterozygotes 
on a C57BL/6 background. CD45.1
+
 C57BL/6 mice were provided by Professor S.M. 
Anderton (University of Edinburgh) and have been described (O'Connor et al., 2010). These 
mice were used for adoptive transfer experiments as CD45.1 positive cells can be identified 
by flow cytometry, but as they are derived from the same background mouse strain should 
not induce an immune response in the recipient animal. CD11c-DOG mice were provided by 
Dr A.S. MacDonald (University of Edinburgh). These mice have been described (Phythian-
Adams et al., 2010) and enable depletion of CD11c positive dendritic cells in response to 
diphtheria toxin administration. Mice were bred under specific pathogen-free conditions at 
the University of Edinburgh and all experiments had local ethical approval and were 
conducted under UK home office legislation. 
CCl4 Murine Models 
For the CCl4 model, adult male C57BL/6 mice aged at least 6 weeks were used. Hepatic 
fibrosis was induced by twice-weekly intraperitoneal carbon tetrachloride (CCl4; 0.4μl/g; 
Sigma) diluted 1:3 in olive oil (Sigma). Injury was continued for 4 weeks (9 injections). 
Animals were culled at stated timepoints following the final CCl4 injection.  
For depletion studies in male CD11b-DTR mice, diphtheria toxin (DT; 10ng/g in PBS; List 
Biological Laboratories Inc.) or PBS control was administered intravenously via the tail vein 
to mice following CCl4 injury for 4 weeks (9 injections) at the stated timepoints. As an 
additional control, DT (10ng/g) or PBS was administered intravenously to wild-type 
C57BL/6 mice at identical timepoints following 4 weeks of CCl4 injury. 
For dendritic cell depletion, adult male CD11c-DOG mice were injured with 4 weeks of 
CCl4 followed by administration of DT (12ng/g) or PBS control intraperitoneally at the 
stated timepoints following the final CCl4 injection.  
For macrophage depletion studies using liposomal clodronate, adult male C57BL/6 wild type 
mice were injured with 4 weeks (9 injections) of CCl4. Liposomal clodronate was obtained 
from Nico van Rooijen (Van Rooijen and Sanders, 1994). 250μl of liposomal clodronate (or 
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PBS control) was administered to mice intravenously via the tail vein 48, 72 and 96 hrs 
following the final CCl4 injection, followed by harvest at 120 hrs.  
For lineage tracing of monocytes, wild-type adult male CD57BL/6 mice (CD45.2
+
) were 







 monocytes suspended in 200μl of RPMI 1640 medium (or RPMI vehicle control) were 
injected via the tail vein. Livers were harvested at 24, 72 and 168 hrs after the final CCl4 
injection. 
For in situ fluorescent labelling of monocytes, wild-type C57BL/6 mice were injured with 4 
weeks of CCl4 as before. 4 hours following the final CCl4 injection, 250μl of fluorescent 
latex beads (0.5μm Fluoresbrite polychromatic red microspheres; 2.5% solids [wt/vol] 
diluted 1:25 in PBS for injection; Polysciences Inc.) or PBS vehicle control was injected 
intravenously via the tail vein, followed by harvest 24, 72 and 168 hrs after the final CCl4 
injection. 
To modify PPAR-γ signalling in vivo, wild-type adult male C57BL/6 mice were injured with 
4 weeks of CCl4 as before. At 24, 48 and 72 hrs following the final CCl4 injection, mice were 
given intraperitoneal injections of either the PPAR-γ activator rosiglitazone (10mg/kg 
dissolved in DMSO) or DMSO control. Animals were harvested at 96 hours. 
To inhibit the phosphatidylserine binding molecule MFG-E8 in vivo, wild-type adult male 
C57BL/6 mice were injured with 4 weeks of CCl4 as before, followed by intraperitoneal 
administration of the monoclonal anti-MFG-E8 blocking antibody (Clone 18A2-G10; Caltag 
Medsystems) or hamster IgG isotype control (Santa-Cruz Biotechnology) at a dose of 
2mg/kg. Antibodies were given 24, 48 and 72 hrs following the final CCl4 injection with 
harvest at 96 hours. 
To attempt to block the phagocytic receptor Integrin αv (ITGAV) in vivo, wild-type adult 
male C57BL/6 mice were injured with 4 weeks of CCl4. At 24, 48 and 72 hrs after the final 
CCl4 dose, mice were administered intraperitoneal injections of 200 µg of anti-ITGAV 
antibody (Clone RMV-7; Cambridge Biosciences) or Rat IgG1 κ isotype control (Clone 
RTK2071; Cambridge Biosciences). Animals were harvested at 96 hrs. 
To induce phagocytosis in hepatic macrophages during fibrosis resolution in vivo, wild-type 
adult male C57BL/6 mice were injured with 4 weeks of CCl4. At 48, 72 and 96 hrs after the 
final CCl4 injection, mice were administered 250μl of liposomal PBS (multilamellar 
liposomes made with 8mg of cholesterol and 86mg phosphatidylcholine with 10mls PBS as 
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described (Van Rooijen and Sanders, 1994) and provided by Nico Van Rooijen), or PBS 
control intravenously via the tail vein. Animals were harvested at 120 hrs. In order to trace 
the in vivo fate of administered liposomes, this experiment was repeated using CM-DiI – 
labelled liposomes (CM-DiI from Invitrogen and used to label liposomes as per 
manufacturers’ instructions) or PBS control. 
TAA Murine Models 
For the TAA model of liver fibrosis, adult male C57BL/6 mice with a weight of at least 25g 
were treated continuously with thioacetamide (Sigma) in the drinking water at a dose of 
300mg/l or 600mg/l. Control animals remained on normal water. Free access to normal chow 
diet continued throughout. For the progressive fibrosis TAA model, mice were treated with 
TAA for up to 52 weeks, with harvests at 8, 12, 16, 20, 36 and 52 weeks of treatment. 
Animals were weighed weekly throughout to assess the effect of TAA treatment on expected 
weight gain. 
For the reversible TAA model, only the 600mg/l dose of TAA was used and comparison 
made to normal drinking water. Mice were treated with TAA for either 8 weeks or 52 weeks. 
Following reaching the treatment duration, they were changed onto normal drinking water. 
In addition to harvests at the end of TAA treatment (8 weeks and 52 weeks), mice were 
harvested at 72 hrs, 1 week, 2 weeks and 8 weeks after conversion to normal water for the 8 
week model, and 1 week, 2 weeks and 8 weeks after conversion to normal water for the 52 
week model. 
Hepatic Non-parenchymal cell isolation 
Isolation of hepatic non-parenchymal cell (NPC) fraction was performed using a modified 
MACS protocol 
(http://www.miltenyibiotec.com/download/protocols_gentlemacs_en/1105/gentleMACS-
Liver-04.pdf), from Miltenyi Biotech. In summary, mouse livers in situ were perfused with 
10ml of 0.9% NaCl solution via the Inferior Vena Cava (IVC) followed by cutting the portal 
vein, to remove circulating cells. Livers were then harvested, weighed and either the whole 
liver or the right lobe homogenised using a scalpel and digested in RPMI 1640 medium 
containing Collagenase B (1.6mg/ml; Roche) and DNase I (100μg/ml; Roche) for 45 minutes 
at 37
o
C. Digested livers were passed through 40μm cell strainers and enzymes inactivated by 
addition of RPMI 1640 with 10% FCS. Contaminating hepatocytes were removed by 2x 
centrifugation at 50G for 5 minutes, with the supernatant preserved. Erythrocytes were lysed 
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by adding lysis buffer (NH4Cl 0.15M, KHCO3 10mM, EDTA 0.1mM in H2O) for 5 minutes 
on ice. The remaining non-parenchymal cell fraction, containing hepatic macrophages, was 
then harvested by centrifugation at 300G for 10 minutes. Total cell number was counted 
using an aliquot of cell suspension and analysis using nucleocassettes (941-0002, 
Chemometec, Denmark) and a nucleocounter (SCC-100, Chemometec, Denmark). The non-
parenchymal cell fraction was then used for flow cytometry and FACS sorting. 
Flow cytometry and FACS sorting 
Flow cytometry (using BD LSR Fortessa II) and FACS sorting (using BD FACSAria II) 
were performed on hepatic non-parenchymal cells containing the total hepatic leukocyte 
population.  
Initially, non-specific antibody binding was blocked by incubating cells with 10% mouse 
serum for 20 minutes at 4
o
C, followed by incubation with combinations of primary 
antibodies (each used at 1/100 dilution unless stated) for 30 minutes at 4
o
C in the dark. The 
following pre-conjugated antibodies were used: CD11b (Clone M1/70, Rat IgG2b kappa), 
CD11c (Clone N418, Armenian Hamster IgG), Ly-6C (Clone HK1.4, Rat IgG2c kappa), 
CD45.2 (Clone 104, Mouse IgG2a kappa), CD45.1 (Clone A20, Mouse IgG2a kappa), 
CD115 (Clone AFS98, Rat IgG2a kappa), CD36 (Clone No.72-1, Rat IgG2a kappa) (All 
Ebioscience), F4/80 (Dilution 1:50; Clone BM8, Rat IgG2a kappa; Invitrogen), Ly-6G 
(Clone 1A8, Rat IgG2a kappa), CD3 (Clone 17A2, Rat IgG2b kappa), NK1.1 (Clone PK136, 
Mouse IgG2a kappa), B220 (Clone RA3-6B2, Rat IgG2a kappa), CD14 (Clone Sa14-2, Rat 
IgG2a kappa), CD16/32 (Dilution 1:200; Clone 93, Rat IgG2a lambda), CD80 (Clone 16-
10A1, Armenian Hamster IgG), CD86 (Clone GL-1, Rat IgG2a kappa), CD81 (Clone Eat-2, 
, Armenian Hamster IgG) (All Biolegend). Fluorophores used were varied depending on the 
staining combination. However, commonly used combinations included Ly-6G-Pacific Blue, 
CD11b-AF488, CD11c-PE, Ly-6C-PerCp.Cy5.5, F4/80-APC, CD45.2-AF700, CD3-PE.Cy7, 
NK1.1-PE.Cy7, B220-PE.Cy7. Flow cytometry compensations were set up using single 
stained samples and stained CompBeads (BD biosciences). In samples, staining was 
confirmed by comparison to appropriate isotype antibodies where available. Cell viability 
was assessed with Propidium Iodide (Sigma, UK) or Fixable Viability Dye eFluor780® 
(Ebioscience) according to manufacturers protocols. Ki-67 staining for flow cytometric 
analysis was performed using Ki-67 staining kit (Clone B56, Mouse IgG1 kappa, BD 
biosciences) and Fix and perm kit (Ebioscience) as described (Jenkins et al., 2011). 
Following antibody staining, samples were either analysed immediately or fixed with 10% 
buffered-formalin. For FACS sorting, stained cells were resuspended in GIBCO Hank’s 
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balanced salt solution supplemented with 1% FCS. Cells were collected into RPMI 1640 
medium supplemented with 10% FCS. Data was analysed using FlowJo7.5 software 
(Treestar). 















 cells from NPC fraction of digested livers and used to identify macrophage subsets. 
Subsets were expressed as proportions of total hepatic macrophages or total hepatic CD45
+
 
cells. Quantification of absolute numbers of cells per liver was performed by expressing each 
subset as a proportion of NPCs, counting total number of NPCs in the digested portion of 
liver, calculating the total number of NPCs in the whole liver by weight differential and thus 
the total number of each subset. Where stated these values were expressed relative to the 
mean of the control liver, which was assigned a value of 1. 
For identification of circulating monocytes, whole blood was obtained from tail vein nicks 
prior to cull and diluted 1:1 in 4.8% Sodium Citrate buffer. This was stained with antibodies 
to CD11b (Clone M1/70, Rat IgG2b kappa), Ly-6C (Clone HK1.4, Rat IgG2c kappa), 
CD115 (Clone AFS98, Rat IgG2a kappa), CD45 (Clone 104, Mouse IgG2a kappa) (All 
Ebioscience) and Ly-6G (Clone 1A8, Rat IgG2a kappa; Biolegend), all at a dilution of 1:200 
for 30 mins at 4
o
C in the dark. Comparison was made to appropriate isotype control staining. 
Following staining, cells were washed x3 followed by red cell lysis and fixation using BD 













 cells from whole blood and expressed as a percentage 
of total peripheral mononuclear cells. Alternatively, the number of each cell type per ml of 
blood was quantified using counting beads. Specifically, 20µl of the blood:citrate mix 
(equivalent to 10µl of whole blood) was stained with antibodies as described. Prior to flow 
cytometric analysis, 10µl of Flow Count fluorospheres (Beckman Coulter; A91346) with a 
known concentration were added. Hence the number of beads per ml of whole blood could 
be quantified. Flow cytometry was then performed, with cell counts expressed relative to the 
number of beads in the sample and hence the number of cells per ml of blood could be 
calculated. 
For isolation of bone-marrow derived Ly-6C
hi
 monocytes, whole bone marrow was obtained 
from adult male CD45.1
+
 C57BL/6 mice by harvesting of femurs and tibias and flushing 
using 10ml RPMI 1640 culture medium supplemented with 10% FCS under aseptic 
conditions. Cells were incubated with Fc block (rat anti-mouse CD16/CD32, BD Europe) for 
15 minutes at 4
o
C. Cell suspensions were spun at 300g for 5 minutes and re-suspended in 
GIBCO Hank’s balanced salt solution (14170120, Invitrogen, UK). Antibodies to CD11b 
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(Clone M1/70), Ly-6C (Clone HK1.4), CD115 (Clone AFS98), CD45 (Clone 104) (All 
Ebioscience) and Ly-6G (Clone 1A8; Biolegend), were added all at a dilution of 1:200 for 30 
mins at 4
o
C in the dark. Cells were then spun at 300g for 5 minutes, washed x 2, and re-
suspended in GIBCO Hank’s balanced salt solution supplemented with 1% FCS for FACS 
sorting. Cells were sorted using a BD FACSAria II and collected into RPMI 1640 
supplemented with 10% FCS. Ly-6C
hi











 cells and used for adoptive transfer experiments. FACS sorting 
routinely yielded cell purity levels of over 95%. Cells were then spun at 300g for 5 minutes, 
washed x 2 with RPMI 1640 and resuspended in RPMI 1640 at a concentration of 
4.5x10
6
/ml, with 200µl (9x10
5
 cells) or 200µl of RPMI 1640 alone injected to mice via the 
tail vein.  
Detection of in vivo MMP activity  
To detect in vivo MMP activity, 2 nmol of the MMPsense 680 (Perkin Elmer) (or vehicle 
control) was administered to animals via the tail vein, 24 hrs prior to harvest, according to 
the manufacturers protocol. Hepatic macrophages were identified using flow cytometry of 
hepatic non-parenchymal cells as before, followed by identification of MMPsense positive 
macrophages with excitation laser at 635nm (Cortez-Retamozo et al., 2008). 
Microarray analysis  
50ng of RNA from FACS-sorted cells was processed using Ovation® Pico WTA system 
(NuGen) according to manufacturers protocol (n=3 per group). Processed RNAs were 
hybridized to Affymetrix GeneChip Mouse Gene 1.0 ST Arrays. RNA/microarray 
processing was carried out by ARK Genomics (Roslin Institute, Edinburgh, UK).  
Data extraction and analysis were performed by Donald Dunbar and Johnathan Manning. 
Data were extracted through the GCOS software, and CEL files used for further data 
processing. CEL files were imported into Bioconductor (Gentleman et al., 2004), normalised 
by RMA in the Oligo (http://www.bioconductor.org/packages/2.0/bioc/html/oligo.html) 
module, and statistically analysed with the Limma (Smyth, 2004). A fold change of >2 with 
adjusted P-value <0.05 was considered significant for individual gene changes. Gene 
ontology and KEGG pathway enrichment analysis was done with the DAVID tool (Dennis et 
al., 2003, Huang da et al., 2009b), on genes which were significantly differentially 
expressed. Microarray data are available in the ArrayExpress database 
(www.ebi.ac.uk/arrayexpress) under accession number E-MEXP-3177. 
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In vitro phagocytosis assay  
Bone marrow derived macrophages (BMDMs) were prepared from adult male C57BL/6 
mice as previously described (Henderson et al., 2008). Whole bone marrow was isolated 
under aseptic conditions by flushing femurs with 10ml of DMEM/F12 Glutamax (Gibco, 
UK) medium with 10% Fetal Calf Serum (FCS). Whole bone marrow was then cultured for 
7 days at 37
o
C 5% CO2 in DMEM/F12 Glutamax (Gibco, UK) medium with 10% Fetal Calf 
Serum (FCS) and 20% L929 conditioned medium (as a source of M-CSF), under non-
adherent conditions using Ultra Low Adherence Flasks (Corning, UK). 25% of the medium 
was replaced at days 2, 4 and 6 of the culture process. After 7 days, cells were analysed by 
flow cytometry. Briefly, cells were harvested by centrifugation at 300g for 5 mins, washed 
x2 with PBS, incubated with 10% mouse serum in PBS to block non-specific staining, and 
then stained with antibodies to F4/80 (Clone BM8; Invitrogen; Dilution 1:50), CD11b (Clone 
M1/70; Ebioscience; Dilution 1:100) and CD11c (Clone N418; Ebioscience; Dilution 1:100) 
for 30 mins at 4
o
C in the dark. Cells were then washed x 2 with PBS, resuspended in PBS 
and either analysed immediately or fixed with 10% formalin solution. Analysis was 
performed on BD LSR Fortessa II. This routinely yielded a macrophage population of >90% 
purity as assessed by flow cytometry for CD11b and F4/80. Alternatively, to assess cell 
morphology, cells were counted using nucleocassettes (941-0002, Chemometec, Denmark) 
and a nucleocounter (SCC-100, Chemometec, Denmark) and cytospins created (20-40,000 
cells per slide) using a Shandon Cytospin 4 cytocentrifuge (Thermo Scientific). Cells were 
then fixed and stained using Quik-Diff kit (Reagena, UK).  
Primary murine hepatocytes were prepared using a modified two-stage perfusion technique 
(http://tools.invitrogen.com/content/sfs/manuals/3736.pdf). Briefly, adult male C57BL/6 
mice were anaesthetised with intraperitoneal Ketamine and Medetomidine. Following 
cannulation of the portal vein with a 24G intravenous cannula (BD biosciences), livers were 
perfused with 50ml Liver Perfusion Medium (Gibco, UK) followed by 50ml Liver Digestion 
Medium (Gibco, UK), the perfusion fluid exiting via a cut in the IVC. Livers were then 
removed aseptically into a 50ml BD falcon tube containing 15ml of Williams E culture 
medium (Gibco, UK) on ice. Hepatocytes were then released gently by pipetting with a 5ml 
pipette. Cells were filtered through a 100µm cell strainer (BD biosciences) and harvested by 
low speed centrifugation at 50G for 5 mins. Hepatocytes were washed x3 in cold hepatocyte 
wash medium (Gibco, UK), then plated into tissue culture flasks (T162) which had been 
precoated with collagen (10μg/cm
2
 Rat Tail Collagen; Sigma) for 4 hours.  Hepatocytes were 
cultured overnight at 37
o
C 5%CO2 Williams E medium (Gibco, UK) supplemented with 
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10% FCS and 1% Pen/Strep solution. For preparation of hepatocyte debris, adherent viable 
hepatocytes were washed with PBS then detached using trypsin and washed x 2 with PBS. 
Hepatocytes in suspension were counted then cultured in suspension in serum-free Williams 
E medium containing Anti-Mouse CD95 (1/500 dilution; Clone Jo-2; BD Pharmingen) at 
37
o
C for 8 hours. This yielded a population >95% trypan blue positive hepatocytes. 
Apoptotic thymocytes were prepared as previously described (Ferenbach et al., 2010). 
Briefly, thymi were removed aseptically from C57BL/6 mice, aged 3-5 weeks. Thymi were 
aseptically homogenised between microscope slides in RPMI 1640 medium, enabling 
extraction of thymocytes. Thymocytes were cultured in RPMI 1640 medium supplemented 
with Dexamethasone (1 µM; Mayne Pharma, UK) and 1% FCS at 37
o
C 5%CO2 for 16 hours. 
Cells were then harvested by centrifugation at 300g for 10 mins and washed x 3 with PBS 
before use in further experiments. An aliquot of cells was taken for cell counting and was 
also stained with trypan blue. Routinely, this methodology yielded a population of dead 
thymocytes, with over 90% trypan blue positive. 
For the phagocytosis assay, 2x10
5
 BMDMs were seeded per well in 12-well plates followed 
by addition of 5x10
5
 washed dead hepatocytes (or control medium), 1 x 10
6
 washed dead 
thymocytes or Liposomes (liposomal PBS, provided by Nico Van Rooijen (Van Rooijen and 
Sanders, 1994) 1:10 dilution by volume (or PBS control)) and cultured for 16 hrs (or 12 hrs 
for thymocytes) at 37
o
C 5%CO2 in DMEM/F12 Glutamax (Gibco, UK) medium with 10% 
FCS. Where stated, inhibitors PD98059 (50µM; Cayman Chemical), UO126 (20µM; New 
England Biolabs), SB203580 (10 µM; Cayman Chemical) or DMSO control were added to 
the plated BMDMs, for 1 hr prior to and maintained throughout the 16 hr incubation with 
hepatocyte debris. Supernatants were then harvested, cellular debris removed by 
centrifugation at 400g for 15 mins and residual supernatant removed and stored at -80
o
C. For 
cellular data, non-ingested hepatocytes or liposomes were removed by vigorous washing x3 
with PBS and residual adherent macrophages used for further analysis. Prior to harvest, these 
adherent macrophages were viewed by phase contrast microscopy using a Nikon Eclipse 
E600 microscope and photographed. In control wells containing hepatocyte debris alone,  no 
adherent cells were detected.  
In some studies, after harvest of the cultured murine hepatocytes and prior to the incubation 
in suspension with anti-CD95, hepatocyte debris was fluorescently labelled using the red 
membrane dye PKH26 (Sigma-Aldrich) according to the manufacturers’ protocol. Induction 
of hepatocyte death then proceeded as described, apart from cells being incubated in the 
dark. In the same experiment, BMDMs, after 7 days of differentiation and prior to plating in 
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12 well plates for phagocytosis assay, were fluorescently labelled using Celltracker™ Green 
(Invitrogen) as per the manufacturers protocol. Co-culture with PKH26 labelled hepatocyte 
debris (or medium control) was then performed for 16 hours. Following vigorous washing, 
cells were examined by fluorescence microscopy using a Nikon Eclipse E600 microscope 
and NIS-Elements D3.1 Software. 
RNA extraction and quantitative RT-PCR 
For whole liver, the caudate lobe was snap frozen in liquid nitrogen and stored at -80
o
C. 
RNA was extracted using Trizol reagent (Invitrogen) and RNeasy mini columns (Qiagen) 
according the manufacturers protocol, followed by quantification using Nanodrop 
Spectrophotometer (Thermo Scientific). 1μg of RNA was reverse transcribed using 
Superscript III (Invitrogen) according to the manufacturers protocol. Gene expression was 
calculated using the ΔΔCT method relative to housekeeping gene 18S. 
For FACS sorted cells, RNA was extracted using RNeasy micro plus kit (Qiagen) according 
to the manufacturers protocol. RNA was quantified using Nanodrop Spectrophotometer 
(Thermo Scientific) and 10ng of RNA was reverse transcribed and amplified using Whole 
Transcriptome kit (Qiagen) as per the manufacturers’ protocol. Gene expression was 
calculated using the ΔΔCT method relative to housekeeping gene β2M. 
For the in vitro phagocytosis assay, RNA was extracted using RNeasy micro plus kit 
(Qiagen) and 100ng RNA reverse transcribed using Superscript III (Invitrogen) as per the 
manufacturers protocol. Gene expression was calculated using the ΔΔCT method relative to 
housekeeping gene β2M. 
Where stated relative gene expression was calculated by normalising to the mean expression 
of one group which was assigned a value of 1. 
The following primer or primer/probe sets were purchased - 18S eukaryotic primer/probe set 
(Ambion AM1718), β2M (ABI, Mm00437762_m1), Chi3l3 (ABI, Mm00657889_mH), Ccr2 
(ABI, Mm00438270_m1), Cx3cr1 (ABI, Mm02620111_s1), Igf1 (Qiagen QT 00154469), 
Thbs1 (Qiagen QT01748187), Il-1β (Qiagen QT01048355) and Cxcl10 (Qiagen, 
QT00093436). The remaining primer sequences were designed using primer express 
software and the sequences are as follows:  
TIMP-1 (Forward CAT GGA AAG CCT CTG TGG ATA TG; Reverse AAG CTG CAG 
GCA CTG ATG TG; Probe CTC ATC ACG GGC CGC CTA AGG AAC) 
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MMP9 (Forward CGA ACT TCG ACA CTG ACA AGA AGT; Reverse GCA CGC TGG 
AAT GAT CTA AGC; Probe TCT GTC CAG ACC AAG GGT ACA GCC TGT TC) 
MMP12 (Forward GAA ACC CCC ATC CTT GAC AA; Reverse TTC CAC CAG AAG 
AAC CAG TCT TTA A; Probe AGT CCA CCA TCA ACT TTC TGT CAC CAA AGC) 
CCL2 (Forward CTT CTG GGC CTG CTG TTC A; Reverse CCA GCC TAC TCA TTG 
GGA TCA) 
Genes were then analysed using either TaqMan Express qPCR supermix (Invitrogen) or 
Quantifast SYBR green PCR kit (Qiagen), on an ABI 7500Fast Realtime system, according 
to the manufacturers’ instructions. 
Immunohistochemistry and Immunofluorescence 
Following harvest, liver tissue was fixed overnight in 10% neutral buffered formalin (Sigma) 
or Methacarn (60% Methanol: 30% Chloroform: 10% Glacial Acetic acid) solution, followed 
by paraffin embedding. Human cirrhotic liver was fixed in formalin. 4μm tissue sections 
were dewaxed and rehydrated in decreasing concentrations of ethanol. Where stated, antigen 
retrieval was performed by boiling for 15 mins in 10mM Sodium Citrate buffer, pH6. 
Endogenous peroxidise activity was inhibited with 3% hydrogen peroxide followed by 
Avidin/biotin block (Vector Labs) and then non-specific binding minimised using protein 
block solution (Dako). Primary antibody was then applied. All primary antibodies were 
incubated overnight at 4
o
C. Species appropriate anti-IgG biotinylated secondary antibodies 
(Dako) were used at 1/300 dilution, at room temperature for 1hr. Immunostaining was 
developed using 3,3’-diaminobenzidine (DAB; Dako, UK). The following primary 
antibodies and conditions were used: Collagen 1 (Southern Biotech 1310-08; 1/100 dilution; 
Formalin-fixed; Antigen Retrieval), Collagen 3 (Southern Biotech 1330-01; 1/100 dilution; 
Formalin-fixed; Antigen Retrieval), α-SMA (Sigma-Aldrich Clone 1A4; 1/4000 dilution; 
Formalin-fixed; Antigen Retrieval), F4/80 (Abcam ab6640; 1/200 dilution; Formalin-fixed; 
No Antigen Retrieval), Chi3l3 (Stemcell Technologies 01404; 1/100 dilution; Formalin-
fixed; Antigen Retrieval), MMP-12 (Santa Cruz sc-8839; 1/240 dilution; Formalin-fixed; 
20mins Antigen Retrieval), Murine and Human Gpnmb (Santa Cruz sc-47006; 1/200 
dilution; Formalin-fixed; 15mins antigen retrieval), Human MMP-12 (Abcam AB52897; 
1/400 dilution; 20 mins antigen retrieval by boiling in Tris-EDTA pH9). Picrosirius red 
staining was performed according to standard protocols. Where stated, morphometric pixel 
analysis to quantify histological staining was performed. Briefly, sections were blinded and a 
minimum of 20 non-overlapping fields per section were photographed at x100 magnification 
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using a Nikon Eclipse E600 microscope and camera (DXM1200F) and acquired using NIS-
Elements D3.1 Software. All images had a matched exposure time and light intensity. Pixel 
counts of positive staining were performed in Adobe Photoshop CS2 and expressed as a % of 
the total pixel count and hence % area. Where stated relative % area was calculated by 
normalising to the mean % area of one group which was assigned a value of 1. Where stated, 
cell counts were performed at x200 magnification on blinded slides, with a minimum of 20 
non-overlapping fields counted per mouse. 
Dual immunofluorescence for F4/80 and phospho-ERK was performed on formalin fixed 
paraffin embedded sections. Tissue was prepared and blocked with protein block solution 
(Dako) then sequentially incubated first with F4/80 (Abcam ab6640) or isotype control at 
1:100 for 2 hours, rinsed, then rabbit anti-rat HRP (1/300 Dako P0450) was added followed 
by the TSAT Plus Cyanine 3 System (PerkinElmer NEL744B001KT). Sections were then 
antigen retrieved for 10 mins with 10mM sodium citrate buffer and blocked again with 
protein block solution (Dako). The second primary antibody pERK (Cell signalling 4370) or 
isotype control was incubated at 1:100 overnight followed by donkey anti-rabbit Alexa 488 
(Invitrogen A21206). Sections were mounted in dapi hard set mounting medium (Vector 
Labs H1500). All photographs were taken using a Nikon Eclipse e600 microscope and 
camera (DXM1200F) and acquired using NIS–Elements D software (Nikon) 
For dual immunofluorescence on human tissue for CD68 and MMP-12, antigen retrieval 
(20mins; Tris EDTA pH9) was followed by protein block (Dako X0909), then sequential 
incubation with anti-MMP-12 (Abcam ab52897; 1/100 dilution; overnight) or isotype control 
then donkey anti-rabbit Alexa 488 (Invitrogen A21206), followed by protein block, followed 
by anti-CD68 (Dako M0867; 1/50 dilution; 2 hrs) or isotype control followed by donkey 
anti-mouse Alexa 555 (Invitrogen A31570). For CD68 and GPNMB, antigen retrieval 
(15mins; Tris EDTA pH9), followed by protein block (Dako X0909), then sequential 
incubation of GPNMB (Santa Cruz sc47006; 1/100 dilution; overnight) or isotype control 
followed by donkey anti goat Alexa 488 (Invitrogen A11055) followed by protein block, 
followed by anti-CD68 (Dako M0867; 1/50 dilution; 2 hrs) or isotype control followed by 
donkey anti mouse Alexa 555 (Invitrogen A31570). For both, sections were then blocked 
with 0.1% Sudan Black B (Sigma) and mounted with Dapi hard set mounting medium 
(Vector Labs H1500). All photographs were taken using a Nikon Eclipse e600 microscope 








 macrophage subsets was performed 
using TACS
®
 TdT-Fluor In Situ Apoptosis Detection Kit – Fluorescein (R&D systems) 
according to the manufacturers’ protocol. Briefly, cells were obtained by FACS sorting of 
liver digests as before. Cells were resuspended in 3.7% buffered formaldehyde for 10 mins, 
then in 80% ethanol and spotted onto microscope slides. They were then dried for 2 hours at 
45
o
C, then immersed in 70% ethanol for 10 mins and then dried at room temperature 
overnight. Slides were then stored at -20
o
C. For labelling, cells were rehydrated by 
immersing for 5 minutes each in 100%, 95%, and 70% ethanol, then immersed PBS and 
stained according to the manufacturers’ protocol. The association between apoptotic debris 
and macrophages was assessed using a Leica SP5 Confocal microscope with z-stacks on 
each field. Images were blinded and analysed using ImageJ software for the presence of cell-
surface or intracellular apoptotic debris. A minimum of 25 macrophages were counted per 
slide. The percentage of macrophages associated with TUNEL-positive nuclei was quantified 
followed by quantification of the localisation of the apoptotic debris. 
Western blotting and Zymography 
For TIMP-1 western blotting, whole tissue protein extracts were made by homogenisation of 
samples in lysis buffer (50mM HEPES, 1mM DTT, 0.1mM EDTA, 0.1% CHAPS, pH 7.4). 
Protein concentration was determined by Bradford Assay and equal amounts (20µg of 
protein/well) were subjected to SDS-PAGE on 12% gels. Following electrophoresis, samples 
were transferred onto nitrocellulose membranes and blocked for 2 hrs at room temperature in 
5% non-fat dry milk in tris-buffered saline + 0.1% Tween (TBST). Membranes were 
incubated overnight at 4
o
C with primary antibody in TBST containing 5% BSA (TIMP-1 at 
1:500 dilution, Calbiochem, UK, 7-6C1). Membranes were then washed (x3, 15 minutes 
each) in TBST before the addition of an HRP-conjugated secondary antibody (1:2000 
dilution; Abcam) in TBST containing 5% non-fat dry milk for 1 hour at room temperature. 
Following incubation, membranes were washed again (x3) in TBST for 15 minutes each, 
followed by development using enhanced chemiluminescence (ECLplus, Amersham, UK) 
and visualization on a VersaDoc. 
For western blotting and zymography on in vitro phagocytosis assays, culture supernatants 
were harvested. Protein levels were quantified using Bradford reagent (Sigma-Aldrich) and 
equalised with PBS to ensure equal protein loading. Gelatin zymography was performed as 
previously described (Souza-Tarla et al., 2005). Briefly, samples were subjected to 
electrophoresis on a 10% SDS-PAGE gel co-polymerised with 1% gelatin substrate. 
Following electrophoresis, gels were renatured in 2.5% Triton X-100 for 30 minutes before 
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incubation in activity buffer (50mM Tris, 200mM NaCl, 5mM CaCl2 (anhydrous), 0.02% 
Brij-35, pH 7.5) at 37
0
C for 16-24 hrs. Gels were then stained with 0.5% Coomassie Brilliant 
Blue before destaining in 40% methanol, 10% acetic acid. MMP-9 gelatinolytic activity was 
detected as destained bands against a background of coomassie stained gelatin. The active 
form of MMP-9 was detected at 92kDa. Casein zymography was performed as previously 
described (Poppelmann et al., 2002, Pellicoro et al., 2011). Equalised culture supernatants 
were subjected to electrophoresis on a 12% SDS-PAGE gel containing 0.25% skimmed milk 
powder. Following electrophoresis, gels were rinsed in deionised water and renatured in 
2.5% Triton X-100 for 1 hour before incubation in activity buffer (50mM Tris, 200mM 
NaCl, 5mM CaCl2, 0.02% Brij-35, pH 7.5) at 37°C for 72 hours. Subsequently, the gel was 
stained with SimplyBlue Safe Stain (Life Technologies, UK) before destaining in water. 
Proteolytic activity was detected as destained bands against a background of SimplyBlue 
stained casein. For MMP-12 western blotting, media from the phagocytosis assay were 
freeze-dried and equalised resuspended samples were subjected to SDS-PAGE on a 10% 
gels. Following electrophoresis, samples were transferred onto nitrocellulose membranes and 
blocked for 2hrs at room temperature in 3% BSA (Sigma-Aldrich) in tris-buffered saline + 
0.05% Tween (TBST). Membranes were incubated overnight at 4
o
C with primary antibody 
in TBST containing 3% BSA (MMP-12 at 1:1000 dilution, Biomol International, SA453-
0100). Membranes were then washed (x3, 10 minutes each) in TBST before the addition of 
an HRP-conjugated secondary antibody (1:2000 dilution; Abcam) in TBST containing 5% 
non-fat dry milk for 1 hour at room temperature. Following incubation, membranes were 
washed again (x3) in TBST for 10 minutes each, followed by development using Immobilon 
western Chemiluminescent HRP Substrate (Millipore, UK) and visualization on a 
VersaDoc
TM
 Imaging system (BioRad). 
ELISA 
For tissue cytokine ELISA, whole tissue protein extracts were made in T-PER (Thermo 
Scientific) (containing protease inhibitors aprotinin 10µg/ml, leupeptin 10µg/ml and PMSF 
1mM). A Bradford assay was performed and samples equalised to a total protein 
concentration 50μg/μl. These were then assayed using Bio-plex mouse cytokine assay (Bio-
Rad, UK) according to the manufacturers’ protocol. 
Serum analysis 
At the time of harvest, whole blood was collected from the Inferior Vena Cava (IVC) and 





and analysed for Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) 
levels using a standard bioanalyser. 
Statistical Analysis  
All data are expressed as Mean±S.E.M. Statistical analysis was performed using GraphPad 
Prism 5 software. For analysis, data was first tested for normality. If data was normally 
distributed, statistical evaluation of multiple groups was performed using a one-way 
ANOVA with post-hoc Tukey test. Statistical evaluation of 2 groups was performed using a 
Student’s t-test. If not normally distributed, comparison between multiple groups was 
performed using a Kruskal-Wallis test with Dunn’s multiple comparison and comparison 
between 2 groups was performed using a Mann-Whitney test.  A value of P < 0.05 was 




CHAPTER 3 – CHARACTERISATION OF 
HEPATIC MACROPHAGE 
HETEROGENEITY IN MURINE MODELS 





The overall aim of this work was to study macrophage heterogeneity in the resolution of 
hepatic fibrosis. As discussed previously, the majority of the work identifying and 
characterising distinct monocyte and macrophage subsets has been done in murine models, 
requiring identification of a number of cell surface markers to distinguish distinct 
populations. Currently there is much more limited data on differentiating macrophage 
subsets with more limited reagents available in rats. I therefore aimed to establish a robust, 
reproducible and predictable murine model of reversible hepatic fibrosis to enable in depth 
study of monocyte and macrophage dynamics. 
Carbon tetrachloride (CCl4), a solvent previously used as a refrigerant, is the most widely 
used hepatotoxin in experimental hepatic fibrosis models. CCl4, when administered in vivo, 
is metabolised by the hepatic Cyp2E1 enzyme system, forming trichloromethyl peroxy free 
radicals, which result in lipid peroxidation followed by cell membrane damage and loss of 
integrity, activation of intracellular calcium-dependent proteases, ultimately leading to 
hepatocyte death, via apoptosis and necrosis (Manibusan et al., 2007, Shi et al., 1998). Given 
that Cyp2E1 is predominantly expressed in centrilobular (zone 3) hepatocytes, the majority 
of cell death occurs in this region of the liver (Shi et al., 1998). This is analogous to alcohol 
related liver damage and NASH which are also related to hepatic Cyp2E1 activity, resulting 
in free radical production, lipid peroxidation and zone 3 hepatocyte damage (Lieber, 2004). 
Chronic iterative administration of CCl4 results in recurrent hepatocellular death, leading to a 
wound-healing response and ultimately to liver fibrosis and cirrhosis, showing histological 
similarities to human chronic liver disease (Perez Tamayo, 1983). Furthermore, in rodent 
models, cessation of chronic CCl4 dosing results in matrix remodelling and fibrosis 
resolution in a manner very similar to that seen in human disease (Issa et al., 2004, Wanless 
et al., 2000). Bile duct ligation followed by biliary re-anastamosis, the other widely-used 
model of reversible hepatic fibrosis (Issa et al., 2001), is generally only used in rats and 
would be very technically challenging to perform reliably in mice. Thus, a CCl4 model of 
reversible hepatic fibrosis would be a reproducible, tractable and clinically relevant model 
with which to study hepatic macrophage biology. 
Thioacetamide (TAA) is another hepatotoxin, widely-used in experimental fibrosis models. 
TAA is hepatotoxic via effects on DNA, RNA and protein synthesis and induction of 
changes in intrahepatic metabolism (Noda et al., 1996). Continuous administration of TAA 
to rats in drinking water causes a distinct pattern of fibrosis/cirrhosis to that seen with CCl4 
administration. Specifically, marked biliary proliferation is seen, with an associated fibrotic 
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response and the progressive development of micronodular cirrhosis (Jeong et al., 2001, 
Noda et al., 1996). Furthermore, whilst some reversibility still exists, overall the liver 
fibrosis in this model seems less reversible than CCl4, with persistent cirrhosis seen after 
protracted recovery times (Gu et al., 2011, Noda et al., 1996). The use of oral TAA in mice, 
however, is only rarely described in the literature (Hung et al., 2005, Salguero Palacios et al., 
2008), with very limited data on the degree of fibrosis regression observed following 
cessation of injury. 
Given the role of macrophages in liver fibrosis resolution (Duffield et al., 2005), I sought to 
study macrophage heterogeneity in these fibrosis models, with the aim of identifying a 
specific macrophage subtype associated with the regression of liver fibrosis. As previously 
described, macrophages are multifunctional and plastic cells and the identification of 
macrophage subsets in the liver largely relies on flow cytometric analysis to simultaneously 
assess the expression of a number of cell surface markers (Holt et al., 2008, Karlmark et al., 
2009). Therefore, having developed and characterised murine liver fibrosis models, I sought 
to identify distinct hepatic macrophage populations, with the overall aim of identifying 
specific populations which were most associated with fibrosis resolution. 
In terms of the cell surface markers to be used, Holt and colleagues defined that the hepatic 
macrophage pool is principally made up of 2 populations: resident tissue macrophages 
(Kupffer cells) and a population of “induced macrophages” (IMs) which are derived from 
recruited monocytes (Holt et al., 2008). These could be defined on the basis of expression of 










. An additional marker of increasing interest is 
Ly-6C. This is a cell surface glycoprotein whose function remains uncertain, but is widely 
used to identify functionally distinct murine monocyte subsets (Gordon and Taylor, 2005, 
Ingersoll et al., 2009). More recently differential Ly-6C expression has been employed to 
identify functionally distinct murine macrophage subsets in a range of tissues including 
injured muscle, fibrotic kidney, mouse mammary tumours and ischaemic myocardium 
(Arnold et al., 2007, Lin et al., 2009, Movahedi et al., 2010, Nahrendorf et al., 2007). Indeed, 




) hepatic macrophage population, derived from 
the recruitment of Ly-6C
hi
 circulating monocytes via the CCL2-CCR2 chemokine axis, as 
being the principal pro-fibrogenic macrophage subset in the liver (Karlmark et al., 2009). 
Therefore, differential Ly-6C expression in combination with CD11b and F4/80 may 
potentially be useful in identifying distinct macrophage populations in the fibrotic liver. 
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The markers described, whilst useful in defining distinct macrophage populations, do not 
have known functional effects in liver fibrosis. One of the key features of the macrophage 
population responsible for the resolution of hepatic fibrosis is MMP expression to mediate, 
at least in part, the matrix degradation (Sakaida et al., 2003, Popov et al., 2010, Fallowfield 
et al., 2007, Pellicoro et al., 2011). Hence, when trying to define the pro-resolution hepatic 
macrophage subset, a functional readout of MMP activity will be vital. Furthermore, if this 
can be combined with flow cytometric analysis, the principal MMP expressing macrophage 
subsets could be defined. In order to achieve this, a pan-MMP substrate, MMPsense™ 680 
could be used. This MMP substrate is optically silent in its unactivated state and becomes 
highly fluorescent when cleaved by active MMPs. It is not specific to individual MMPs, but 
rather is activated by a number of key MMPs including MMP-2, -3, -9 and -13, thus giving 
an indication of overall MMP activity. In a recent study, in vivo administration of 
MMPsense™ to mice, enabled flow cytometric identification and quantification of MMP 
activity in lung eosinophils in a model of allergic airway inflammation (Cortez-Retamozo et 
al., 2008). The authors also demonstrated a critical role for MMP-12 in the in vivo activation 
of MMPsense™, an enzyme we have previously shown to be expressed in macrophages in 
the fibrotic liver, and which is critical to elastin turnover (Pellicoro et al., 2011). Hence, the 
use of MMPsense™ 680 in liver fibrosis models might identify the main MMP expressing 
and hence likely restorative macrophage population. 
AIMS 
 To establish and characterise a reversible murine model of CCl4 induced hepatic 
fibrosis 
 To determine the utility of oral TAA as a murine model of reversible hepatic fibrosis 
 To study macrophage heterogeneity in murine models of hepatic fibrosis 
 To identify a macrophage subset associated with the resolution of hepatic fibrosis 
RESULTS 
Distinct Phases of Fibrogenesis and Fibrosis Resolution Following Chronic CCl4 
Administration 
I established and characterised a model of reversible murine hepatic fibrosis by 
administration of twice weekly CCl4 to adult male C57BL/6 mice for 4 weeks (9 injections 
in total), followed by harvests at serial timepoints (24, 48, 72, 96, 168 and 256 hrs) following 
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the final CCl4 injection (as shown in Experimental Schematic Fig. 3.1A). Comparison was 
made to age-matched uninjured control mice. Previous data from within our group has 
demonstrated that olive oil (vehicle) controls are identical to uninjured mice in terms of 
fibrosis, and in any case the experimental aim was to compare time-related changes 
following CCl4 dosing, rendering olive oil controls redundant in this context.  
As shown in Figures 3.1B and 3.1C and described in the associated legend, total hepatic 
fibrosis was quantified by Picrosirius Red staining (PSR) and morphometric pixel analysis at 
each timepoint (24, 48, 72, 96, 168 and 256 hrs; n=4 per timepoint) following the final CCl4 
injection. These data demonstrate that scar accumulation is occurring at 24 hrs after the final 
CCl4 injection in this 4 week model, whilst liver fibrosis peaks 48-72 hours, followed by 
fibrosis resolution. The most rapid resolution occurs between 72 and 96 hours with a more 
progressive protracted regression thereafter. 
As shown in Figures 3.2 and Fig 3.3 and described in detail in the legends, I went on to 
assess hepatic levels of the main fibrillar collagens, Collagen 3 and Collagen 1 respectively, 
by immunohistochemical staining and morphometric pixel analysis. Analysis was again 
performed on tissue harvested 24, 48, 72, 96, 168 and 256 hrs (n=4 per timepoint) following 
the final CCl4 injection after 4 weeks of iterative injury, with comparison to age-matched 
uninjured control mice. These data again demonstrate that net collagen deposition is 
occurring at 24 hrs after the final CCl4 with hepatic collagen levels peaking at 48-72 hrs, 
followed by fibrosis resolution with the most rapid resolution occurring between 72 and 96 
hrs.  
I then proceeded to quantify myofibroblast activation, the main scar producing cells in 
hepatic fibrosis, by immunohistochemistry and morphometric pixel analysis of α-SMA (as 
shown in Fig 3.4 and described in the legend), using the same experimental timepoints as 
before (n=4 per timepoint). In keeping with the observed timing of scar accumulation and 
peak fibrosis, myofibroblast activation is high between 24 and 72 hrs following the final 
CCl4 injection, followed by a rapid loss of α-SMA expression between 72 and 96 hrs with a 
more protracted loss of the residual myofibroblasts thereafter. 
In order to confirm the consistency and reproducibility of these findings, this experimental 
time course has been repeated in our group in 2 independent experiments, with 4-6 mice per 
timepoint (in collaboration with Dr Steven Hartland). These studies showed an identical 
pattern to that presented in Fig 3.1 to 3.4. Furthermore, as shown and described in the 
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respective figure legends, the changes observed in this model show statistically robust 





Figure 3.1 – Murine Model of Reversible of Hepatic Fibrosis 
(A) Schematic representation of model of reversible hepatic fibrosis in C57BL/6 mice by 4 
weeks of twice-weekly intraperitoneal carbon tetrachloride (CCl4) followed by harvest at 
serial timepoints following the final injection. Comparisons were made to control (uninjured) 
animals. (B) Representative images of hepatic picrosirius red staining (PSR) are shown for 
control animals and each timepoint (Scale bar=100μm). (C) Quantification of histological 
changes of PSR by morphometric pixel analysis (Expressed relative to mean % area of 








Figure 3.2 – Quantification of Hepatic Collagen 3 following Cessation of CCl4 Injury 
(A) Representative images of hepatic collagen 3 immunohistochemistry are shown for 
control (uninjured) animals and each timepoint following cessation of CCl4 (Scale 
bar=100μm). (B) Quantification of histological changes of Collagen 3 by morphometric 
pixel analysis (Expressed relative to mean % area of control animals; n=4 per timepoint). 






Figure 3.3 - Quantification of Hepatic Collagen 1 following Cessation of CCl4 Injury 
(A) Representative images of hepatic collagen 1 immunohistochemistry are shown for 
control (uninjured) animals and each timepoint following cessation of CCl4 (Scale 
bar=100μm). (B) Quantification of histological changes of Collagen 1 by morphometric 
pixel analysis (Expressed relative to mean % area of control animals; n=4 per timepoint). 







Figure 3.4 - Quantification of Hepatic Myofibroblast Activation following Cessation of 
CCl4 Injury  
(A) Representative images of hepatic α-smooth muscle actin (α-SMA) 
immunohistochemistry are shown for control (uninjured) animals and each timepoint 
following cessation of CCl4 (Scale bar=100μm). (B) Quantification of histological changes 
of α-SMA by morphometric pixel analysis (Expressed relative to mean % area of control 







Fibrosis Resolution following Chronic CCl4 Occurs Following a Reduction in Hepatic 
Inflammation and TIMP-1 levels 
Given the close relationship between inflammation and fibrosis, I sought to determine the 
temporal relationship between the changes in hepatic fibrosis and hepatic inflammation in 
the 4 week CCl4 model which I have described (Fig 3.1A). Alanine transaminase (ALT) and 
Aspartate transaminase (AST) are enzymes normally present within hepatocytes and are 
released into the circulation following hepatocyte death. Thus, serum levels of ALT and AST 
are surrogates for the degree of liver damage in both human disease and animal models. 
Measurement of serum ALT and AST at 24, 48, 72, 96 and 168 hrs following the final CCl4 
injection after 4 weeks of injury (n=5-6 per timepoint from 2 independent experiments), 
demonstrated that both serum AST and ALT peaked at 24 hrs, the time of active scar 
accumulation above, and had returned to baseline levels by 72 hrs (Fig. 3.5A). 
To more directly study the degree of hepatic inflammation in the 4 week CCl4 model, I 
proceeded to quantify hepatic protein levels of a number of inflammatory cytokines and 
chemokines at 24, 48, 72, 96 and 168 hrs following the cessation of CCl4 injections (Fig 
3.5B; n=7-9 per timepoint from 2 independent experiments). In order to do this I established 
a method utilising a multiplex cytokine ELISA on whole liver homogenates. As shown, 
hepatic levels of important pro-inflammatory cytokines and chemokines IL-1β, CCL2, CCL3 
and CXCL2 peak at the 24 hr timepoint and have rapidly declined by 72 hrs (Fig 3.5B). 
Using the same multiplex ELISA, no significant differences were detected in hepatic levels 
of TNF-α, IFN-γ, IL-4, IL-13, IL-10, IL-6, RANTES, CCL4 or CXCL1 at the studied 
timepoints. However, technical issues such as the sensitivity of the assay or the stability of 
individual proteins during sample preparation must be considered in the interpretation of 
these negative results 
Our group and others have previously shown that a reduction in hepatic TIMP-1 levels 
causes an increase in matrix degrading activity and is a pre-requisite for fibrosis resolution 
(Iredale, 2007, Iredale et al., 1998, Ramachandran and Iredale, 2009). In my 4 week CCl4 
model, I proceeded to quantify whole liver TIMP-1 at a gene (Fig 3.5C; n=4-8 from 2 
independent experiments) and protein level (Fig. 3.5D). These data demonstrate that in this 
model, TIMP-1 levels peak at 24 hrs and have declined by 72 hrs.  
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Figure 3.5 – Quantification of Hepatic Inflammation and TIMP-1 levels following 
Cessation of CCl4 Injury 
(A) Serum Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) levels in 
control (uninjured) mice and at stated timepoint following the final CCl4 injection (n=5-6 per 
timepoint from 2 independent experiments). (B) Whole liver protein levels of IL-1β, CCL2, 
CCL3 and CXCL2 measured by multiplex cytokine assay at stated timepoint following final 
CCl4 injection (Expressed relative to mean protein concentration at 24 hr timepoint for each; 
n=7-9 per timepoint from 2 independent experiments). (C) Whole liver Timp-1 gene 
expression measured by qPCR at stated timepoints following the final CCl4 injection 
(Expressed relative to mean expression at 24 hr timepoint; n=4-8 from 2 independent 
experiments). (D) Whole liver TIMP-1 protein expression assessed by western blot 
(representative blot shown; Blot performed in collaboration with Dr Timothy Gordon-







High Dose Oral TAA Administration to Mice Causes a Progressive Fibrotic Response 
I sought to determine the utility of oral thioacetamide (TAA) as a second murine model of 
hepatic fibrosis. I established cohorts of C57BL/6 mice on either low dose (300mg/l) or high 
dose (600mg/l) thioacetamide in their drinking water, with tissue harvests following 8, 12, 
16, 20, 36 and 52 weeks of treatment (as shown in Fig 3.6A and described in the legend). 
These animals were compared to uninjured control animals, maintained on normal water.  
Animals were weighed weekly throughout the experimental protocol. As shown, both doses 
of TAA caused a significant reduction in the animals’ weight, and inhibited weight gain 
throughout the treatment period (Fig 3.6B). Livers were analysed for total hepatic fibrosis by 
picrosirius red (PSR) staining and morphometric pixel analysis following treatment with 
each dose of TAA for 8, 12, 16, 20, 36 and 52 weeks (Fig 3.6C and 3.6D; n=2-7 per 
timepoint). As shown, treatment with low dose TAA, even for 52 weeks, did not induce a 
significant degree of hepatic fibrosis (Fig 3.6C and 3.6D). However, high dose TAA caused 
a progressively worsening degree of hepatic fibrosis over the treatment duration, with 
statistically significant increases in PSR staining detectable as early as 8 weeks of treatment 
(Fig 3.6C and 3.6D). Indeed, morphological analysis of livers from animals after 52 weeks 
of high dose TAA demonstrates established cirrhosis (Fig 3.6C). Importantly administration 




Figure 3.6 – High Dose Oral Thioacetamide induces a Progressive Hepatic Fibrosis 
(A) Schematic representation of model of thioacetamide (TAA) induced hepatic fibrosis in 
male C57BL/6 mice. TAA was administered continuously in the drinking water at either low 
dose (300mg/L; blue) or high dose (600mg/L; red) to adult mice. Animals were harvested 
following stated durations on TAA treatment. Comparisons were made to control animals, 
maintained on normal drinking water. (B) Average mouse weight was measured on a weekly 
basis during treatment with low dose and high dose TAA and compared to weight on normal 
drinking water (n=3-39). (C) Representative images of hepatic picrosirius red staining (PSR) 
are shown for treatment with low and high dose TAA for the stated duration (Scale 
bar=100μm). (D) Quantification of histological changes of PSR by morphometric pixel 
analysis compared to control (8 weeks of water) animals (Expressed relative to mean % area 








Liver Fibrosis following High Dose Oral TAA is Irreversible in the Short-Term 
Having established that high dose oral TAA induces detectable hepatic fibrosis by 8 weeks 
of treatment and cirrhosis by 52 weeks (Fig 3.6C and 3.6D), I then aimed to determine 
whether fibrosis induced by oral TAA was reversible and could be used as a fibrosis 
regression model. C57BL/6 mice were administered high dose oral TAA (600mg/l) 
continuously in the drinking water for either 8 weeks or 52 weeks. Cohorts of animals were 
then changed back onto normal drinking water and organs harvested at 72 hrs (for 8 week 
treatment group only) and 1, 2 and 8 weeks following the cessation of TAA treatment (as 
shown in Fig 3.7 and described in the legend). Comparison was made to an age-matched 
control group, kept on normal water throughout. To assess hepatic fibrosis, livers were 
harvested and stained for PSR followed by morphometric pixel analysis. As shown, 
following 8 weeks of 600mg/l TAA treatment, no significant regression of liver fibrosis was 
observed for recovery times of up to 8 weeks (Fig 3.7A; n=4-5 per timepoint). Similarly, 
after high dose TAA treatment for 52 weeks, no significant fibrosis reversibility was evident 




Figure 3.7 – Liver Fibrosis following High Dose Oral TAA is Irreversible in the Short 
Term 
(A) Quantification of histological changes of PSR by morphometric pixel analysis  in 
C57BL/6 mice treated with high dose TAA for 8 weeks, followed by conversion onto normal 
drinking water (recovery) for the stated amount of time (Expressed relative to mean % area 
of control (uninjured) animals; n=4-5). (B) Quantification of histological changes of PSR by 
morphometric pixel analysis  in C57BL/6 mice treated with high dose TAA for 52 weeks, 
followed by conversion onto normal drinking water (recovery) for the stated amount of time 









Macrophages Localise around Hepatic Scars at Maximal Fibrosis Resolution 
Having characterised the CCl4 and TAA models in terms of fibrosis, I then wished to study 
the macrophage populations. I initially wanted to assess whether there were any gross 
differences in macrophage localisation during the distinct phases of 
inflammation/fibrogenesis, maximal fibrosis resolution and late resolution in the 4 week 
CCl4 model. I focussed on key timepoints of 24 hrs, 72 hrs and 168 hrs following the final 
CCl4 injection. As shown previously (Fig 3.1 to 3.4), these points represent a time of active 
scar deposition (24 hrs), the initiation of maximal scar resolution (72 hrs) and a time of more 
protracted fibrosis regression (168 hrs). 
F4/80 is a cell surface glycoprotein, which is used a murine pan-macrophage maker. 
Immunohistochemistry for F4/80 in livers in the CCl4 model demonstrated a clear 
topographic change during the distinct phases (Fig 3.8A). At 24 hrs, the time of hepatic 
inflammation and fibrogenesis, F4/80 positive macrophages are diffusely infiltrating the liver 
parenchyma, with numerous cells in Zones 1 and 2, surrounding the areas of maximal 
hepatocyte death (centrilobular, Zone 3). At 72 hrs, the time of maximal fibrosis resolution, 
there is a clear association between liver macrophages and the hepatic scars. Indeed, the 
areas of scar can be easily identified by the localisation of F4/80 staining, without the need 
for collagen staining. By 168 hrs, when the majority of scar has resolved, F4/80 hepatic 
macrophages were fairly homogenously distributed through the liver parenchyma. 
Hepatic Macrophage Number Peaks at Maximal Fibrosis Resolution 
I proceeded to study the hepatic macrophage populations in the 4 week CCl4 model, using 
multicolour flow cytometry at the key timepoints of 24 hrs, 72 hrs and 168 hrs, compared to 
livers from age-matched uninjured mice. Hepatic Non-Parenchymal Cells (NPCs), 
containing the hepatic leukocyte pool, were isolated from livers at the stated timepoints 
using a digestion technique as described in detail in Chapter 2. Of note, livers were perfused 
with saline prior to harvest to remove contamination from circulating cells. Hepatic 
macrophages were then identified using flow cytometry of NPCs. In order to specifically 
identify hepatic macrophages a stringent gating strategy was used (Fig. 3.8B). In summary, 
non-viable cells were excluded initially using a live-dead marker. I then proceeded to define 
all hepatic leukocytes using the pan-leukocyte marker CD45. On this viable CD45
+
 




cells and T cells, B cells and 
NK cells identified by positivity for CD3, B220 and NK1.1. Both the neutrophils and these 
other immune populations were excluded from further analysis when defining the 
87 
 



















cells. The genuine nature of all staining was confirmed by comparison to appropriate 
isotype control antibodies. This strategy robustly and reproducibly identified macrophages 
on the basis of expression of 2 specific markers, whilst minimising contamination from other 
immune cells such as neutrophils, NK cells, B cells and T cells. This therefore represents the 
most specific method for studying macrophage heterogeneity. 
Having identified hepatic macrophages by flow cytometry, I proceeded to quantify the total 
number of macrophages in the CCl4 model during inflammation/fibrogenesis (24 hrs), 
maximal resolution (72 hrs) and late resolution (168 hrs), in comparison to age matched 
uninjured mice (Fig 3.8C; n=8-12 per timepoint). Macrophage number was initially 
quantified as a proportion of total NPCs by flow cytometry, which enabled quantification of 
absolute number per liver on the basis of total NPC counts. As shown in Fig 3.8C and 
described in the legend, hepatic macrophage number, whilst increased compared to uninjured 
controls at the 24 hr timepoint, actually peaked at the 72 hr timepoint and returned towards 
baseline by 168 hrs.  This indicates that the maximum numbers of macrophages are present 
at the initiation of scar resolution (72 hrs) in this model.  
I was also able to quantify the number of hepatic neutrophils, which have also been 
associated with fibrosis resolution by some authors (Harty et al., 2008, Harty et al., 2010). 
As shown, hepatic neutrophil number peaked at 24 hrs, having returned to near control levels 




Figure 3.8 – Identification and Quantification of Hepatic Macrophages in 
Reversible Fibrosis Model 
Analysis of hepatic macrophages after the final CCl4 injection following 4 weeks of injury. 
(A) F4/80 immunohistochemistry of livers at stated timepoint following the final CCl4 
injection indicates that macrophages localise around areas of scar at time of maximal fibrosis 
resolution (72 hrs) (representative images shown; scale bar=100μm). (B) Gating strategy for 
identification of hepatic macrophages. The hepatic non-parenchymal cell fraction was 
isolated. Viable cells were selected by propidium iodide (PI) exclusion. CD45 positive viable 
cells were gated. Cells positive for CD3, B220 or NK1.1 were excluded from subsequent 
macrophage gating. Neutrophils were identified as Viable CD45+ CD11b+ and Ly-6G+ 
cells, and were excluded from subsequent macrophage gating. Macrophages were selected as 
viable CD45+ Ly-6G- NK1.1- B220- CD3- and dual-positive CD11b+ F4/80+ cells. 
Representative flow cytometry plots are shown. (C) Total hepatic macrophage number was 
quantified by flow cytometry at stated timepoint following the final CCl4 injection or in 
control (uninjured) mice (Expressed relative to mean number of macrophages in control 
liver; n=8-12 per timepoint from 2 independent experiments). (D) Total hepatic neutrophil 
number was quantified by flow cytometry at stated timepoint following the final CCl4 
injection or in control (uninjured) mice (Expressed relative to mean number of neutrophils in 
control liver; n=10-17 per timepoint from 3 independent experiments). Data shown as 










Resident Kupffer Cells are reduced during Fibrogenesis and Reaccumulate during 
Fibrosis Resolution 
Having identified hepatic macrophages on flow cytometry, I then sought to study the 
heterogeneity of these cells by examining differential expression of additional cell surface 
markers. I initially focussed on identifying the previously defined resident tissue 
macrophages (Kupffer cells) and monocyte-derived macrophages on the basis of CD11b and 
F4/80 expression (Holt et al., 2008). I performed a similar analysis on hepatic macrophages 
isolated from the CCl4 model (Fig. 3.9A). I could clearly identify 2 distinct macrophage 















resident macrophages, as expected these cells represented 
the predominant macrophage subset in uninjured control livers, making up 67.5±6.6% of the 
total macrophage pool (Fig. 3.9A and 3.9C; n=10-17 per timepoint). Using the 4 week CCl4 
fibrosis model, the relative contribution of resident macrophages to the hepatic macrophage 
pool had declined significantly at the 24 hr timepoint (12.2±3% at 24 hrs). There was then a 
progressive reaccumulation of the resident macrophage subset during fibrosis resolution, 
making up 24.9±2.5% at maximal resolution (72 hrs) and 48.7±26% during late resolution 
(168 hrs) (Fig. 3.9A and 3.9C). A similar trend was seen when absolute numbers of resident 
macrophages were quantified, and expressed relative to the total macrophage number in 
control livers (Fig. 3.9D; n=12-17 per timepoint). This confirms a reduction in resident 
macrophage number at 24 hrs and a progressive increase during fibrosis resolution. 
Differential Ly-6C Expression Identifies a Novel Hepatic Monocyte-Derived 
Macrophage Population which Accumulates at Maximal Fibrosis Resolution 
As described above, differential Ly-6C expression is potentially useful for defining distinct 





 monocyte-derived macrophage subset, isolated from livers at 24, 72 and 168 hrs 
after the final CCl4 injection in the 4 week CCl4 model (Fig. 3.9B). Using this strategy, I 





. Critically, these changed dynamically during these key timepoints. As 
shown in Fig 3.9B, quantified in Fig 3.9C (n=10-17 per timepoint) and described in detail in 
the accompanying legend, Ly-6C
hi
 macrophages represented the principal subset at 24 hrs 
(43.44±2.1% of the total macrophage pool). However at 72 hrs, the time of maximal fibrosis 
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resolution, there is loss of the Ly-6C
hi
 population and a significant increase in Ly-6C
lo
 
monocyte-derived macrophages, making up 63.6±2.8% of the macrophage population at this 
timepoint (Fig. 3.9B and 3.9C). This dramatic change is even more pronounced when 
macrophage number is quantified, demonstrating that Ly-6C
lo
 macrophages at 72 hours are 
the most numerous macrophage subset at any studied timepoint during the fibrogenesis-
resolution model, 4.14±0.5 times more than the total macrophage number in control liver 
(Fig. 3.9D; n=12-17 per timepoint). 
During late resolution (168 hrs), both the proportion and number of Ly-6C
hi
 macrophages 
had returned to control levels. There remained an increase in the number and proportion of 
Ly-6C
lo
 macrophages, but these had declined compared to the 72 hr timepoint, when matrix 




Figure 3.9 – Dynamic Changes in Hepatic Macrophage Subsets in Reversible 
Fibrosis Model 
Analysis of hepatic macrophages at stated timepoints after the final CCl4 injection following 

















 monocyte-derived macrophages on the basis of differential Ly-6C expression 




 with dynamic changes during injury 
and resolution (Representative percentages indicate each subset as a proportion of total 




 and Resident macrophage 
subsets, as a proportion of total hepatic macrophage number (n=10-17 per timepoint from 4 
independent experiments). (D) Relative number per liver of each macrophage subset at stated 
timepoint (Expressed relative to mean total macrophage number in control liver; n=12-17 per 
timepoint from 4 independent experiments). All data shown as Mean±S.E.M; *P<0.05, 








Increased Circulating Monocyte Subsets During Fibrogenesis and Fibrosis Regression 




 monocyte-derived macrophages during 
fibrogenesis and resolution, suggests changes in monocyte recruitment during these phases. I 
therefore sought to identify analogous changes in circulating monocyte number in the 4 week 
CCl4 fibrogenesis-resolution model. 
As discussed previously, 2 functionally distinct murine monocyte populations have been 
identified. Ly-6C
hi




 human monocytes) are 
recruited early to inflammatory environments and thought to be pro-inflammatory whilst Ly-
6C
lo




 human monocytes) are a more “patrolling” 
cell-type and can replenish resident tissue macrophages (Gordon and Taylor, 2005, Ingersoll 










 subsets (Fig 3.10A). 
I proceeded to quantify each monocyte subset in our 4 week CCl4 model. As shown, 
compared to normal (uninjured) animals, circulating Ly-6C
hi
 “inflammatory” monocytes, as 
a proportion of total peripheral mononuclear cells, were increased during at the 24 hr 
timepoint (Fig 3.10B; n=5 per timepoint). As shown previously, this corresponds with 
maximal hepatic levels of CCL2, the principal chemokine for this monocyte subset (Fig 
3.5B). The increase in Ly-6C
hi
 monocytes persisted at 72 hrs, whilst the relative number of 
these cells returned towards control levels by 168 hrs (Fig 3.10B). Ly-6C
lo
 “patrolling” 
monocytes were also increased at the 24 hr timepoint, although this increase was much more 















 cells. (B) Ly-6C
hi
 monocytes were quantified as a 
proportion of total circulating mononuclear cells at stated timepoints during injury and 
resolution following chronic CCl4 administration and uninjured control mice (normal) (n=5) 
(C) Ly-6C
lo
 monocytes were quantified as a proportion of total circulating mononuclear cells 
during injury and resolution following chronic CCl4 administration and uninjured control 
mice (normal) (n=5). All data expressed as Mean±S.E.M; *P<0.05, **P<0.01. 









 Macrophages Represent the Principal MMP-Expressing Subset during 
Maximal Fibrosis Resolution 
Our group and others have identified MMP expression as a key feature of the macrophage 
population responsible for the resolution of hepatic fibrosis (Sakaida et al., 2003, Popov et 
al., 2010, Fallowfield et al., 2007, Pellicoro et al., 2011). I therefore sought to determine the 
principal MMP-expressing macrophage subset in our 4 week CCl4 model, both during 
inflammation/fibrogenesis (24 hrs) and at the time of maximal fibrosis resolution (72 hrs), as 
this would indicate a functional role for these cells in scar degradation. To do this, I utilized 
the pan-MMP substrate, MMPsense™ 680, described above. I administered MMPsense™ 
680 or vehicle control to mice, 0 or 48 hrs following the final CCl4 dose in my 4 week 
model, followed by tissue harvest and flow cytometry analysis at 24 or 72 hrs respectively 
(Fig. 3.11A). Hepatic macrophages were identified by flow cytometry, as described before 
(Fig. 3.8B), and assessed for MMPsense™ fluorescence. A population of MMPsense™ 
positive macrophages could be clearly distinguished on flow cytometry, indicative of active 
MMP expression by these cells (Fig. 3.11B). I then performed macrophage subset analysis 
on the MMPsense™ positive hepatic macrophages, using the previously discussed markers 
CD11b, F4/80 and Ly-6C. As shown, this methodology identified the Ly-6C
lo
 monocyte-
derived macrophages as the predominant MMPsense™ positive subset at both 24 and 72 hrs, 
representing 70.4±4% of the detected MMP-expressing macrophages during maximal 
fibrosis regression (Fig. 3.11C).  
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Figure 3.11 - Identification of MMP-expressing Macrophage Subsets during 
Inflammation and Fibrosis Resolution 
(A) Following 4 weeks of CCl4, mice were given fluorescent MMP substrate (MMPsense™) 
or vehicle control at 0 or 48 hrs with harvest at 24 or 72 hrs respectively. (B) Identification 
of MMPsense™ positive macrophages at 24 and 72 hrs by flow cytometry. (C) Macrophage 
subset analysis of the MMPsense™ positive hepatic macrophage population at 24 and 72 hrs 








A Lack of a Dynamic Macrophage Population Response in the Irreversible Oral 
Thioacetamide Model 
Having identified dynamic changes in hepatic macrophage subsets in the reversible 4 week 
CCl4 model, I then sought to study macrophage dynamics in the irreversible TAA model. 
Adult male C57BL/6 mice were administered high dose oral TAA (600mg/l) in their 
drinking water for 8 weeks. They were then converted onto normal drinking water, with 
livers harvested at serial timepoints following the conversion. Comparison was made to 
uninjured mice. As described previously, this model induces liver fibrosis with no reduction 
in PSR staining seen at 8 weeks of recovery (Fig 3.7A).  
Hepatic macrophages were identified using flow cytometry on hepatic non-parenchymal 















populations (Fig 3.12B). 
I proceeded to quantify macrophage subsets at timepoints following the cessation of TAA, in 
comparison to control (uninjured liver). Interestingly, and in contrast to the CCl4 model, the 
contribution of macrophages to the hepatic leukocyte population actually declines with TAA 
injury, and is gradually replenished to control levels during the first 2 weeks of recovery (Fig 
3.12C). Subset analysis demonstrated that this reduction in macrophages is due to a loss of 
“resident” macrophages (Fig 3.12D), which again reaccumulate during the first 2 weeks 
following the cessation of TAA. This loss of “resident” macrophages and gradual 
repopulation after stopping the injury mirrors what I observed in the CCl4 model (Fig 3.9 A 









Figure 3.12 – A lack of Dynamic Macrophage Population Response in the Irreversible 
Oral TAA Model 
Adult male C57BL/6 mice were administered high dose oral TAA (600mg/l) in their 
drinking water for 8 weeks. They were then converted onto normal drinking water, with 
livers harvested at the stated timepoints following the conversion. Comparison was made to 
uninjured mice. (A) Hepatic macrophages were identified by flow cytometry as viable 









 monocyte-derived macrophages. (B) 





 subsets. (C) Quantification of total hepatic 
macrophages as a percentage of hepatic CD45-positive leucocytes in uninjured (control) 
mice and at stated timepoint following cessation of TAA (n=4). (D to F) Quantification of 
stated macrophage subset as a percentage of total hepatic CD45-positive leucocytes in 
uninjured (control) mice and at indicated timepoint following cessation of TAA (n=4). All 








In this chapter, I have established and analysed 2 distinct models of murine liver fibrosis and 
gone on to extensively characterise the dynamics of the hepatic macrophage populations 
following withdrawal of hepatic injury. As previously described, the CCl4 model of murine 
liver fibrosis is the most widely used and characterised model and shows robust reversibility 
following the withdrawal of injury (Issa et al., 2004, Wanless et al., 2000). In this work I 
have utilised a short 4 week CCl4 model in C57BL/6 mice. As shown in Figures 3.1 to 3.4, 
this model induces a robust hepatic fibrosis and myofibroblast activation. This shows a 
characteristic portal-portal bridging pattern, albeit without the animals being cirrhotic. 
However, more importantly, serial analysis following the final CCl4 injection in this model 
shows a reproducible pattern of fibrosis resolution in a tractable timeframe, enabling detailed 
analysis of cellular dynamics. Specifically, hepatic fibrosis and myofibroblast activation 
peak 48-72 hours after the final CCl4 injection. Hence, 24 hours after the final CCl4 injection 
is a time of active scar deposition. Correspondingly, this pro-fibrogenic 24 hour timepoint 
also shows the highest hepatocellular death as assessed by serum AST and ALT levels (Fig 
3.5A), the highest hepatic levels of a number of pro-inflammatory cytokines and chemokines 
(Fig 3.5B) and the highest hepatic levels of the critical MMP-inhibitor TIMP-1 (Fig 3.5C). 
Thus, 24 hours after the final CCl4 injection in this 4 week model can reliably be used as a 
pro-inflammatory pro-fibrogenic timepoint. 
On the other hand, maximal scar regression and myofibroblast loss commences at 72 hours 
after the final CCl4 injection and occurs by 96 hrs, followed by a more protracted resolution 
of the residual scar thereafter. This initiation of the rapid phase of fibrosis regression in the 4 
week CCl4 model at the 72 hour timepoint occurs after a reduction in AST and ALT levels to 
baseline, after a significant decline in inflammatory cytokines and chemokines (IL-1β, 
CCL2, CCL3 and CXCL2) and a reduction in hepatic TIMP-1. Hence, this 72 hour timepoint 
represents a pro-resolution environment and an ideal time to identify the presence of pro-
resolution cell types. During the later timepoints following the final CCl4 dose, scar 
resolution is much slower and hence the chance of detecting the pro-resolution macrophage 
population in sufficient number is likely to be lower. 
The second murine fibrosis model I have described in this chapter is the much less well 
characterised oral TAA model. As shown in Fig 3.6C and D, administration of chronic high-
dose (600mg/l) but not low dose (300mg/l) TAA in the drinking water of C57BL/6 mice 
induces a statistically significant liver fibrosis by 8 weeks of treatment, which progresses 
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over time and results in cirrhosis by 52 weeks of treatment. However, after either 8 or 52 
weeks of TAA, no reversibility in this fibrotic response could be seen following conversion 
on to normal drinking water for up to 8 weeks (Fig 3.7). Hence, this TAA model is likely to 
have limited utility in identifying the pro-resolution macrophage population. However, the 
contrast to the more reversible CCl4 model could provide novel insights. 
Having identified the robust timepoints of fibrogenesis and resolution in the 4 week CCl4 
model, I proceeded to characterise macrophage dynamics. Previous studies by our group 
have identified scar-associated macrophages (SAMs) as the major source of collagenases to 
degrade scar during liver fibrosis regression (Fallowfield et al., 2007). Perhaps 
unsurprisingly, morphological analysis of macrophage distribution in the CCl4 model using 
F4/80 immunostaining, demonstrated that at the time of initiation of fibrosis resolution (72 
hrs), macrophages localised around the scars topographically in a prime position to 
orchestrate matrix degradation (Fig 3.8A).  
Currently there are no known entirely specific markers for functionally distinct 
subpopulations of hepatic macrophages, and the subsets can only be identified by the 
simultaneous assessment of variable degrees of expression of multiple cell surface markers. 
Hence, the distinct populations cannot currently be identified by immunohistochemistry and 
I proceeded to use multicolour flow cytometry to study macrophage heterogeneity in more 
depth. Firstly, I developed a method to specifically identify hepatic macrophages with 
minimal contamination from other cell types. This stringent flow cytometric gating strategy 
is the most robust and reproducible way of doing this (Fig 3.8B). Interestingly, when total 
hepatic macrophage number was quantified by this flow cytometric method, it was seen to 
peak at 72 hours following the final CCl4 injection, the time of initiation of fibrosis 
regression and after the most pro-inflammatory phase of this model (Fig 3.8C). This is 
particularly relevant, as increasing macrophage number has been associated with worsening 
hepatic inflammatory scores (McElroy and Peterson, 2011), whilst in this model, it is clear 
that macrophage number actually peaks following a reduction in hepatic inflammation. This 
should be borne in mind when using macrophage number to quantify disease activity. Total 
hepatic neutrophil number, on the other hand, peaks during the more inflammatory pro-
fibrogenic phase of the model, 24 hours after the final CCl4 dose (Fig 3.8D). Thus, an 
increase in hepatic macrophage and not neutrophil number coincides with hepatic fibrosis 
regression. This makes it less likely that hepatic neutrophils are the key effector cells in 




Proceeding to analyse the macrophage subsets in the 4 week CCl4 model, it is clear that the 




 cells, actually 
decline in number during active inflammation/fibrogenesis (24 hrs after the last CCl4 
injection) (Fig 3.9). Whilst there is a subsequent increase during fibrosis resolution, they still 
represent the minority of hepatic macrophages at the time of initiation of scar degradation 
(72 hrs) in this model and do not account for the large increase in total macrophage number 
seen at this timepoint. These findings suggest that resident macrophages are unlikely to 
represent the principal macrophage subset responsible for fibrosis regression. 




 monocyte-derived macrophage population in the liver, 
more dynamic changes could be seen in the different phases of the 4 week CCl4 model. The 
importance of the monocyte-derived macrophage population in this model is emphasised by 
the increase in circulating monocytes I observed at the 24 and 72 hour timepoints after the 
final CCl4 injection (Fig 3.10). This was most prominent for the inflammatory Ly-6C
hi
 
circulating monocytes, which peaked at the 24 hour timepoint, when the key chemokine 
CCL2 is at its highest levels in the inflamed liver (Fig 3.5B).  




 monocyte-derived macrophage 
population in more detail. Key to defining the dynamics of this population was the 
identification of differential Ly-6C expression in these cells. Specifically, they could be 




 expression populations (Fig 3.9B). The Ly-6C
hi
 
population accumulated principally at the time of maximal hepatic inflammation and 
fibrogenesis, 24 hours after the last CCl4 injection (Fig 3.9). This is in keeping with previous 
work which has identified this subset as the main pro-fibrogenic macrophage population in 
the liver, potentially having direct fibrosis promoting actions on HSCs via TGF-β  (Karlmark 
et al., 2009). When analysing the key 72 hour timepoint, when fibrosis regression 
commences in my model, there was a reduction in the pro-fibrogenic Ly-6C
hi
 subset and a 
clear and striking increase in the hepatic Ly-6C
lo
 monocyte-derived macrophage population. 
Indeed, this Ly-6C
lo
 macrophage subset was by far the most numerous macrophage subset at 
this timepoint, accounting for the increase in total hepatic macrophage number seen (Fig 
3.9C and D). Hence, given the numerical and temporal association between these Ly-6C
lo
 
macrophages and fibrosis resolution in this model, they were identified as representing the 
prime candidate subset responsible for mediating hepatic matrix degradation. 
To study the functionality of these macrophage subsets in more detail, I utilised the 
MMPsense™680 probe, which when administered in vivo can detect cells expressing active 
MMPs by flow cytometry (Cortez-Retamozo et al., 2008). Critically, when this probe was 
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administered to mice following CCl4 injury, I could identify hepatic macrophages showing 
MMPsense fluorescence (Fig 3.11B). Analysing which of the macrophage subsets 
predominantly expressed MMPs, demonstrated that the Ly-6C
lo
 monocyte-derived 
macrophages were the main MMP expressing subset at both the 24 and 72 hour timepoint 
(Fig 3.11C). Hence, these Ly-6C
lo
 macrophages accumulate maximally at the initiation of 
fibrosis regression and represent the main MMP expressing subset, highlighting their likely 
functional role in liver fibrosis resolution in this CCl4 model. 
The non-reversible 8 week TAA model in contrast, shows quite different macrophage 
population dynamics to those observed in the CCl4 model. Following 8 weeks of high dose 
TAA treatment, the contribution of hepatic macrophages to the liver leukocyte pool had 
actually declined compared to control animals. This decline was mainly due to a reduction in 
the resident macrophage population. During 2 weeks of recovery from TAA injury on 
normal drinking water, the resident macrophage population progressively recovered to 





 monocyte-derived macrophages to the hepatic leucocyte pool in response to TAA 
or during the recovery phase (Fig 3.12). This clearly contrasts to the dynamic changes in 
these populations in the CCl4 model. This lack of hepatic accumulation of potentially matrix 
degrading Ly-6C
lo
 macrophages in the TAA model may potentially explain the lack of 





 Administration of 4 weeks of intraperitoneal CCl4 to mice induces a robust and 
reproducible hepatic fibrosis which rapidly resolves 
 Fibrosis resolution occurs after a reduction in hepatocyte death, a decline in hepatic 
inflammatory cytokines and chemokines and following a loss of hepatic TIMP-1 
 In this model distinct phases can be identified following cessation of CCl4 injury: 
active inflammation and scar deposition (24 hrs), peak fibrosis (48-72 hrs), maximal 
fibrosis regression and myofibroblast loss (72-96 hrs) followed by a more protracted 
loss of residual scar. 
 Continuous treatment of mice with high dose oral TAA (600mg/l) in drinking water 
induces significant hepatic fibrosis by 8 weeks and cirrhosis by 52 weeks. 
 Liver fibrosis induced by high dose TAA in C57BL/6 mice does not show any 
resolution with recovery times of up to 8 weeks  
 In the reversible CCl4 fibrosis model, hepatic macrophages localise around scars at 
time of maximal fibrosis regression. 
 Hepatic macrophage number peaks at the time of maximal fibrosis resolution 
 Circulating Ly-6Chi inflammatory monocytes are increased at times of hepatic 
inflammation/fibrogenesis and maximal fibrosis regression 
 Distinct hepatic macrophage subsets can be identified by flow cytometry 
o F4/80hi CD11bint resident Kupffer cells 
o CD11bhi F4/80int Ly-6Chi monocyte-derived macrophages 
o CD11bhi F4/80int Ly-6Clo monocyte-derived macrophages 
 Dynamic changes in macrophage subsets characterise the reversible CCl4 fibrosis 
model 
 The Ly-6Clo hepatic macrophage subset accumulates predominantly at the time of 
maximal fibrosis resolution 
 Ly-6Clo hepatic macrophages represent the main MMP-expressing subset during 
fibrogenesis and fibrosis regression 
 A lack of dynamic changes in hepatic monocyte-derived macrophages is seen in the 










As described previously, cells of the MPS, in particular macrophages but also DCs have 
been implicated in fibrosis resolution. In order to define the function of specific cell 
populations in vivo, a number of methods have previously been described to deplete cells of 
the mononuclear phagocyte system (MPS), including monocytes, macrophages and dendritic 
cells. These can broadly be classified as non-genetic or genetic methods of depletion (Chow 
et al., 2011). The most widely used non-genetic method utilizes the administration of 
clodronate-encapsulated liposomes, which are engulfed by cells of the MPS, causing 
intracellular release of the clodronate and subsequent cell death via apoptosis. Whilst a 
degree of tissue specificity of depletion can be gained by varying the route of administration, 
this system is based on the ability of the cells to phagocytose, a fairly ubiquitous feature of 
many monocytes, macrophages and dendritic cells, and thus the depletion is often 
widespread. This can make it difficult to draw conclusions about the specific role of 
subpopulations of MPS cells. Another non-genetic strategy involves the use of blocking 
antibodies to the M-CSF receptor (CSF1R/CD115/c-fms) (Lim et al., 2009, Ma et al., 2009, 
MacDonald et al., 2010). This can also cause broad-spectrum protracted depletion, 
sometimes making interpretation of results challenging.  
The alternative is to use genetic depletion strategies. A number of models have been 
developed for this purpose, using a variety of cell-specific promoters, enabling conditional 
depletion at a designated time. The most widely used transgenic systems for this purpose 
utilize the human diphtheria toxin receptor (DTR) gene also known as the membrane 
anchored form of heparin-binding epidermal growth factor-like growth factor (hbEGF). This 
receptor binds diphtheria toxin (DT), which is then internalized, inhibits protein synthesis 
and rapidly results in apoptosis in both dividing and terminally differentiated cells. The 




 times more sensitive to diphtheria toxin (DT) then the murine 
DTR. Thus, murine cells which express the human DTR will die in the presence of DT. 
CD11b-DTR mice express the human DTR under the control of the CD11b promoter. The 
administration of DT to these animals therefore causes depletion of CD11b-expressing cells, 
specifically cells of the MPS. This system has been widely used to deplete myeloid 
populations in bone marrow, circulation, spleen, peritoneum, kidney, pancreas and liver 
amongst other organs (Chow et al., 2011). Whilst this method of depletion cannot be entirely 
specific for macrophage subsets, it does offer some advantages over non-genetic strategies, 
in that relative selectivity can be obtained for CD11b
hi
 monocytes and monocyte-derived 
macrophages compared to CD11b
lo
 tissue “resident” macrophages. The relative sparing of 
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resident macrophages following DT administration in these mice has been demonstrated for 
lung alveolar macrophages (Altmann et al., 2012) and in the liver (Cailhier et al., 2005, 
Devey et al., 2009). Concerns exist with the potential depletion of other CD11b-expressing 
populations such as neutrophils, NK cells and a subset of CD3 positive cells. However, 
existing data suggests that these populations are preserved in CD11b-DTR mice despite DT 
administration (Duffield et al., 2005, Stoneman et al., 2007, Cailhier et al., 2005). The 
explanation for this finding remains unclear, although it may be dependent on the degree of 
active CD11b gene rather than protein expression.  
Dendritic cells (DCs) have also been targeted using a conditional depletion strategy. As 
discussed in Chapter 1, CD11c expression is relatively specific to DCs. CD11c-DTR mice 
have been generated, which express the human DTR under the control of the CD11c 
promoter. Such mice have been utilised in various studies to deplete hepatic DCs (Bamboat 
et al., 2010, Jiao et al., 2012, Phythian-Adams et al., 2010). One of the key problems in 
studying the relative role of macrophages and DCs in disease pathogenesis is the lack of 
entirely specific markers for each cell type. It was long thought that MHCII and CD11c 
positivity was a marker of DCs (Hashimoto et al., 2011). However, it is now apparent that 
subsets of monocytes and macrophages can also express these markers under certain 
conditions (Hashimoto et al., 2011, Hume, 2008). Similarly, subsets of DCs can arise from 
circulating monocytes and can express more traditional macrophage markers such as CD11b 
or F4/80 (Hashimoto et al., 2011). Thus caution must be exerted when attributing functions 
specifically to macrophages or DCs using these markers. 
Overall, cellular depletion provides an excellent experimental method to determine the 
functional role of a particular population in vivo. Therefore, in order to define the function of 
specific macrophage subsets during the resolution of hepatic fibrosis, I sought to deplete 
macrophages during this critical phase. As discussed, a number of depletion strategies exist, 
each with pros and cons. Given that the most pronounced changes in macrophage subsets 
that we observed in the 4 week CCl4 fibrosis resolution model were dependent on the 
CD11b
hi
 monocyte-derived macrophages (Fig 3.9B to 3.9D), I focused on the CD11b-DTR 
transgenic system, which could potentially offer some selectivity to this hepatic macrophage 
population. Comparison was made to alternative MPS depletion strategies using liposomal 






 To characterise hepatic macrophage subset depletion in CD11b-DTR mice during 
fibrosis regression following CCl4 injury 
 To study the effect of macrophage depletion in CD11b-DTR mice on fibrosis 
resolution 
 To characterize hepatic macrophage depletion using liposomal clodronate during 
fibrosis resolution following CCl4 injury  
 To compare the phenotypic effects of macrophage depletion using CD11b-DTR 
mice and liposomal clodronate  
 To determine the contribution of dendritic cells to subsets during fibrosis regression 
using CD11c-DTR mice 
RESULTS 
DT Administration to CD11b-DTR Mice causes Depletion of Circulating Monocytes 
Adult male CD11b-DTR mice maintained on a C57BL/6 background, were injured with 4 
weeks of CCl4, using the same schedule and dosing previously described for wild type 
animals. In order to ensure maximal macrophage depletion during the time of maximal 
fibrosis regression, intravenous diphtheria toxin (DT; 10ng/g) or PBS control was 
administered 48, 72 and 96 hrs following the final CCl4 dose, with harvest at 120 hrs, 
according to the schedule shown (Fig 4.1A). 









 monocyte subsets were identified at 120 hrs in the 
peripheral blood of CD11b-DTR mice that received DT or PBS control and quantified (Fig 
4.1B). As shown in Fig. 4.1B and 4.1C, described in detail in the associated legend and in 
keeping with previous data using CD11b-DTR mice (Lin et al., 2009), administration of DT 
to these mice during liver fibrosis regression induced a significant reduction in the number of 
both circulating monocyte subsets (n=11-13). Ly-6C
hi
 “inflammatory” monocytes were 
depleted by 75.4±3.1% following DT administration, whilst Ly-6C
lo
 “patrolling” monocytes 




Figure 4.1– DT Administration to CD11b-DTR Mice causes Depletion of Circulating 
Monocytes 
(A) Schematic representation of model of macrophage depletion during fibrosis resolution in 
CD11b-DTR mice after 4 weeks of injury, by administration of diphtheria toxin (DT) (or 
PBS control) 48, 72 and 96 hrs following the final CCl4 injection with harvest at 120 hrs. (B) 














 circulating monocyte number per ml of blood in CD11b-
DTR mice given DT or PBS control (n=11-13 from 2 independent experiments). All data 







Selective Depletion of Ly-6C
lo
 Hepatic Macrophages during Fibrosis Resolution in 
CD11b-DTR Mice 
Having confirmed monocyte depletion during fibrosis resolution following DT 
administration to CD11b-DTR mice, I proceeded to characterize the effects of depletion on 
hepatic macrophage subsets. CCl4 and DT (or PBS control) were again administered 
according to the schedule shown (Fig 4.1A). Hepatic macrophages and macrophage subsets 
were identified from digested livers by flow cytometry of hepatic non-parenchymal cells, as 
described previously (Fig 3.8B, 3.9A and B). 
As shown in Fig 4.2A and Fig 4.2B and described in detail in the associated legend, 
administration of DT to CD11b-DTR mice resulted in a clear depletion of hepatic  Ly-6C
lo
 
macrophages at the 120 hr timepoint (n=11-13). Indeed, I observed a 76.7 ± 3.16% reduction 
in the relative number of Ly-6C
lo
 macrophages at 120 hrs (Fig 4.2B). Furthermore, no 
significant depletion was detected for hepatic Ly-6C
hi
 macrophages, whilst the “resident” 
macrophage population actually showed a small increase in number following DT 
administration (Fig 4.2B). Additionally, flow cytometric analysis of hepatic neutrophil (Fig 
4.2C; n=11-13) and CD3 positive cell number (Fig 4.2D; n=11-13) at the same timepoint 
showed no significant depletion of either population in CD11b-DTR mice in response to DT.  
Thus, in the CCl4 model, macrophage depletion in CD11b-DTR mice during maximal 
fibrosis regression causes specific depletion of hepatic Ly-6C
lo
 monocyte-derived 






Figure 4.2 - Selective Depletion of Ly-6C
lo
 Hepatic Macrophages during Fibrosis 
Resolution in CD11b-DTR Mice 





 hepatic macrophages (Percentages shown indicate mean±SEM of 
each subset as a proportion of total hepatic macrophages; n=11-13). (B) Quantification of 
relative number of each hepatic macrophage subset (Expressed relative to mean total 
macrophage number in PBS-treated livers; n=11-13 pooled from 2 independent 
experiments). (C) Quantification of relative number of hepatic neutrophils in DT and PBS-
treated mice (Expressed relative to total neutrophil number in PBS-treated livers; n=11-13 
pooled from 2 independent experiments). (D) Quantification of relative number of hepatic 
CD3 positive cells in DT and PBS-treated mice (Expressed relative to total CD3 cell number 
in PBS-treated livers; n=11-13 pooled from 2 independent experiments). All data shown as 








Macrophage Depletion during Fibrosis Resolution in CD11b-DTR Mice Induces a 
Failure of Scar Remodelling 
I then proceeded to ascertain the effect of macrophage depletion in the CD11b-DTR mice, on 
the resolution of hepatic fibrosis. Injury and depletion were performed as shown (Fig 4.1A).  
As described previously (Fig 3.1 to 3.3), the degree of fibrosis was analysed by 
immunohistochemistry with morphometric pixel analysis of Picrosirius Red (PSR), Collagen 
3 and Collagen 1. As shown in Fig 4.3A to 4.3C and described in detail in the legend, DT 
administration to CD11b-DTR mice resulted in higher levels of hepatic fibrosis as assessed 
by all 3 measures, when compared to vehicle (PBS) control-treated animals (n=10-12). 
Additionally, as shown in Fig 4.3D, immunohistochemical analysis of α-SMA expression 
following macrophage depletion with DT, showed no significant difference compared to 
PBS control indicating a similar degree of myofibroblast activation with either treatment 
(n=10-12).  
Thus, macrophage depletion during the fibrosis resolution phase results in a failure of scar 
regression. As described above, depletion in this model predominantly affected Ly-6C
lo
 




Figure 4.3 - Macrophage Depletion during Fibrosis Resolution in CD11b-DTR Mice 
Induces a Failure of Scar Remodelling 
(A) Representative Picrosirius red (PSR) staining and quantification of histological changes 
by pixel analysis following DT or PBS administration to CD11b-DTR mice during fibrosis 
resolution (Expressed relative to mean % area in PBS-treated liver; n=10-12 pooled from 2 
independent experiments). (B) Representative liver immunohistochemistry of Collagen 3 and 
quantification of histological changes by pixel analysis following DT or PBS administration 
to CD11b-DTR mice during fibrosis resolution (Expressed relative to mean % area in PBS-
treated liver; n=10-12 pooled from 2 independent experiments). (C) Representative liver 
immunohistochemistry of Collagen 1 and quantification of histological changes by pixel 
analysis following DT or PBS administration to CD11b-DTR mice during fibrosis resolution 
(Expressed relative to mean % area in PBS-treated liver; n=10-12 from 2 independent 
experiments). (D) Representative liver immunohistochemistry of α-SMA and quantification 
of histological changes by pixel analysis following DT or PBS administration to CD11b-
DTR mice during fibrosis resolution (Expressed relative to mean % area in PBS-treated 
liver; n=10-12 pooled from 2 independent experiments). All data shown as Mean±S.E.M; 













 Macrophage Number Correlates with the Degree of Fibrosis Resolution 
Having demonstrated that in CD11b-DTR mice, DT administration during fibrosis regression 
results in selective depletion of hepatic Ly-6C
lo 
macrophages, and that this induces a failure 
of scar remodelling, I sought to strengthen the association been these findings by assessing 
for the presence of correlations between macrophage subset number and the degree of 
fibrosis which could indicate a more causal link.  
In order to do this, CD11b-DTR mice, were injured with 4 weeks of CCl4 and given  DT or 
PBS control at 48, 72 and 96 hrs with harvest at 120 hrs, according to the previous schedule 
(Fig 4.1A). For each mouse, a proportion of the liver was harvested for hepatic macrophage 
subset counts by flow cytometry and the remainder of the liver was fixed and assessed 
histologically for the degree of liver fibrosis using PSR staining and immunohistochemistry 
for collagen 3 and collagen 1 as before. Thus, I could make a simultaneous assessment of 
hepatic macrophage populations and the degree of fibrosis in individual mice and hence 
determine if there is a correlation between the number of each hepatic macrophage subset 
and fibrosis levels between different mice. As shown in Fig 4.4A, and described in detail in 
the associated legend, the number of hepatic Ly-6C
lo
 macrophages showed a statistically 
significant inverse correlation with the degree of fibrosis, as assessed by PSR, Collagen 3 or 
Collagen 1 staining (n=22). No correlations were detected between Ly-6C
hi
 macrophage (Fig 
4.4B, n=22) or resident macrophage (Fig 4.4C, n=22) number and the degree of fibrosis. 
This indicates a “dose-response” effect, in that the degree of depletion of Ly-6C
lo
 hepatic 
macrophages directly relates to the degree of residual scar. 
DT has No Effect on Hepatic Macrophages in Wild Type Mice 
In order to exclude a non-specific effect of DT contributing to our findings, DT or PBS 
control was administered to fibrotic wild-type C57BL/6 mice using an identical treatment 
schedule to that used for CD11b-DTR mice (Fig 4.1A). DT had no effect on hepatic 
macrophage subsets in wild-type mice (Fig 4.4D, n=2). Furthermore, administration of DT 
to these animals did not affect fibrosis resolution, as assessed by PSR quantification (Fig 




Figure 4.4 – Ly-6C
lo
 Macrophage Number Correlates with the Degree of Fibrosis 
Resolution 
(A) Correlation of degree of fibrosis assessed by PSR, Collagen 1 and Collagen 3 % area, 
with the relative number of Ly-6C
lo
 macrophages (n=22 pooled from 2 independent 
experiments). (B) Correlation of degree of fibrosis assessed by PSR, Collagen 1 and 
Collagen 3 % area, with the relative number of hepatic Ly-6C
hi
 macrophages in CD11b-DTR 
mice (n=22 from 2 independent experiments). (C) Correlation of degree of fibrosis assessed 
by PSR, Collagen 1 and Collagen 3 % area, with the relative number of resident hepatic 
macrophages in CD11b-DTR mice (n=22 from 2 independent experiments). (D & E) 
Administration of DT or PBS to wild-type mice after 4 weeks of injury at 48, 72 and 96 hrs 
following the final CCl4 injection with harvest at 120 hrs (experiments in collaboration with 
Dr A Pellicoro). (D) Analysis of hepatic macrophage subsets in wild-type mice receiving DT 
or PBS (Percentages shown indicate mean±SEM of each subset as a proportion of total 
hepatic macrophages; n=2). (E) Quantification of fibrosis in wild-type mice receiving DT or 
PBS by picrosirius red staining and morphometric pixel analysis (Expressed relative to mean 
% area for PBS-treated liver; n=2). All data shown as Mean±S.E.M; NS-non-significant. 









Liposomal Clodronate Administration to Mice Causes Depletion of Ly-6C
lo
 Monocytes 
For comparison, I also used liposomal clodronate as an alternative macrophage depletion 
strategy during fibrosis regression. Wild type C57BL/6 mice were injured with 4 weeks of 
CCl4 as before, followed by intravenous administration of 200µl of liposomal clodronate (or 
PBS control) 48, 72 and 96 hrs after the final CCl4 injection, with harvest at 120 hrs, 
according to the schedule shown (Fig 4.5A). 









 monocyte subsets were identified at 120 hrs in the 
peripheral blood of mice that received liposomal clodronate or PBS control and quantified 
(Fig 4.5B). As shown in Fig. 4.5B and 4.5C and described in detail in the associated legend, 
liposomal clodronate administration caused a significant reduction in circulating Ly-6C
lo
 
monocytes, amounting to 55.3±4.9% depletion (n=12-14). However, Ly-6C
hi
 monocyte 
number actually increased by 72.6±12.6% following clodronate administration (Fig 4.5 B 
and C, n=12-14). Interestingly, both monocyte subsets show reduced CD115 expression 
following liposomal clodronate administration, suggesting that a change in monocyte 









(A) Schematic representation of model of macrophage depletion during fibrosis resolution in 
C57BL/6 mice after 4 weeks of injury, by administration of liposomal clodronate (or PBS 
control) 48, 72 and 96 hrs following the final CCl4 injection with harvest at 120 hrs. (B) 














 circulating monocyte number per ml of blood in 
C57BL/6 mice given liposomal clodronate or PBS control (n=12-14 pooled from 2 
independent experiments). All data shown as Mean±S.E.M; ***P<0.001. Representative 






Liposomal Clodronate Administration Causes Generalized Hepatic Macrophage 
Depletion 
I proceeded to determine the effects of liposomal clodronate on hepatic macrophage subsets 
and other immune cell populations. Wild type C57BL/6 mice were injured with 4 weeks of 
CCl4 as before, followed by intravenous administration of 200µl of liposomal clodronate (or 
PBS control) 48, 72 and 96 hrs after the final CCl4 injection, with harvest at 120 hrs, 
according to the schedule shown (Fig 4.5A). Hepatic macrophages and other cell types were 
identified by flow cytometry on hepatic non-parenchymal cells isolated from digested livers 
as before (Fig 3.8B, 3.9A and B).  
As demonstrated in Fig 4.6A, liposomal clodronate induced depletion of all 3 macrophage 
subsets in the liver when compared to PBS control. The degree of depletion for the critical 
Ly-6C
lo
 subset was 60.9±7.8% following clodronate administration (Fig 4.6A, n=13-14). 
Furthermore, liposomal clodronate administration caused a 25.8 ± 5.5% reduction in hepatic 
Ly-6C
hi
 monocyte-derived macrophages and an 80.9 ± 3.0% depletion of resident hepatic 
macrophages (Fig 4.6A, n=13-14).  
Additionally, as shown in 4.6B and 4.6C, the effect of liposomal clodronate administration 
on hepatic neutrophil and CD3 positive cell number was assessed by flow cytometry. 
Liposomal clodronate caused a statistically significant increase in hepatic neutrophil number 
(Fig 4.6B, n=13-14) and a significant reduction in hepatic CD3 positive cells suggesting 
reduced hepatic T cell number (Fig 4.6C, n=13-14).  
Liposomal Clodronate Administration does not Alter Hepatic Fibrosis Resolution 
I proceeded to assess the effect of liposomal clodronate administration on the regression of 
hepatic fibrosis in the model described and shown in Fig 4.5A. Liver fibrosis was assessed 
by picrosirius red staining and morphometric pixel analysis as before. As shown in Fig 4.6D, 
no difference in total hepatic fibrosis was detected following liposomal clodronate 
administration, when compared to PBS-treated control animals (n=13-14). This indicates that 






Figure 4.6 – Liposomal Clodronate causes Generalized Hepatic Macrophage Depletion 
and No Effect on Fibrosis 
(A) Hepatic macrophage subsets were identified by flow cytometry from livers of PBS and 
liposomal clodronate treated mice. Quantification of relative number of each hepatic 
macrophage subset (Expressed relative to mean total macrophage number in PBS-treated 
livers; n=13-14 pooled from 2 independent experiments). (B) Quantification of relative 
number of hepatic neutrophils by flow cytometry in liposomal clodronate and PBS treated 
mice (Expressed relative to total neutrophil number in PBS-treated livers; n=13-14 from 2 
independent experiments). (C) Quantification of relative number of hepatic CD3 positive 
cells by flow cytometry in liposomal clodronate and PBS treated mice (Expressed relative to 
total CD3 cell number in PBS-treated livers; n=13-14 from 2 independent experiments). (D) 
Quantification of histological changes by picrosirius red staining and pixel analysis 
following liposomal clodronate or PBS administration to C57BL/6 mice during fibrosis 
resolution (Expressed relative to mean % area in PBS-treated liver; n=13-14 from 2 









DT Administration to CD11c-DTR Mice has No Effect on Hepatic Macrophage Subsets 
As previously discussed, there can be significant overlap between function and cell surface 
marker expression between macrophages and DCs. I therefore wished to assess if there is a 
contribution of hepatic DCs to the defined macrophage subsets during resolution of liver 
fibrosis.  
I initially determined the degree of expression of the putative DC marker CD11c, on the 
previously defined hepatic macrophage subsets by flow cytometry. I focussed on the time of 
maximal fibrosis resolution (72 hrs) following 4 weeks of CCl4 injury. As shown in Fig 
4.7A, some CD11c expression was detected in each of the macrophage populations at the 72 
hr timepoint. Whilst expression was lowest in the Ly-6C
hi
 macrophage subset and highest in 
the resident macrophage population, the likely pro-resolution Ly-6C
lo
 macrophages, 
expressed showed only intermediate levels (n=5). 
I went on to utilize CD11c-DTR mice, in which hepatic DC depletion has been demonstrated 
in response to DT (Phythian-Adams et al., 2010). Adult male CD11c-DTR mice were injured 
with 4 weeks of CCl4 as before, followed by intraperitoneal administration of DT (12ng/g) or 
PBS control, 48 and 72 hrs following the final CCl4 injection, with harvest at 96 hrs. This 
dose of DT in this mouse strain is higher than the dose that has previously been shown to 
deplete hepatic DCs (Phythian-Adams et al., 2010), and thus we can be confident of 
achieving DC depletion in our model. As shown in Fig 4.7B, administration of DT to these 
mice did not cause a significant change in the total hepatic macrophage number when 
compared to PBS-treated controls, as assessed by flow cytometry (n=7). I proceeded to study 
the 3 defined liver macrophage subsets in these mice. There was no significant change in any 





Figure 4.7 – No depletion of Hepatic Macrophage Subsets in CD11c-DTR Mice 
(A) CD11c expression of each macrophage subset 72 hrs following the final CCl4 injection 
after 4 weeks of injury (Expressed as Mean Fluorescence Intensity (MFI) of CD11c assessed 
by flow cytometry, n=5). (B & C) Adult male CD11c.DOG mice were administered twice-
weekly intraperitoneal CCl4 for 4 weeks, followed by 12ng/g diphtheria toxin (or PBS 
control) 48 and 72 hrs following the final CCl4 injection. Mice were harvested at 96 hrs. (B) 
Quantification of total hepatic macrophage number as a proportion of CD45 positive hepatic 
non-parenchymal cells following DT or PBS control (n=7). (C) Quantification of number of 
each macrophage subset as a proportion of total hepatic macrophages following DT or PBS 








In this chapter I have characterised distinct macrophage depletion strategies in our 4 week 
CCl4 model and utilised these data to confirm that the Ly-6C
lo
 hepatic macrophage subset is 
functionally responsible for liver fibrosis regression. 
For both CD11b-DTR and liposomal clodronate based depletion during the resolution phase 
following CCl4 injury, I initially characterised the effects on circulating monocytes. DT 





circulating monocytes, with a more profound depletion of the Ly-6C
lo
 population. This is in 
keeping with Ly-6C
lo
 monocytes being a more mature cell type, formed from differentiation 
of Ly-6C
hi
 monocytes, and thus taking longer to replenish following depletion (Gordon and 
Taylor, 2005, Yona et al., 2013). Similarly, liposomal clodronate administration resulted in a 
significant reduction in Ly-6C
lo
 circulating monocytes. However, in this model I observed an 
increase in Ly-6C
hi
 circulating monocytes.  This was in contrast to previous data, where 
liposomal clodronate caused depletion of Ly-6C
hi
 monocytes for up to 24 hrs (Sunderkotter 
et al., 2004). The reason for this difference is not clear. Of note previous analysis of 
monocyte dynamics following liposomal clodronate have been based on a single injection. In 
contrast, I have administered 3 doses of liposomal clodronate. It is therefore likely that 
repeated dosing may alter the sensitivity of the cells to depletion and hence the overall 
response of the animals. What is apparent when comparing these 2 depletion methods, is that 
CD11b-DTR based depletion induced a more profound loss of Ly-6C
lo
 monocytes whilst 
having the opposite effect on Ly-6C
hi
 monocyte number compared to liposomal clodronate. 
It is therefore feasible that this difference may contribute to differing functional effects. 
I proceeded to characterise the effects of depletion during the resolution phase following 
CCl4, on hepatic macrophage subsets. With the CD11b-DTR system, I observed a significant 
depletion of hepatic Ly-6C
lo
 monocyte-derived macrophages, with Ly-6C
hi
 monocyte-
derived macrophage number unchanged, whilst resident macrophage numbers actually 
increased slightly (Fig 4.2B). The selectivity of depletion for the hepatic monocyte-derived 
macrophages compared to the “resident” macrophage population is likely related to the 
higher CD11b expression in this subset (Fig 3.9A). This is in keeping with the previously 
described resistance of resident Kupffer cells to depletion using the CD11b-DTR system 
(Cailhier et al., 2005, Devey et al., 2009). The fact we have observed a small increase in 
resident macrophage number, may represent a selection pressure favouring this population 
following depletion of the Ly-6C
lo
 monocyte-derived macrophages. The reasons behind the 
selectivity of depletion for hepatic Ly-6C
lo





macrophages is likely to be multi-factorial. Firstly, we have shown that the Ly-6C
lo
 
macrophage subset expresses higher levels of CD11b than the Ly-6C
hi
 population 
(Ramachandran et al., 2012) and Appendix 2). Additionally, the timing of depletion is likely 
to be critical. I have deliberately administered DT at 48, 72 and 96 hrs to maximize depletion 
during the rapid phase of fibrosis resolution. At these times, pro-fibrotic Ly-6C
hi
 
macrophages have already declined significantly in number, whilst Ly-6C
lo
 macrophages 
make up the vast majority of the CD11b
hi
 monocyte-derived macrophages (Fig 3.9B to D). 
Therefore, administration of DT is likely to preferentially deplete the more numerous 
population. Published data do demonstrate that in this model, DT administration at an earlier 
timepoint during the inflammatory/fibrogenic phase when Ly-6C
hi
 cells are more numerous, 




 hepatic macrophages (Ramachandran et al., 2012) 
and Appendix 2). Furthermore, as discussed for circulating monocytes, depletion is more 
profound and protracted for the more mature population as it takes longer to replenish. It is 
likely that the Ly-6C
lo
 hepatic macrophage population also represents a more mature subset 
than Ly-6C
hi
 monocyte-derived macrophages, and therefore depletion with DT is more 
effective for these cells. 
I was also able to define potential off target effects of the macrophage depletion methods on 
other cell types. In keeping with previous work (Cailhier et al., 2005, Duffield et al., 2005, 
Stoneman et al., 2007), there was no depletion of hepatic neutrophils (identified as shown in 
Fig 3.8B) following DT administration (Fig 4.2C). Furthermore, DT did not cause a change 
in hepatic CD3 positive cells, a marker of T cells (Fig 4.2D). This emphasises the specificity 
of depletion in the CD11b-DTR model. 
Using this CD11b-DTR model, macrophage depletion during the resolution phase following 
CCl4 resulted in higher levels of hepatic fibrosis as measured by picrosirius red, collagen 1 
and collagen 3 staining. This indicates a failure of scar remodelling with macrophage 
depletion in this model, analogous to previous data (Duffield et al., 2005). Interestingly, I did 
not observe a significant difference in α-SMA staining following DT administration in these 
animals, suggesting that the observed phenotype is a result of failed matrix degradation 
rather than increased myofibroblast activation. To exclude a non-specific effect of DT 
administration on hepatic macrophages and fibrosis, I also administered DT (or PBS control) 
to wild-type mice during fibrosis resolution, using the same schedule. Importantly, this had 
no effect on macrophage subsets or hepatic fibrosis (Fig 4.4). These data, together with the 
previously described timing-dependent effects of DT in CD11b-DTR mice (Duffield et al., 
2005), argue strongly against a non-specific effect. 
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I proceeded to use this CD11b-DTR model to determine associations between macrophage 
subset number and the degree of fibrosis resolution for individual animals. Strikingly, the 
number of Ly-6C
lo
 macrophages in the liver showed a statistically significant inverse 
correlation with the degree of liver fibrosis, emphasising that in mice with higher numbers of 
this Ly-6C
lo
 subset, fibrosis seems to regress more rapidly. No such correlation existed for 
either Ly-6C
hi 
or resident hepatic macrophages. These data, taken along with the previous 
evidence that hepatic Ly-6C
lo
 monocyte-derived macrophages accumulate in the liver 
maximally during the rapid phase of scar resolution (Fig. 3.9) and are the principal MMP-
expressing subset (Fig. 3.11), identify them as the restorative hepatic macrophage, 
responsible for fibrosis regression and the restoration of normal tissue architecture following 
chronic injury. 
The hepatic effects of liposomal clodronate administration to wild type mice during 
resolution from CCl4 induced liver fibrosis were also studied. In contrast to the specific 
depletion seen in the CD11b-DTR system, liposomal clodronate resulted in significant 




 and Resident). Additionally, 
the degree of depletion for the critical Ly-6C
lo
 population was less when using liposomal 
clodronate (60.9±7.8%) when compared to CD11b-DTR (76.7 ± 3.16%). Furthermore, no 
effect on hepatic fibrosis was observed with liposomal clodronate administration during 
fibrosis resolution (Fig. 4.6D). The reason for this lack of effect, when compared to the 
striking changes in fibrosis resolution with depletion in the CD11b-DTR model despite 
identical depletion times, is probably multi-factorial. Ly-6C
hi
 hepatic macrophages have 
previously been shown to be the main pro-fibrogenic population (Karlmark et al., 2009), 
whilst my data suggests that Ly-6C
lo
 macrophages are the main restorative population. It is 
therefore likely that the balance of these populations of macrophages will determine whether 
active fibrogenesis or fibrosis regression occurs and hence the overall tissue phenotype. The 
fact that liposomal clodronate administration results in depletion of both these populations, 
whilst DT administration has selectivity for Ly-6C
lo
 cells and depletes this to a greater 
degree may well explain the differences in end effect. The other principal difference in 
hepatic macrophages when comparing CD11b-DTR depletion with liposomal clodronate is 
the effect on resident macrophages. These are increased slightly in CD11b-DTR whilst 
depleted significantly with liposomal clodronate. It is feasible that a potential pro-fibrogenic 




Analysis of the effect of liposomal clodronate administration on other immune cells in the 
liver, demonstrated a significant increase in hepatic neutrophil number with a reduction in 
CD3 positive cells (Fig 4.6B and C). This increase in tissue neutrophils with liposomal 
clodronate treatment has also been observed in other studies (Wang et al., 2006, Mircescu et 
al., 2009). Thus, systemic liposomal clodronate administration during fibrosis resolution, has 
effects on cell types in the liver other than macrophages, potentially contributing to the 
differences observed with CD11b-DTR based depletion, and making it more difficult to draw 
specific conclusions about the functional role of individual macrophage populations. 
Finally, the administration of liposomes alone has been shown to alter macrophage 
phenotype in vivo (Harel-Adar et al., 2011, Ma et al., 2011). This could potentially 
counteract the effects of depletion and thus must also be compared to administration of 
liposomes alone (See CHAPTER 8). 
Finally, in this chapter, I sought to define the potential contribution of DCs to the 
macrophage populations I defined in the liver during fibrosis resolution. Using a CD11c-
DTR system, which has previously been shown to deplete hepatic DCs (Phythian-Adams et 
al., 2010), no effect on macrophage subsets was observed following DT administration to 
these animals (Fig. 4.7). Thus, in our model it seems that DCs do not make any significant 
contribution to the dynamic changes we have seen during maximal fibrosis regression. 
Specifically, the Ly-6C
lo
 macrophage subset, the main MMP-expressing population which is 




 DT administration to CD11b-DTR mice during liver fibrosis resolution results in 
selective depletion of the Ly-6C
lo
 macrophage subset 
 DT administration to CD11b-DTR mice during liver fibrosis resolution results in a 
failure in scar remodelling and hence persistent fibrosis 
 Hepatic Ly-6Clo macrophage number shows a statistically significant inverse 
correlation with the degree of persistent fibrosis, whilst other macrophage subsets do 
not. This confirms Ly-6C
lo
 hepatic macrophages as the likely restorative subset 
 Liposomal clodronate administration to C57BL/6 mice during liver fibrosis 
resolution causes generalised hepatic macrophage depletion and alterations in liver 
neutrophil and T cell numbers 
 Liposomal clodronate administration has no effect on liver fibrosis resolution  





CHAPTER 5 – IDENTIFICATION OF THE 
CELLULAR SOURCE OF RESTORATIVE 
LY-6C
lo




I have identified a novel Ly-6C
lo
 hepatic macrophage subset which accumulates maximally 
immediately prior to the rapid phase of fibrosis resolution following CCl4 injury, represents 
the principal MMP-expressing macrophage population in the liver and whose selective 
depletion in CD11b-DTR mice causes a failure of matrix degradation. This population is 
therefore highly likely to be the hitherto elusive “restorative” hepatic macrophage. One of 
the key questions from previous data exploring the dual role of macrophages in hepatic 
fibrogenesis and fibrosis resolution was if these distinct functions were performed by 
resident or recruited cells and whether one population might change phenotype in situ, to 
cause differing effects (Friedman, 2005, Wynn, 2011). As described previously (Fig 3.9B), 
the Ly-6C
lo




, in keeping with being a recruited 
monocyte-derived population (Holt et al., 2008). This would therefore indicate that this 





Previous work has identified hepatic Ly-6C
hi
 macrophages, derived from CCR2-dependent 
recruitment of Ly-6C
hi
 monocytes, as being the key pro-fibrogenic subset (Karlmark et al., 
2009). Therefore, if restorative Ly-6C
lo
 macrophages also derive from Ly-6C
hi
 monocytes, 
this would indicate a change in macrophage phenotype in vivo. Conversely, if restorative Ly-
6C
lo
 hepatic macrophages derive from Ly-6C
lo
 monocytes, it would suggest distinct phases 
of recruitment. Both of these mechanisms have been shown to be relevant in other forms of 
tissue injury and repair (Arnold et al., 2007, Nahrendorf et al., 2007). Additionally, recent 
data has suggested that local macrophage proliferation is important in chronic inflammation 
(Jenkins et al., 2011). The contribution of macrophage proliferation in liver fibrosis has not 
previously been defined. 
AIMS 
 To use adoptive transfer and lineage tracing of Ly-6Chi monocytes to identify a 
phenotypic switch forming Ly-6C
lo
 macrophages 
 To use in situ labelling to determine the contribution of circulating Ly-6Clo 
monocytes to the restorative hepatic macrophage population 
 To determine the contribution of local macrophage proliferation to the formation 
of restorative Ly-6C
lo











As previously shown, circulating Ly-6C
hi
 “inflammatory” monocytes were increased during 
fibrogenesis (24 hrs) and maximal fibrosis resolution (72 hrs) following 4 weeks of CCl4 
injury (Fig 3.10B). In contrast Ly-6C
lo
 “patrolling” monocytes were only increased in 
number during fibrogenesis (24 hrs) and had returned to basal levels by the resolution phase 
(72 hrs) (Fig 3.10C), the time when restorative Ly-6C
lo
 hepatic macrophages peak in 
number. These changes in monocyte populations could suggest Ly-6C
hi
 monocytes as a 
possible source for restorative Ly-6C
lo
 hepatic macrophages. In order to demonstrate this, I 
performed adoptive transfer experiments.  
I initially developed a method for isolating Ly-6C
hi
 monocytes from bone marrow in 
sufficient numbers for adoptive transfer. Ly-6C
hi
 monocytes were identified using flow 








 cells from whole bone marrow in 
keeping with previous studies (Getts et al., 2008) (Fig 5.1A).  




) C57BL/6 mice with 4 weeks of CCl4 
in an identical manner to that described previously. Ly-6C
hi
 monocytes were then identified 
in bone marrow from CD45.1
+ 
C57BL/6 mice by flow cytometry and isolated by FACS 
sorting (Fig 5.1A). These CD45.1
+ 
mice are maintained on a C57BL/6 background, enabling 
adoptive transfer of immune cells to wild type C57BL/6 mice without generating an immune 
response but allowing detection of donor
 
 cells in recipient animals by identifying CD45.1 






 monocytes (or vehicle control) 
were injected via the tail vein into the injured wild type mice, 4 hrs following the final CCl4 
injection. Livers were harvested at 24, 72 and 168 hrs after the final CCl4 injection, and 
assessed for the presence of CD45.1
+











 monocytes for adoptive transfer were isolated by FACS sorting of whole bone 
marrow from male CD45.1+ C57BL/6 mice, gating on the cells, excluding the neutrophils 
(CD11b+ Ly-6G+) and selecting CD115+ CD11b+ Ly-6C
hi
 cells. Representative flow 
cytometry plots shown. (B) Schematic representation of model of adoptive transfer of 
CD45.1+ Ly-6C
hi
 monocytes (or vehicle control) into C57BL/6 mice (CD45.2+), 4 hrs 








 Monocytes Differentiate into Hepatic Ly-6C
lo
 Macrophages 
Having adoptively transferred Ly-6C
hi
 monocytes, I sought to identify the donor cells in the 
livers of recipient animals. As shown in Fig 5.1B, livers were harvests at 24, 72 and 168 hrs 
following the final CCl4 injection. Flow cytometry was performed on hepatic non-
parenchymal cells; staining for CD45.1 in addition to the leukocyte and macrophage markers 
I have used previously (Fig 3.8B, 3.9A and B).  
As shown in Fig 5.2A and described in detail in the legend, a population of CD45.1
+
 cells 
could be identified in livers at the 24 and 72 hr timepoints, whilst they were no longer 
detectable by 168 hrs (n=3 per timepoint). By definition, these hepatic cells must be derived 
from the adoptively transferred injected Ly-6C
hi
 monocytes. To exclude non-specific 
CD45.1 staining, livers from CCl4 treated animals injected with a vehicle control rather than 
cells were also harvested and stained in an identical manner. As shown, no significant 
CD45.1 staining was seen in these animals (Fig 5.2A). Additionally, no CD45.1
+ 
cells were 
detected in the circulation by flow cytometry.  
I went on to further characterize the hepatic CD45.1
+
 positive cells on the basis of the 







, indicative of a hepatic monocyte-derived macrophage population 
(Fig 5.2B, n=3). Analysis of Ly-6C expression on the CD45.1
+
 monocyte-derived 
macrophages identified the majority of the donor cells as being Ly-6C
lo
 hepatic macrophages 
(Fig 5.2C, n=3). Overall, as shown in Fig 5.2D, at least 90% of the CD45.1
+
 hepatic 
macrophages, derived from donor Ly-6C
hi
 monocytes, had formed Ly-6C
lo 
macrophages at 




Figure 5.2 - Ly-6C
hi
 Monocytes Differentiate into Hepatic Ly-6C
lo 
Macrophages  
(A) Identification of injected CD45.1+ cells in digested livers at 24 and 72 hr timepoints 





 monocyte-derived macrophages. (C) CD45.1+ 
monocytes have largely formed the restorative Ly-6C
lo 
macrophage subset. (D) 
Quantification of proportion of identified CD45.1+ hepatic macrophages forming each of the 
macrophage subsets (n=3 per timepoint). All data shown as Mean±S.E.M; ***P<0.001; 










Selective In Vivo Labelling of Ly-6C
lo
 Monocytes to Enable Lineage Tracing 
In order to determine the contribution of circulating Ly-6C
lo
 “patrolling” monocytes to 
hepatic macrophage subsets during fibrogenesis and fibrosis resolution, I employed a well-
described in vivo labelling method. Intravenous administration of inert 0.5µm fluorescent 
latex microspheres selectively labels a proportion Ly-6C
lo
 monocytes, without activating the 
cells or altering their ability to traffic to sites of inflammation (Tacke et al., 2007, Tacke et 
al., 2006). The subsequent identification of latex positive cells in tissues identifies them as 
having a likely origin from Ly-6C
lo
 monocytes. 
Wild type C57BL/6 mice were injured with 4 weeks of CCl4, as before. According to the 
schedule shown in Fig 5.3A, mice then received an intravenous injection of 200µl 
fluorescent latex beads or vehicle control, 4 hours following the final CCl4 dose. Blood and 





 monocytes were identified by flow cytometry as previously 
described (Fig 3.10A). As shown in Fig 5.3B, I could then determine the proportion of each 
monocyte subset that was latex positive, indicating bead ingestion. Quantification of this at 
each timepoint, determined that using this method only a very small proportion of Ly-6C
hi
 
monocytes contained latex beads, whilst up to 9% of Ly-6C
lo
 monocytes were labelled 
during early timepoints declining to around 4% at 168 hours (Fig 5.3C, n=4). This is broadly 




 Monocytes Traffic to the Liver during Late Resolution and form 
Resident Macrophages 
I then proceeded to assess hepatic macrophages for the presence of latex beads by flow 
cytometric analysis of livers at 24, 72 and 168 hr timepoints. As shown in Fig 5.4A, no 
hepatic latex positive macrophages were seen at 24 or 72 hrs, despite concurrent latex 
positive circulating Ly-6C
lo
 monocytes (Fig 5.3C). However, a latex positive hepatic 
macrophage population became apparent during late resolution, 168 hours following the 
final CCl4 injection (Fig 5.4A). Further flow cytometric analysis of this latex positive 
population, using the previously described panel of cell surface markers, showed that the 




, in keeping with a “resident” 
macrophage phenotype (Fig 5.4B). As shown in Fig 5.4C, quantification of the phenotype of 
hepatic latex positive macrophages using this flow cytometry panel, demonstrated that over 
146 
 















Figure 5.3 – Selective In Vivo Labelling of Ly-6C
lo
 Monocytes to Enable Lineage 
Tracing 
(A) Schematic representation of model of in situ labelling of circulating Ly-6Clo monocytes, 
by intravenous injection of fluorescent latex beads (or vehicle control) 4 hrs following the 
final CCl4 injection, with harvests at 24, 72 and 168 hrs. (B) Circulating monocytes were 




 cells. Flow 




 monocyte subsets for latex positivity, 





 monocytes containing latex beads, as assessed by flow 
cytometry, at the stated timepoints following the final CCl4 injection (n=4). All data shown 









Figure 5.4 – Labelled Ly-6C
lo
 Monocytes Traffic to the Liver during Late Resolution 
and form Resident Macrophages 















cells and assessed for latex positivity. Latex positive macrophages 
were identified in the liver only at 168 hrs (Representative proportion of latex positive 
macrophages as % of total hepatic macrophages shown). (B) The phenotype of hepatic latex 









). Representative proportion of each subset as a % of total latex positive macrophages 
shown. (C) Quantification of the proportion of latex positive macrophages forming each of 

















) at 168 hrs (Expressed as a % of latex positive macrophages; n=4). 






Local Proliferation of Hepatic Ly-6C
hi
 Macrophages Contributes to Changes in Subsets 
during Fibrogenesis and Fibrosis Resolution 
Recent work has identified a role for local proliferation of macrophages in the expansion of 
the population during chronic inflammation (Jenkins et al., 2011). The role of this during 
hepatic fibrosis and fibrosis resolution has not previously been defined. In order to assess 
this, I injured wild type C57BL/6 mice with 4 weeks of CCl4 as before, followed by liver 
harvests 24, 72 and 120 hrs after the final CCl4 injection. Hepatic non parenchymal cells 
were isolated as before and stained with the previously described panel of markers (Fig 
3.8B). On this occasion, cells were also co-stained for the proliferation marker Ki-67 (or 
isotype control) in a manner similar to that published (Jenkins et al., 2011). As shown in Fig 
5.5A, using this method I was able to identify Ki-67 positive hepatic macrophages, when 
compared to an isotype control. This is indicative of active proliferation of these cells.  
Using flow cytometry at each timepoint, I proceeded to subdivide the macrophages into the 

















. Each of these was then assessed for the degree Ki-67 positivity, to 
determine which of the hepatic macrophage subsets was proliferating at which timepoint. As 
shown in Fig 5.5B, the pro-inflammatory Ly-6C
hi
 hepatic monocyte-derived macrophage 
population was the predominant Ki-67 positive macrophage subset at all 3 timepoints studied 
(n=3-6). Indeed, during the inflammatory/fibrogenic phase (24 hrs), 38.2±8.3% of these cells 
were Ki-67 positive indicative of a high level of proliferative activity (Fig 5.5B). 
Proliferative activity, whilst present, was at a significantly lower level in both Ly-6C
lo
 and 




Figure 5.5 - Local Proliferation of Hepatic Ly-6C
hi
 Macrophages Contributes to 
Changes in Subsets during Fibrogenesis and Fibrosis Resolution 
Wild type C57BL/6 mice were injured with 4 weeks of CCl4, followed by liver harvests 24, 
72 and 120 hrs after the final CCl4 injection. Hepatic non-parenchymal cells were isolated at 














cells by flow cytometry. (A) Ki-67 (or isotype control antibody) co-staining of 
hepatic non-parenchymal cells to enable identification of Ki-67 positive macrophages by 
flow cytometry. (B) Percentage of stated macrophage subset at indicated timepoint identified 
as Ki-67 positive (n=3-6). All data shown as Mean±S.E.M; *P<0.05; Representative flow 








In this chapter, using an adoptive transfer of Ly-6C
hi
 bone-marrow derived monocytes, I 
have demonstrated that the restorative Ly-6C
lo
 hepatic macrophage subset is derived from 
Ly-6C
hi
 “inflammatory” monocytes. Given that previous work has shown pro-fibrotic Ly-
6C
hi
 hepatic monocyte-derived macrophages also derive from recruited Ly-6C
hi
 monocytes 
(Karlmark et al., 2009), these data suggest that the restorative Ly-6C
lo
 hepatic macrophages 
form following a switch in macrophage phenotype in situ. This is strengthened by the close 
temporal relationship between the loss of hepatic Ly-6C
hi
 and increase in Ly-6C
lo
 
macrophages (Fig 3.9 B to D) and the fact that the maximal increase in hepatic Ly-6C
lo
 
macrophages (72 hrs) occurs after a decline in hepatic CCL2 levels (Fig 3.5B), the principal 
chemokine implicated in mediating recruitment of inflammatory monocytes. 
I proceeded to study the contribution of Ly-6C
lo
 circulating monocytes to hepatic 
macrophage subsets during resolution from CCl4 induced liver fibrosis. Using a well 
described in situ labelling technique with fluorescent latex beads (Tacke et al., 2007, Tacke 
et al., 2006), Ly-6C
lo
 circulating monocytes do not seem to contribute to any of the hepatic 
macrophage populations during inflammation/fibrogenesis (24 hrs) or maximal fibrosis 
resolution (72 hrs) phase following the final CCl4 injection. Specifically, I have found no 
evidence that Ly-6C
lo
 monocytes form restorative Ly-6C
lo
 hepatic macrophages. 





 hepatic macrophage subset was latex positive. This could suggest that Ly-6C
lo
 
circulating monocytes may be relevant in repopulating the “resident” hepatic macrophages 
during late resolution. This has been a suggested function of this monocyte population by 
other authors (Gordon and Taylor, 2005). However, caution should be made in making this 
interpretation without further evidence, as hepatic macrophages are well known scavengers 
and may simply accumulate latex beads at this late juncture from dead or dying monocytes. 
Overall, these data demonstrate that in the resolution from CCl4-induced liver fibrosis, the 
key functional Ly-6C
lo
 macrophage subset derives from Ly-6C
hi
 and not Ly-6C
lo
 monocytes, 
indicating that an in situ change in macrophage phenotype rather than a separate phase of 
recruitment is critical. This is analogous to findings by Arnold et al. in skeletal muscle, 
where inflammatory Ly-6C
hi
 monocytes are recruited in response to injury and change 
phenotype to gain anti-inflammatory properties and promote muscle growth and regeneration 
(Arnold et al., 2007). In contrast, a murine model of myocardial infarction results in an initial 
recruitment of inflammatory Ly-6C
hi





 monocytes, which promote wound healing (Nahrendorf et al., 2007). 
Thus, the cellular dynamics of the macrophage response to tissue injury can vary 
significantly depending on the tissue involved and the nature of the injury. 
I have also defined the relative contribution of local macrophage proliferation to hepatic 
macrophage subsets following CCl4 injury. Interestingly, Ly-6C
hi
 monocyte-derived 
macrophages were the most proliferative subset during both the inflammatory/fibrogenic 
phase and fibrosis resolution phase. The fact that the number of these hepatic Ly-6C
hi
 
macrophages declines rapidly during the switch to fibrosis regression (Fig 3.9B and C), 
despite active proliferation of this population (Fig 5.5B), emphasizes the point that this 
subset undergoes a change in phenotype in situ, leading to the formation of restorative Ly-
6C
lo
 hepatic macrophages. The finding of proliferation of the monocyte-derived 
macrophages in the liver is seemingly in contrast with a recent study by Jenkins et al., 
whereby resident, rather than recruited macrophage populations were the principal 
proliferative population in the context of chronic parasitic infection in the lung (Jenkins et 
al., 2011). However, on closer analysis the authors also showed the capacity of recruited 
monocyte-derived macrophages to proliferate in response to Il-4 stimulation in the context of 
more “classical” inflammatory stimuli (Jenkins et al., 2011), mirroring our observations. 
Therefore, it seems likely that the relative contribution of local proliferation of distinct 
macrophage subsets following injury will be critically dependent on the nature of the injury 






 Restorative Ly-6Clo hepatic macrophages derive from circulating inflammatory Ly-
6C
hi
 monocytes, a common origin to pro-fibrotic Ly-6C
hi
 hepatic macrophages, 
indicating that a switch in macrophage function in vivo confers pro-resolution 
properties. 
 Circulating Ly-6Clo monocytes do not contribute to the restorative Ly-6Clo hepatic 
macrophage population but may replenish “resident” macrophages following the 
cessation of injury. 
 Pro-inflammatory Ly-6Chi hepatic macrophages show a high level of Ki-67 staining 
during both liver fibrogenesis and early resolution, demonstrating that local 
proliferation of this subset contributes to macrophage expansion and potentially the 




CHAPTER 6 – CHARACTERISATION OF 






Having identified hepatic Ly-6C
lo
 monocyte-derived macrophages as the principle 
“restorative” population, responsible for the regression of liver fibrosis following chronic 
injury with CCl4, I sought to characterize the phenotype of this population more extensively. 
In particular, I aimed to identify the specific mediators produced by this population that 
confer its pro-resolution properties. In order to do this, I compared the pro-resolution 72 hr 
Ly-6C
lo
 macrophages with pro-fibrotic 24 hr Ly-6C
hi
 hepatic macrophages given their 
common origin from Ly-6C
hi
 monocytes, their distinct functional roles and their relative 
predominance at the critical timepoints in the 4 week CCl4 fibrogenesis-resolution model. 
This comparison could also enable the identification of factors that might promote the switch 
in macrophage phenotype from one enhancing fibrogenesis to one inducing fibrosis 
regression. 
Traditional views of macrophage phenotype and polarization has focused on the M1 
(classically activated) and M2 (alternatively activated) paradigm. It has been thought that M1 
macrophages were pro-inflammatory, whilst M2 macrophages were responsible for wound 
healing responses (Mantovani et al., 2004, Mosser and Edwards, 2008). This classification 
was largely based on in vitro work and thus numerous markers of each activation state have 
been suggested. By analyzing the changes in expression of such markers from the unbiased 
microarray dataset, I also aimed to determine how the inflammatory and restorative hepatic 
macrophage subsets fitted into the traditional M1/M2 macrophage classification. 
AIMS 
 To profile gene expression of restorative Ly-6Clo hepatic macrophages compared to 
pro-fibrotic Ly-6C
hi
 hepatic macrophages using microarray to identify key mediators 
produced by each subset 
 To use gene expression profiles to identify key pathways that are expressed in each 
macrophage population 
 To use gene expression profiles to identify specific markers of each subset which 
will enable identification by immunohistochemistry in murine and human tissue 
 To utilize pathway analysis to identify factors that might induce the switch from pro-









 Macrophage Subsets to Study Distinct 
Phenotypes 





 hepatic macrophage subsets, I developed a method for isolating 
and purifying these populations. Wild type C57BL/6 mice were injured as before with 4 
weeks of CCl4. Livers were then harvested at 24 or 72 hrs following the final CCl4 injection, 
the times of inflammation/fibrogenesis and maximal fibrosis resolution respectively. 
Digested livers were analysed by flow cytometry as before and macrophage subsets defined 
(Fig 3.9 A and B). The predominant macrophage population (Ly-6C
hi
 for 24 hrs; Ly-6C
lo
 for 
72 hrs) at each timepoint was isolated by cell sorting using FACS (Fig 6.1A). This enabled 
direct comparison between pro-fibrotic 24 hr Ly-6C
hi
 hepatic macrophages and pro-
resolution 72 hr Ly-6C
lo
 macrophages, given their common origin and opposing functional 
roles in this model. 
I confirmed the effectiveness of cell sorting by FACS by analyzing the sorted population 
compared to the original flow cytometric gates (Fig 6.1B). Overall, sorting by this method 
routinely yielded over 95% purity of the targeted cell population (Fig 6.1B). Thus, this 
method enables robust comparisons between these populations to be made, with minimal 








 Macrophage Subsets to Study 
Distinct Phenotypes 
(A) Isolation of hepatic macrophage subsets by FACS. Adult male C57BL/6 mice were 
injured with 4 weeks of CCl4 with liver harvest at 24 or 72 hrs following the final CCl4 dose. 
Macrophages were defined as viable CD45+ Ly-6G- NK1.1- B220- CD3- and dual-positive 












macrophages were then isolated by FACS. (B) Confirmation of effectiveness of cell sorting. 
24 hr Ly-6C
hi
 hepatic macrophage subset was identified by flow cytometry and purified by 
FACS. Proportion of sorted cells lying within the Ly-6C
hi
 macrophage gate was then 








Gene Expression Profiling Demonstrates that Ly-6C
lo
 Hepatic Macrophages have a 
Number of Pro-Resolution Properties 
Having established a robust method for isolating and purifying hepatic macrophage subsets 
using FACS, I proceeded to isolate RNA from inflammatory (24 hr Ly-6C
hi
) and restorative 
(72 hr Ly-6C
lo
) hepatic macrophages and performed whole transcriptome analysis using 
Affymetrix GeneChip microarrays. This provided an unbiased analysis of the expression of 
the whole mouse transcriptome (28,853 genes) in each of the critical macrophage 
populations. Given the low amounts of RNA obtained and the desire to avoid pooling 
animals, RNA had to be amplified using a commercially available kit, designed for purpose 
(See Materials and Methods). Data extraction and analysis was performed by Donald 
Dunbar and Jonathan Manning (QMRI Bioinformatics department). Overall, individual 
genes with a fold-change of >2 and P-value <0.05 between the 2 subsets were considered to 
be significantly different. Using these criteria, a full list of genes which are significantly 
more highly expressed in inflammatory macrophages and a list of genes more highly 
expressed in restorative macrophages are published (Ramachandran et al., 2012) and shown 
in Appendix 2, Table S1 and S2. 
A number of relevant genes showed differential expression between the 2 subsets, 
highlighting some key features of each subset (Fig 6.2A and 6.2B, n=3). The full names of 
these genes are shown in Appendix 1. Our group and others have previously defined the key 
role of macrophage matrix metalloproteinase (MMP) expression in matrix degradation 
during fibrosis regression (Fallowfield et al., 2007, Pellicoro et al., 2011, Popov et al., 2010). 
In keeping with these findings, my data demonstrates an upregulation in macrophage MMP 
expression following the switch from inflammatory to restorative cells (Fig 6.2A). 
Conversely, a number of pro-inflammatory cytokines and chemokines are downregulated in 
the restorative macrophage subset (Fig 6.2A). TGF-β, the archetypal pro-fibrotic cytokine, 
showed mildly reduced expression in the restorative macrophages than the pro-fibrotic Ly-
6C
hi
 macrophage subset (Fig 6.2A). However, more striking was the reduction in the 
expression of Thrombospondin-1, an important activator of latent TGF-β in vivo and a 
mediator that is increased in the fibrotic liver (Breitkopf et al., 2005, Crawford et al., 1998, 
Elpek et al., 2008, El-Youssef et al., 1999), in restorative macrophages when compared to 
pro-inflammatory macrophages (Fig 6.2A).  
Restorative macrophages also showed increased expression of other genes which have been 
associated with an anti-fibrotic effect. For example, CX3CR1 expression has been associated 
with hepatic macrophage survival and the development of an anti-inflammatory macrophage 
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phenotype which restricts the degree of liver fibrosis following chronic injury (Karlmark et 
al., 2010). I have shown a trend towards increased CX3CR1 expression in the pro-resolution 
macrophages (Fig 6.2A). Similarly, macrophage migration inhibitory factor (MIF), acting 
via its receptor CD74, has been shown to have anti-fibrotic effects in the liver, potentially via 
an effect on hepatic stellate cells (Heinrichs et al., 2011). My data demonstrates an increase 
in CD74 expression in restorative macrophages (Fig 6.2A), potentially suggestive of an 
additional anti-fibrotic mechanism for this pathway. I have also identified increases in 
potentially relevant growth factors in restorative macrophages. For example, insulin like 
growth factor-1 (IGF-1) gene transfer to cirrhotic rats has been shown to induce matrix 
degradation and fibrosis resolution and to improve liver function (Sobrevals et al., 2010). 
Pro-resolution Ly-6C
lo
 hepatic macrophages show a striking increase in Igf-1 expression 
(Fig 6.2A). 
Hepatic Macrophage Subsets do not Conform to the Traditional M1/M2 Paradigm 
As shown in Fig 6.2B and described in detail in the legend, Ly-6C
lo
 restorative hepatic 
macrophages showed increased expression of some previously described M2 macrophage 
markers such as Mrc1 (Macrophage Mannose Receptor 1), Arg1 (Arginase-1) and Retnla 
(Fizz-1) (n=3). However, these cells also downregulated other traditional M2 markers such 
as Chi3l3 (YM-1), Il1rn (Il-1 receptor antagonist), Kdm6b (Jmjd3), Ccl24, Il-10 and TGF-β 
(Fig 6.2A and 6.2B) (Lawrence and Natoli, 2011, Mantovani et al., 2004). Simultaneously, 
Ly-6C
lo
 macrophages upregulated traditional M1 genes such as Ciita (MHC class II 
transactivator), CD16, CD32 and Serpine1 (PAI-1, plasminogen activator inhibitor type 1) 
(Fig 6.2A and 6.2B) (Shi et al., 1998, Lawrence and Natoli, 2011, Mantovani et al., 2004). 
Thus, both inflammatory Ly-6C
hi
 and restorative Ly-6C
lo
 hepatic macrophages demonstrate 




Figure 6.2 – Differential Expression of Key Genes Define Inflammatory and 
Restorative Hepatic Macrophages 
Microarray analysis of inflammatory Ly-6C
hi
 and restorative Ly-6C
lo
 hepatic macrophage 
populations isolated by FACS sorting from livers 24 and 72 hrs following the final CCl4 
injection respectively. Full names of abbreviated genes are shown in Appendix 1. (A) 
Differential regulation of cytokines, chemokines, chemokine receptors, growth factors and 
matrix degrading enzymes between the inflammatory and restorative macrophage 
populations (Expressed as fold change between the 2 macrophage subsets) (B) Differential 
expression of opsonins, phagocytosis-related genes, PPAR-γ target genes and macrophage 
phenotype markers (M1-classical, M2-alternative) between the macrophage subsets on 
microarray (Expressed as fold change between the 2 macrophage populations). All 








Pathway Analysis of Differentially Expressed Genes Identifies Phagocytosis as a Key 
Feature of Restorative Macrophages 
Having identified numerous genes which were differentially regulated between inflammatory 
and restorative hepatic macrophages (see Appendix 2, Table S1 and S2), I proceeded to 
perform a further analysis on these genes to determine which pathways might be relevant in 
each subset. I utilized the DAVID tool, which enables the classification of large lists of 
genes into functional clusters, on the basis of known pathways including gene ontology and 
KEGG, to identify pathways which show enrichment in the list (Dennis et al., 2003, Huang 
da et al., 2009b, Huang da et al., 2009a). I inputted the list of genes from the microarray 
which were statistically more highly expressed in inflammatory (see Appendix 2, Table S1) 
or restorative macrophages (see Appendix 2, Table S2). Using these lists, the DAVID tool 
identified pathways which were statistically enriched in inflammatory (Fig 6.3A) and 
restorative (Fig 6.3B) macrophages, at a P-value of < 0.05.  
Analysis of genes more highly expressed in inflammatory 24hr Ly-6C
hi
 hepatic macrophages 
demonstrated enrichment for pathways such as response to wounding, coagulation cascade 
and chemotaxis (Fig 6.3A). These pathways have all been associated with fibrogenesis 
(Anstee et al., 2009, Sahin et al., 2010), in keeping with the known pro-fibrotic role of this 
cell population.  
Pathway analysis of genes upregulated in restorative 72hr Ly-6C
lo
 hepatic macrophages 
demonstrated enrichment in lysosomes, endocytosis, scavenger receptors and antigen 
processing and presentation, all of which are implicated in phagocytosis (Fig 6.3B). 
Additionally, I identified enhancement of fatty acid metabolism and PPAR signalling 
pathways (Fig 6.3B) 
The enrichment of phagocytosis related pathways in restorative macrophages was 
particularly striking. I therefore went on to confirm the upregulation of phagocytosis-related 
genes in this macrophage subset on an individual basis (Fig 6.2B). Specifically, Ly-6C
lo
 
macrophages upregulated a number of opsonins, receptors and genes involved in the 
clearance of cellular debris. Additionally, a number of specific PPAR-γ target genes were 




Figure 6.3 – Pathway Analysis of Differentially Expressed Genes from Macrophage 
Subsets 
Pathway analysis using the DAVID tool of genes upregulated in each macrophage subset as 
identified on microarray (Expressed as number of upregulated genes in the stated pathway). 
(A) Pathways enriched in pro-inflammatory macrophage subset. (B) Pathways enriched in 
the restorative macrophage subset. Microarray data based on n=3 per group taken from 2 








Confirmation of Microarray Findings at a Gene and Protein Level 
In order to confirm the reliability of the microarray findings, I performed standard qPCR on 
amplified cDNA from each of the sorted macrophage subsets, for a number of the 
differentially expressed genes previously identified (Fig 6.4A, n=7-10). Importantly, the 
differences in gene expression were very similar with this method to those observed using 
the microarray (Fig 6.2 A and B), demonstrating the reliability and validity of the 
microarray data. 
I went on to assess protein expression of a number of the identified differentially expressed 
genes on both inflammatory and restorative macrophages using flow cytometry (Fig 6.4B, 
n=3-6). These data confirmed that observed differences in gene expression on the microarray 
were also translated into differences in protein expression in each of the macrophage subsets. 
I also determined and compared the overall MMP activity of inflammatory and restorative 
macrophage subsets. MMPsense was administered to mice according to the schedule 
previously shown (Fig 3.11A), followed by isolation of inflammatory (24  hr Ly-6C
hi
) and 
restorative (72 hr Ly-6C
lo
) macrophages and assessment of the degree of MMPsense 
fluorescence and hence MMP activity. Importantly, each subset was isolated 24 hrs after an 
MMPsense injection. Comparison of MMPsense fluorescence, identified that restorative 
macrophages have greater MMP activity than inflammatory macrophages, mirroring the 
increase in MMP gene expression (Fig 6.4B, n=3-6). Thus, the switch forming restorative 




Figure 6.4 – Confirmation of Microarray Findings at a Gene and Protein Level 
Comparison of inflammatory Ly-6C
hi
 and restorative Ly-6C
lo
 hepatic macrophage 
populations isolated by FACS sorting from livers 24 and 72 hrs following the final CCl4 
injection respectively. (A) Expression of stated gene in restorative hepatic macrophages 
relative to mean expression in inflammatory macrophages as assessed by qPCR (n=7-10). 
(B) Flow cytometric analysis assessing the expression of stated marker in restorative 
macrophages relative to the mean expression in inflammatory macrophages. MMPsense was 
administered 24 hrs prior to the time of harvest to compare MMP activity between 
macrophage subsets. (MFI=Mean fluorescence Intensity; Relative to average MFI for 
inflammatory macrophage subset; n=3-6). All data shown as Mean±S.E.M; *P<0.05, 






Identification of Macrophage Subsets by Immunohistochemistry in Murine and 
Human Liver 
One of the key problems in studying macrophage heterogeneity is the lack of specific 
markers that identify functionally distinct populations in situ. This necessitates the use of 
multi-colour flow cytometry on freshly isolated tissue to identify distinct populations. This is 
obviously particularly problematic when attempting to study human disease. Having 





hepatic macrophages, I sought to utilize these data to identify specific markers of each subset 
which could be used to identify these populations in vivo. Chi3l3 (YM-1) was very highly 
expressed in inflammatory Ly-6C
hi
 macrophages and rapidly downregulated following 
transition to the Ly-6C
lo
 phenotype (Fig 6.2B). Conversely MMP-12 and GPNMB showed a 
significant upregulation in the restorative macrophage population (Fig 6.2A and 6.2B).  
I proceeded to perform immunohistochemistry for these markers in livers during the 
inflammatory (24 hrs) and maximal resolution (72 hrs) phases of our 4 week CCl4 model. 
Numerous Chi3l3 positive cells were detected in livers at 24 hrs with a significant decline in 
number at 72 hrs (Fig 6.5A), mirroring the changes in Ly-6C
hi 
macrophage number seen on 
flow cytometry at these timepoints (Fig 3.9 B to D). Conversely, the number of hepatic 
MMP-12 and GPNMB positive cells increased from 24 to 72 hrs (Fig 6.5A), mirroring the 
flow cytometric changes in Ly-6C
lo
 macrophages (Fig 3.9 B to D). Furthermore, the spatial 
distribution of these MMP-12 and GPNMB positive cells are closely related to the hepatic 
scars at 72 hrs (Fig 6.5A), in keeping with a role in matrix degradation.  
For further confirmation of the utility of these markers in identifying the distinct macrophage 
subsets, I determined the number of hepatic Chi3l3 and MMP-12 positive cells in my 
CD11b-DTR model (Fig 4.1A). Blinded cell counts showed that MMP-12 positive cells 
were reduced following DT administration (Fig 6.5B, n=5-6), whilst no difference in Chi3l3 
positive cells was observed (Fig 6.5C, n=5-6). Once again these data mirror previous flow 
cytometric findings (Fig 4.2B), and highlight the potential utility of Chi3l3 and MMP-12 as 
specific markers of inflammatory (Ly-6C
hi
) and restorative (Ly-6C
lo
) hepatic macrophages 
respectively.  
I went on to attempt to identify similar macrophage populations in human liver disease. 
Unfortunately, no human equivalent of Chi3l3 exists. I therefore focused on MMP-12 and 
GPNMB as potential markers of the human hepatic restorative macrophage. 
Immunohistochemistry of cirrhotic human liver identified both MMP-12 and GPNMB 
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positive cells, in association with hepatic scars (Fig 6.5A). In order to confirm that these 
populations represent macrophage subsets, I proceeded to perform dual immunofluorescence 
for MMP-12 and GPNMB with the macrophage marker CD68 in cirrhotic human liver. Both 
MMP-12 (Fig 6.5D) and GPNMB (Fig 6.5E) co-localized with CD68, indicating that they 
are expressed by a subpopulation of human hepatic macrophages, analogous to the murine 




Figure 6.5 - Identification of Macrophage Subsets by Immunohistochemistry in Murine 
and Human Liver 
(A) Immunohistochemistry for genes differentially-regulated on microarray in murine liver 
at 24 and 72 hr timepoints and in cirrhotic human liver (Scale bars=100μm; Representative 
Images shown). (B & C) CD11b-DTR mice were injured for 4 weeks with CCl4 followed by 
administration of DT or PBS 48, 72 and 96 hrs after the final CCl4 injection with harvest at 
120 hrs. Immunohistochemistry for MMP-12 and Chi3l3 was performed. (B) Average cell 
counts of MMP-12 positive cells per x200 field (Expressed relative to average count from 
PBS-treated mice; n=5-6). (C) Average cell counts of Chi3l3 positive cells per x200 field 
(Expressed relative to average count from PBS-treated mice; n=5-6). (D) Dual 
immunofluorescence for CD68 (red), MMP-12 (green) and DAPI (blue) in cirrhotic human 
liver (scale bar=10µm; arrows indicate cells with co-localization; staining in collaboration 
with R. Aucott). Comparison was made to tissue stained with isotype control antibodies. (E) 
Dual immunofluorescence for CD68 (red), GPNMB (green) and DAPI (blue) in cirrhotic 
human liver (scale bar=10µm; arrows indicate cells with co-localization; staining in 
collaboration with R. Aucott). Comparison was made to tissue stained with isotype control 








Restorative Macrophages are Post-Phagocytic 
Phagocytosis and the removal of dead or dying cells is a critical function of tissue 
macrophages in inflammation, and has an important effect on the resultant macrophage 
phenotype (Devitt and Marshall, 2011, Erwig and Henson, 2007, Savill et al., 2002). As 
described, I defined an upregulation of pathways (Fig 6.3B) and individual genes (Fig 6.2B) 
which are important in phagocytosis, as a key feature of the restorative macrophage subset. 
Furthermore, the greatest increase in restorative macrophage number occurred after a 
significant reduction in hepatocyte death as assessed by serum AST and ALT levels (Fig 
3.5A), suggesting that this macrophage subset emerges following the clearance of hepatocyte 
debris. I therefore sought to determine whether the restorative macrophage population 
showed evidence of prior phagocytosis. This could implicate the ingestion of debris as an 
important factor in the switch from inflammatory to pro-resolution macrophages. 
I first investigated the morphological characteristics of hepatic inflammatory (24 hr Ly-6C
hi
) 
and restorative (72hr Ly-6C
lo
) macrophages. Using flow cytometry, restorative macrophages 
were larger (FSC-A) and showed increased granularity/complexity (SSC-A) (Fig 6.6A, 
n=13). Furthermore, hepatic scar associated macrophages were visually larger at 72 hrs than 
24 hrs when examined using immunohistochemistry (Fig 6.6B). These changes could 
represent an effect of phagocytosis or simply differentiation of a more monocytic population 
into a more mature macrophage subset.  
I therefore sought to identify the presence of intracellular debris in the macrophage subsets 
as categorical evidence of post-phagocytic phenotype. Inflammatory and restorative hepatic 
macrophages were FACS sorted as before (Fig 6.1A). Each subset was then fixed on slides, 
TUNEL stained and assessed using confocal microscopy to quantify the presence of intra- 
and extracellular apoptotic debris (Fig 6.6C). I then performed blinded cell counts on each 
subset. Importantly, no difference was seen between the percentage of inflammatory or 
restorative macrophages which were associated with TUNEL-positive apoptotic debris (Fig 
6.6D, n=3-4). However, when the localization of apoptotic debris was compared between the 
2 macrophage populations, a clear difference was observed (Fig 6.6E, n=3-4). Specifically, 
apoptotic debris was predominantly bound to the cell surface with inflammatory 




Figure 6.6  – Restorative Macrophages are Post-Phagocytic 
Comparison of inflammatory (24 hr Ly-6C
hi
) and restorative (72 hr Ly-6C
lo
) macrophage 
subsets following 4 weeks of CCl4. (A) Size (FSC-A) and complexity (SSC-A) of 
macrophage subsets assessed by flow cytometry (Expressed relative to average MFI for 
inflammatory macrophages; n=13 pooled from 3 independent experiments). (B) F4/80 
immunohistochemstry demonstrates larger scar-associated macrophages at 72 hrs (Scale 
bar=50μm). (C to E) TUNEL-staining and confocal microscopy of FACS-sorted 
inflammatory and restorative hepatic macrophage subsets. (C) Stained DAPI, TUNEL, F4/80 
and merged image for macrophage subsets (Scale Bars=10μm; Arrowheads=cell-surface 
debris; Arrows=ingested debris). (D) Percentage of each subset associated with TUNEL-
positive nuclei by cell counting (n=3-4). (E) Percentage of TUNEL-associated macrophages 
with ingested or cell-surface debris (n=3-4). Data shown as Mean±S.E.M; *P<0.05, 







In this chapter I have isolated pure populations of “inflammatory” 24 hr Ly-6C
hi
 and 
“restorative” 72 hr Ly-6C
lo
 hepatic macrophages by FACS, enabling in depth analysis of the 
phenotype of these cells. Specifically, using an unbiased microarray approach, I have been 
able to exhaustively characterise these key hepatic macrophage subsets. This is the first such 
analysis of macrophage subsets isolated from fibrotic liver and is certainly the first to relate 
full gene expression profiles of macrophages to function in the liver.  
Overall, these data show that the switch from pro-inflammatory pro-fibrotic Ly-6C
hi
 
macrophages to restorative Ly-6C
lo
 macrophages confers a number of properties that could 
contribute to fibrosis regression. As anticipated, this change in macrophage phenotype 
results in an increase in MMP expression and overall MMP activity. Our group and others 
have previously demonstrated that macrophage MMP expression is critical for liver fibrosis 
regression (Fallowfield et al., 2007, Pellicoro et al., 2011, Popov et al., 2010).  Interestingly, 
MMP-12 seems to be the most upregulated of the matrix degrading enzymes in the 
restorative macrophage subset. MMP-12 has matrix degrading properties important in liver 
fibrosis resolution (Pellicoro et al., 2011). However, the scope of activity of MMP-12 
extends beyond simple matrix degradation and has also been shown to control the 
inflammatory response, particularly through modulation of chemokine activity (Chan et al., 
2013, Dean et al., 2008). A number of other inflammatory cytokines and chemokines are 
reduced in the restorative macrophage population when compared to the pro-fibrogenic 
subset, in keeping with a less inflammatory macrophage phenotype when fibrosis resolution 
commences. TGF-β is the archetypal pro-fibrotic cytokine. Macrophages are a known source 





 hepatic macrophages might result in reduced macrophage TGF-β 
expression. Whilst this was the case (Fig 6.2A), the difference was not statistically 
significant.  Importantly, TGF-β activity is not regulated at the level of gene expression but 
rather it is secreted as a latent precursor complexed with a binding protein, which requires 
cleavage for activation (Leask and Abraham, 2004). Interestingly, thrombospondin-1, a 
molecule which is a key activator of latent TGF- β (Murphy-Ullrich and Poczatek, 2000) 
with a consequent pro-fibrogenic effect on hepatic stellate cells (Breitkopf et al., 2005), 
shows a striking downregulation in restorative macrophages (Fig 6.2A). This suggests a 
possible mechanism linking inflammatory Ly-6C
hi
 macrophages to activation of TGF-β 
signalling and hence a pro-fibrogenic role and thus may provide the link between 
macrophage phenotype and TGF-β activation.  
180 
 
I have also identified a number of other potentially pro-resolution genes which are up 
regulated in restorative Ly-6C
lo
 macrophages. In 2 murine knockout studies, CX3CR1 has 
been shown to have anti-fibrotic effects in the liver (Karlmark et al., 2010, Aoyama et al., 
2010). In keeping with my data, CX3CR1 was predominantly expressed on Ly-6C
lo/negative
 
hepatic macrophages following injury (Aoyama et al., 2010). In both these studies, CX3CR1 
deficiency resulted in increased levels of hepatic inflammation, injury and macrophage 
infiltration in response to CCl4. Furthermore, the lack of CX3CR1 on hepatic macrophages 
resulted in a more pro-inflammatory pro-fibrogenic macrophage phenotype with higher 
expression levels of TNF-α and TGF-β and lower levels of IL-10 and arginase-1 (Aoyama et 
al., 2010). Interestingly, CX3CR1 promotes expression of the anti-apoptotic gene bcl2 in 
hepatic monocyte-derived macrophages and hence may be important for macrophage 
survival as well as differentiation (Karlmark et al., 2010). Thus, CX3CL1-CX3CR1 
signalling may represent an important mechanism in the generation of restorative 
macrophages in my model.  
CD74 has also been shown to have an anti-fibrotic effect in a murine liver fibrosis model 
(Heinrichs et al., 2011). CD74 is upregulated in restorative macrophages (Fig 6.2). However, 
in the published study the anti-fibrogenic effect of MIF-CD74 signalling was felt to be 
mediated by HSCs (Heinrichs et al., 2011), and so nothing is known of the role of this 
pathway in hepatic macrophages. Interestingly, CD74 is also upregulated in resolution phase 
macrophages in the peritoneum (Stables et al., 2011). Hence, the role of CD74 in 
macrophage phenotype would certainly merit further study.  
Insulin-like growth factor-1 (IGF-1) expression was also strongly upregulated in restorative 
hepatic macrophages (Fig 6.2A). IGF-1 has previously been shown to have anti-fibrotic 
effects in the liver in rodents, with gene transfer to rats capable of inhibiting fibrosis 
progression during ongoing injury (Vera et al., 2007) and also enhancing fibrosis regression 
following the cessation of injury (Sobrevals et al., 2010). Indeed, the administration of 
recombinant IGF-1 has undergone a limited clinical study in cirrhotic patients with an 
improvement in serum albumin, albeit with no clinical benefit in a small number of patients 
(Conchillo et al., 2005). This beneficial effect may be mediated via effects on other 
fibrogenic mediators such as increasing levels of MMPs and reducing levels of TGF-β and 
TIMPs (Bonefeld and Moller, 2011). Intriguingly, IGF-1 also stimulates hepatocyte 
proliferation and survival, either directly via the IGF-1 receptor (Kundu et al., 2003, 
Desbois-Mouthon et al., 2006) or by stimulating the production of other growth factors such 
as hepatocyte growth factor (HGF) (Sanz et al., 2005). Hence, IGF-1 expression could link 
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the restorative macrophage population with liver regeneration, although the relative 
functional contribution of macrophage-derived IGF-1 versus that derived from other cell 
types such as hepatocytes or HSCs remains to be defined.   
An additional advantage of the microarray dataset, is that it enabled me to characterise the 
distinct macrophage subsets according to the M1/M2 macrophage activation paradigm. 





hepatic macrophages share features of M1 and M2 cells and the change from 
inflammatory to restorative cells does not conform to this linear model of macrophage 
activation, but rather these cells represent novel phenotypes. In many ways this is 
unsurprising, as the traditional M1/M2 classification is largely based on in vitro studies and 
hence cannot hope to recapitulate the complex milieu seen in vivo (Lawrence and Natoli, 
2011, Mantovani et al., 2004). This highlights the importance of defining macrophage 
populations on the basis of function. Having said that, the lack of specific markers of 
functionally distinct macrophage populations limits the study of macrophage dynamics in 
vivo, as multicolour flow cytometry on freshly isolated tissue is usually needed to define 
distinct populations.  This is particularly relevant in human disease, where tissue samples are 
limited. Hence, identification of markers which specifically select either pro-fibrogenic or 
restorative macrophages and can be studied by immunohistochemistry will be a major 
advantage. Again, my unbiased microarray approach was useful to this end. Specifically, the 
aforementioned MMP-12 and the glycoprotein nonmetastaic melanoma B (GPNMB) were 
strikingly upregulated in restorative macrophages. Immunohistochemically, MMP-12 and 
GPNMB positive cells showed a macrophage morphology and accumulated around hepatic 
scars at the time of maximal scar resolution following CCl4 injury, mirroring the increase in 
Ly-6C
lo
 macrophages seen by flow cytometry (Fig 6.5A). Both of these proteins were also 
detected immunohistochemically in a subset of hepatic macrophages in human cirrhotic liver 
(Fig 6.5A, D and E). Hence, this may represent a method of detecting human hepatic 
restorative macrophages. Conversely, chitinase-3-like 3 (Chi3l3 or YM-1), a characteristic 
M2 marker, is highly expressed in pro-fibrogenic Ly-6C
hi
 macrophages and hence can be 
utilised as an immunohistochemical marker of this macrophage subset (Fig 6.5A). 
Unfortunately, no exact human analogue of this gene exists. However, chitinase-3-like 1 
(Chi3l1 or YKL-40), an enzyme from the same mammalian chitinase-like protein family, has 
been identified as a serum marker of human hepatic fibrosis (Johansen et al., 2000), found to 
be upregulated in fibrotic human liver (Sarma et al., 2012) and shown to be expressed by a 
subpopulation of hepatic macrophages in a rat model (Pizano-Martinez et al., 2011). Hence, 
this may serve as a potential marker of the pro-fibrotic macrophage subset in humans. 
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In addition to the range of individual gene changes identified, the microarray dataset also 
enabled pathway analysis, identifying which gene clusters are enriched in each subset and 
hence shedding light on specific functional characteristics. Whilst the pathways enriched in 
inflammatory Ly-6C
hi
 macrophages could be anticipated by their pro-fibrogenic effects (Fig 
6.3A), restorative Ly-6C
lo
 macrophages showed a striking upregulation in phagocytosis-
related genes (Fig 6.3B). It is well recognized that phagocytosis has significant effects on 
macrophage phenotype (Devitt and Marshall, 2011, Erwig and Henson, 2007, Savill et al., 
2002). Therefore, phagocytosis may represent a key event in the change in phenotype from 
inflammatory to restorative macrophages. Should this be the case, one would anticipate that 
restorative macrophages would show features of being post-phagocytic. I therefore 
developed a technique to prove this, and categorically showed an increased in intracellular 
apoptotic debris in restorative macrophages whilst debris was predominantly bound to the 
cell surface in the inflammatory subset (Fig 6.6C). Hence, I have confirmed that the 
restorative macrophage subset represents a post-phagocytic population. 
SUMMARY 
 FACS can be utilised to isolate functionally distinct inflammatory and restorative 
hepatic macrophage subsets, enabling detailed analysis of the characteristics of each 
of these populations 
 Microarray analysis of inflammatory and restorative hepatic macrophage subsets 
enables an unbiased assessment of genes expressed by each population, and which 
genes change expression in association with the changes in macrophage function 
 Restorative macrophages show a number of pro-resolution features including 
reduced expression of pro-inflammatory cytokines, chemokines and TGF-β 
activating proteins such as thrombospondin-1, whilst upregulating anti-fibrotic genes 
including MMPs and IGF-1. 
 Both inflammatory and restorative macrophages show features of M1 and M2 
macrophage phenotypes and cannot be categorised according to this paradigm 
 Microarray data demonstrated specific markers for each subset (Chi3l3 for 
inflammatory macrophages; MMP-12 and GPNMB for restorative macrophages) 
which enabled identification of these populations in situ using 
immunohistochemistry and hence may permit more detailed study of macrophage 
subsets in human liver disease. 
 Pathway analysis of genes upregulated in restorative macrophages identified 
phagocytosis as a key feature of this subset. 
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 Restorative hepatic macrophages, when compared to inflammatory macrophages, 
show clear evidence of being post-phagocytic, suggesting that phagocytosis may be 





CHAPTER 7 – MODELLING THE 
GENERATION OF RESTORATIVE 






Having identified the key mediators expressed by the restorative Ly-6C
lo
 hepatic 
macrophage population in vivo, determined that this subset was formed from a phenotypic 
switch in situ and demonstrated that a key feature of this population was being post-
phagocytic, I sought to model this macrophage phenotype in vitro. Specifically I aimed to 
ascertain whether macrophage phagocytosis in vitro would induce a similar macrophage 
phenotypic switch and enhance matrix degrading capability. This would enable me to study 
the macrophage signalling cascades that could contribute to this phenotype. Specifically 
MAPK signalling, in particular the ERK and p38 cascades, have previously been reported to 
be activated in macrophages in response to phagocytosis and to regulate a number of 
macrophage responses (Chung et al., 2007, Hu et al., 2002, Jehle et al., 2006, Kurosaka et 
al., 2003, Weigert et al., 2006). 
Furthermore, the development of an in vitro model would enable the study of the effects of 
non-cellular material such as liposomes which could potentially be used to modify 
macrophage phenotype in vivo. 
AIMS 
 To determine whether macrophage phagocytosis of hepatocyte debris in vitro causes 
a similar macrophage phenotypic switch to that observed in vivo 
 To determine whether this results in increased matrix degrading activity 
 To ascertain whether this phenotypic switch occurs with alternative forms of cellular 
debris 
 To determine the signalling pathways that are important for the matrix degrading 
phenotype 
 To determine if a similar macrophage phenotype was induced by liposome ingestion 
which could be used in vivo 
RESULTS 
Differentiation of Primary Bone Marrow Derived Macrophages Results in a Pure 
Population 
In order to develop assays to study the effect of phagocytosis on macrophage phenotype, I 
used primary bone marrow derived macrophages (BMDMs) from C57BL/6 mice. These are 
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the most consistently available and widely used primary murine macrophages in such studies 
(Marim et al., 2010). I utilized a well established 7 day differentiation protocol from whole 
bone marrow in non-adherent flasks (to minimize activation) in the presence of L929 
conditioned medium as a source of M-CSF (Henderson et al., 2008). As shown by Diff Quik 
staining, morphologically this differentiation process yielded a pure population of 
macrophages (Fig 7.1A). I went on to perform flow cytometry to assess the purity of these 
cells. As demonstrated, consistently over 90% of the differentiated BMDMs were positive 
for the macrophage markers F4/80 (Fig 7.1B) and CD11b (Fig 7.1C), with minimal 
positivity for the more dendritic cell marker CD11c (Fig 7.1D). Thus, whilst clearly not 
identical to the isolated hepatic monocyte and macrophage subsets, BMDMs provide a pure 




Figure 7.1 – Differentiation of Bone Marrow Derived Macrophages Yields a Pure 
Population 
Bone marrow derived macrophages (BMDMs) were cultured and differentiated for 7 days in 
L929 containing culture medium. (A) Diff Quik staining of cytospins of day 7 BMDMs 
demonstrated macrophage morphology (x200 magnification). (B to D) Flow cytometric 
analysis of BMDMs for macrophage markers F4/80 (B) and CD11b (C) and the dendritic 
cell marker CD11c (D). Antibody staining (red) was compared with relevant isotype control 







Co-Culture of BMDMs and Primary Hepatocyte Debris Results in an Restorative-like 
Macrophage Phenotype 
Given that the majority of hepatic cell debris in the CCl4 model is from hepatocytes, I 
initially sought to determine the effect of hepatocyte debris on BMDM phenotype. Primary 
murine hepatocytes were isolated from adult C57BL/6 mice using a standard protocol (see 
materials and methods). They were cultured overnight, followed by induction of cell death 
by incubating with anti-CD95 in serum free medium for 8 hours, resulting in >95% trypan 
blue positivity. This hepatocyte debris was then co-cultured with BMDMs for 16 hours. As 
shown in Fig 7.2A, addition of hepatocyte debris resulted in a significant change in 
macrophage morphology, evident on phase contrast microscopy. Importantly, tissue culture 
wells containing hepatocyte debris alone did not show significant cellular attachment 
following washing. To further confirm the interaction between BMDMs and hepatocyte 
debris, macrophages and hepatocytes were fluorescently labelled green (CFSE) and red 
(PKH-26) respectively, followed by co-culture. Fluorescence microscopy following vigorous 
washing, clearly demonstrated a direct interaction between the majority of BMDMs and 
hepatocyte debris, in keeping with macrophage ingestion (Fig 7.2B). 
I then proceeded to identify gene expression changes in BMDMs following co-culture with 
hepatocyte debris by qPCR. In order to compare the macrophage phenotypic changes with 
those I identified in vivo, I focused on genes which were differentially regulated between 
inflammatory (Ly-6C
hi
) and restorative (Ly-6C
lo
) hepatic macrophages (Fig 6.2A and B). As 
an additional control, any genes which showed significant expression in hepatocyte debris 
alone were excluded from further analysis to prevent the potential for contamination of 
macrophage RNA. As shown in Fig 7.2C, a number of relevant genes showed differential 
expression following macrophage phagocytosis of hepatocyte debris (n=11-12). In particular, 
the important matrix metalloproteinase enzymes MMP-12 and MMP-9, both of which are 
upregulated following the switch from inflammatory to restorative hepatic macrophages in 
vivo, are more highly expressed in BMDMs following co-culture with hepatocyte debris. 
Furthermore, the upregulation of IGF-1 and downregulation of Thbs1 and Chi3l3 in response 
to macrophage phagocytosis (Fig 7.2C), also closely mirrors the changes observed in vivo 
(Fig 6.2A and B).  
I wished to confirm the secretion of active MMPs and to determine if the observed changes 
were a general effect of phagocytosis on macrophages, irrespective of the nature of the 
cellular debris. I therefore utilized the well described in vitro model of the phagocytosis of 
apoptotic thymocytes (Ferenbach et al., 2010), routinely using a population of thymocytes 
190 
 
which were >90% trypan blue positive. Culture supernatants were harvested from tissue 
culture wells containing macrophages alone, macrophages and thymocyte debris and 
thymocyte debris alone and subjected to either gelatin zymography or western blotting. As 
shown, co-culture of BMDMs with thymocyte debris resulted in increased secretion of active 
MMP-9 (Fig 7.2D) and MMP-12 (Fig 7.2E), mimicking the changes in gene expression 




Figure 7.2 – Co-Culture of Hepatocyte Debris and BMDMs results in a Restorative-like 
Phenotype 
Co-culture of Bone Marrow-derived Macrophages (BMDMs) with primary murine 
hepatocyte debris. (A) Changes in macrophage morphology on phase-contrast microscopy. 
Hepatocyte debris alone was non-adherent (Scale bar=100 µm). (B) CFSE (green) labelled 
BMDMs were cultured in the absence and presence of PKH-26 (red) labelled hepatocyte 
debris (Scale bar=50µm).   (C) Changes in BMDM gene expression following co-culture 
with hepatocyte debris (Expressed relative to mean expression of macrophages alone; n=11-
12 pooled from 2 independent experiments). (D & E) Co-culture of BMDMs with apoptotic 
thymocytes. (D) Gelatin zymography of culture supernatants equalized for protein content, 
showing active MMP-9 (representative zymogram from n=4 from 2 independent 
experiments; experiments performed in collaboration with Dr Steve Hartland). (E) Western 
blot for MMP-12 on culture supernatants, equalised for protein content (representative blot 
from n=4 from 2 independent experiments; experiments performed in collaboration with Dr 
Antonella Pellicoro). Data shown as Mean±S.E.M; *P<0.05, **P<0.01, ***P<0.001. 







The Phagocytosis Induced Matrix Degrading Macrophage Phenotype is Induced by 
ERK Signalling 
Having developed an in vitro model for studying the role of macrophage phagocytosis in the 
induction of matrix degrading properties, I sought to utilise this system to determine which 
signalling cascades might contribute to this change in phenotype. I therefore used specific 
chemical inhibitors of the ERK and p38 cascades (or vehicle controls), added to my co-
culture system, to ascertain if either of these pathways was relevant to the matrix degrading 
phenotype I observed following the phagocytosis of cellular debris. Initially I used PD98059, 
a specific ERK kinase (MEK1/2) inhibitor, at a dose of 50µM according to published 
effective concentrations in macrophages (Raza et al., 2000, Valledor et al., 2000). As shown 
in Fig 7.3A, PD98059 administration significantly inhibited the upregulation of both MMP-
12 and MMP-9 gene expression in macrophages in response to hepatocyte debris (n=6). 
Furthermore, the observed increase in IGF-1 expression was also prevented (Fig 7.3A). I 
proceeded to confirm these changes at a protein level. As demonstrated in Fig 7.3B, Casein 
zymography shows that PD98059 inhibited the secretion of active MMP-9 and MMP-12 by 
macrophages in response to hepatocyte debris (n=3).  
Given this potential role of ERK signalling in the matrix degrading phenotype, I sought to 
determine if I could identify evidence of in vivo ERK activation in hepatic macrophages at 
the time of maximal scar resolution (72 hrs) in my 4 week CCl4 model. Dual 
immunofluorescence demonstrated the presence of nuclear pERK staining in a proportion of 
F4/80 positive hepatic macrophages (Fig 7.3C), indicative of ERK activation in 
macrophages in vivo, and emphasising the relevance of my in vitro data.  
I proceeded to confirm the specificity of the effects of MEK1/2 inhibition on MMP-12 
expression in macrophages, using an alternative specific inhibitor UӦ126 (20µM), again at a 
published dose (Chi et al., 2006, Shin et al., 2008) (Fig 7.4A, n=3). I then wished to 
determine whether ERK inhibition affected the other relevant macrophage phenotypic 
changes I observed in response to co-culture with hepatocyte debris (Fig 7.2C). As shown in 
Fig 7.4B, administration of PD98059 had no effect on macrophage downregulation of Thbs1 
and Chi3l3 in this system (n=6).  
Finally, I wished to determine whether the p38 in addition to ERK signalling contributed to 
the upregulation of MMPs and matrix degrading phenotype following phagocytosis. As 
shown in Fig 7.4C, administration of the specific p38 inhibitor SB203580 (10µM) (Shin et 
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al., 2008, Chi et al., 2006), had no effect on the MMP-12, MMP-9 and Igf1bgg BMDM 




Figure 7.3 – Phagocytosis induced ERK Signalling Causes Matrix Degrading 
Macrophage Phenotype 
(A & B) Culture of BMDMs ± MEK1/2 inhibitor (PD98059; 50µM) ± hepatocyte debris. 
(A) Changes in macrophage gene expression following co-culture measured by qPCR 
(Expressed relative to mean expression of macrophages alone; n=6). (B) Casein zymography 
of culture supernatants equalised for protein content, showing active MMP-9 and MMP-12 
(representative zymogram from n=3 shown). (C) Dual immunofluorescence for F4/80 (red) 
and phospho-ERK (green) in mouse liver, 72 hrs after final CCl4 dose following 4 weeks of 
injury (Arrows=nuclear pERK and F4/80 dual positive cells; Scale bars=10µm). Comparison 
was made to staining with isotype control antibodies. Staining was performed in 
collaboration with R Aucott. Data shown as Mean±S.E.M; *P<0.05, **P<0.01, ***P<0.001. 








Figure 7.4 – p38 Inhibition has no Effect on Matrix Degrading Macrophage Phenotype 
(A) Co-culture of BMDMs ± MEK1/2 inhibitor (UO126; 20µM) ± hepatocyte debris. 
Changes in macrophage Mmp12 gene expression following co-culture (Data shown relative 
to mean Mmp12 expression of macrophages alone; n=3). (B) Co-culture of Bone Marrow-
derived Macrophages (BMDMs) ± MEK1/2 inhibitor (PD98059; 50µM) ± hepatocyte debris. 
Changes in macrophage gene expression following co-culture (Data shown relative to mean 
expression of macrophages alone; n=6). (C) Co-culture of BMDMs ± p38 MAPK inhibitor 
(SB203580; 10µM) ± hepatocyte debris. Changes in macrophage gene expression following 
co-culture (Data shown relative to mean expression of macrophages alone; n=6). All data 








Macrophage Ingestion of Liposomes Induces a Restorative-Like Phenotype 
The macrophage ingestion of liposomes has been demonstrated to be a genuine phagocytosis 
event (Perry and Martin, 1995, Van Rooijen and Sanders, 1994). Furthermore, recent studies 
have suggested that liposome ingestion by macrophages can induce a change in phenotype at 
least partially via ERK signalling (Lin et al., 2011, Ma et al., 2011). I therefore aimed to 
determine whether the administration of liposomes to BMDMs might mimic the changes 
observed following the phagocytosis of cellular debris, and result in a macrophage 
phenotype analogous to the in vivo restorative macrophage. BMDMs were cultured in the 
presence and absence of liposomes. Gene expression was then analysed by qPCR. As shown 
in Fig 7.5, liposome administration resulted in a significant increase in macrophage MMP-12 
expression (n=6). There were also trends to increased expression of MMP-9 and Igf1. 
Furthermore, liposomes induced a significant downregulation in Thbs1, Cxcl10 and Ccl2 




Figure 7.5 – Macrophage Ingestion of Liposomes Induces a Restorative-like Phenotype 
Culture of BMDMs with and without liposomes. (A) Expression of stated gene in BMDMs 
following in vitro culture with liposomes relative to mean expression in BMDMs  alone 








In this chapter, I have attempted to recapitulate some of the features of the in vivo restorative 
Ly-6C
lo
 hepatic macrophages using an in vitro model, and hence enable me to identify some 
of the key signalling mechanisms responsible for the generation of the matrix degrading 
phenotype. Whilst, in an in vitro setting it is clearly impossible to exactly recapitulate the 
complex range of signals to which in vivo macrophages are exposed, I have previously 
shown in Chapter 6 that evidence of phagocytosis seems to be a key feature of the restorative 
macrophage. I therefore focussed on macrophage phagocytosis as a potential inducer of the 
matrix degrading phenotype. Indeed, other authors have previously identified phagocytosis 
as an inducer of MMP expression in macrophages (Popov et al., 2010, Vos et al., 2003). 
Utilising bone marrow derived macrophages (BMDMs) as a pure population of primary 
murine macrophages, co-culture with cell debris from primary murine hepatocytes resulted 
in macrophage phagocytosis and a change in phenotype mirroring that observed in vivo. 
Specifically, I observed a striking increase in BMDM expression of MMPs -9 and -12 and 
IGF-1 and a reduction in Chi3l3 and Thbs1 in response to hepatocyte debris (Fig 7.2C). 
Hence, a similar change in expression patterns of a number of key genes is seen in BMDMs 
exposed to hepatocyte debris in vitro as I observed during the switch from pro-fibrotic Ly-
6C
hi
 hepatic macrophages to restorative Ly-6C
lo
 macrophages in vivo (Fig 6.2). Interestingly, 
the increased expression of MMP-9 and MMP-12 in BMDMs in response to phagocytosis is 
not specific to hepatocyte debris, but also occurred in separate co-culture experiments with 
apoptotic thymocytes (Fig 7.2D and E), suggesting this may be a more generic response and 
hence may also be relevant in organs other than the liver. 
Using this model, I then wished to determine which signalling pathways might link 
macrophage phagocytosis and the generation of the matrix-degrading phenotype. Clearly, 
phagocytosis is a complex process with multiple receptors involved and hence potential 
activation of a number of signalling cascades at different stages. Whilst full exploration of 
these was beyond the scope of this thesis, MAPK signalling, specifically the ERK and p38 
cascades, have been shown to regulate a range of macrophage responses and are known to be 
activated in response to phagocytosis (Chung et al., 2007, Hu et al., 2002, Jehle et al., 2006, 
Kurosaka et al., 2003, Weigert et al., 2006). I therefore focussed on these pathways and used 
highly specific chemical inhibitors of these in my in vitro phagocytosis model. Principally, 
using the MEK1/2 inhibitor PD98059, which inhibits ERK signalling, prevented macrophage 
upregulation of MMP-12 and -9 in response to phagocytosis (Fig 7.3A and B). Similar 
findings were replicated with a alternative MEK 1/2 inhibitor UӦ126. To confirm the 
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potential in vivo relevance of this, I was able to identify active ERK in hepatic macrophages 
at the time of initiation of scar resolution in my 4 week CCl4 model (Fig 7.3C).  Hence, ERK 
signalling in macrophages via MEK1/2 seems to have an important role in generating the 
matrix degrading properties observed. Conversely, ERK inhibition seemed to have no effect 
on other features of the restorative macrophage such as downregulation of Thbs1 or Chi3l3 
(Fig 7.4B).  These data would suggest, perhaps unsurprisingly, that cross-talk between 
different signalling pathways is required to generate the overall complex phenotype of the 
restorative macrophage. This clearly merits further study. My preliminary ERK data could 
be expanded to determine the timescale of ERK activation in response to phagocytosis. 
Furthermore, I have used published doses of signalling inhibitors, but further strength to my 
findings would be given by replicating these experiments to show a dose response effect, 
with expansion to include other signalling pathways. Most importantly, attempts to inhibit 
ERK signalling in hepatic macrophages in vivo might shed important new insights into the 
functional relevance of these observations. However, given the ubiquitous nature of this 
pathway in a range of cell types, this may be difficult to achieve without confounding off 
target effects. 
Finally in this chapter, I sought to determine whether non-cellular debris might induce a 
similar macrophage phenotype in vivo. As mentioned above, liposome ingestion has been 
demonstrated to be a genuine phagocytosis event (Perry and Martin, 1995, Van Rooijen and 
Sanders, 1994) and interestingly induces ERK signalling in macrophages (Lin et al., 2011, 
Ma et al., 2011). Therefore, it is relevant that liposome administration to BMDMs in vitro 
induced a similar change in phenotype to that I observed with macrophage ingestion of 
hepatocyte debris in vitro (Fig 7.5) and also mirrors the changes I observed in the formation 
of the restorative Ly-6C
lo
 hepatic macrophage subset in vivo (Fig 6.2A and 6.2B). Whilst the 
changes in BMDMs gene expression in response to liposomes seems less pronounced than 
the changes induced by cellular debris, liposome ingestion may provide a novel means of 






 Primary BMDMs, differentiated for 7 days, provide a pure population of 
macrophages for the study of macrophage biology in vitro. 
 Co-culture of BMDMs and primary murine hepatocyte debris induces a change in 
macrophage phenotype including an increase in MMP expression, which mirrors the 
change in hepatic macrophage phenotype seen in vivo. 
 The increase in BMDM matrix degrading activity following co-culture with 
hepatocyte debris, also occurs following co-culture with apoptotic thymocytes 
suggesting this may be a generic phagocytosis effect. 
 The increase in MMP-9, MMP-12 and Igf1 expression in BMDMs in response to 
hepatocyte debris is at least partially mediated by the ERK signalling cascade. 
 BMDM phagocytosis of liposomes induces a number of restorative macrophage 




CHAPTER 8 – MANIPULATION OF 





I have previously defined the macrophage subset responsible for the regression of hepatic 
fibrosis and extensively characterised it, specifically identifying that phagocytosis was likely 
to be a key determinant of the switch in macrophage phenotype in vivo from an 
inflammatory pro-fibrogenic Ly-6C
hi
 population to a pro-resolution Ly-6C
lo
 subset which 
has acquired increased matrix degrading activity. I then wished to utilise this dataset to 
identify methods to manipulate macrophage phenotype in vivo, with the ultimate aim of 
enhancing the formation of restorative macrophages and hence accelerating fibrosis 
resolution. 
Initially, having identified PPAR signalling as being upregulated in the restorative 
macrophage subset (Fig 6.2B and 6.3B), I sought to explore this potential association 
further. PPAR-γ signalling in macrophages has been shown to regulate multiple processes 
including inflammatory gene expression, macrophage polarisation and to be important in 
promoting the resolution of inflammation (Bouhlel et al., 2007, Castrillo and Tontonoz, 
2004, Gautier et al., 2012). Additionally, the administration of PPAR-γ agonists has been 
shown to alter macrophage phenotype in vivo (Li et al., 2011, Hasegawa-Moriyama et al., 
2012, Stienstra et al., 2008). Furthermore, data has suggested an anti-fibrotic effect of 
PPAR-γ agonists in vivo in a number of organs including liver (Aoki et al., 2009, Chen et al., 
2008, Higashi et al., Ihm et al., Kiss et al.). Most recently, a study showed an increased 
susceptibility to CCl4 induced liver fibrosis in mice with macrophage-specific PPAR-γ 
knockout (Moran-Salvador et al., 2013). There is therefore a strong rationale to think that 
manipulation of the PPAR-γ pathway might alter hepatic macrophage phenotype. I therefore 
wished to determine whether the administration of the widely-used PPAR-γ agonist 
rosiglitazone might alter hepatic macrophage subsets and enhance fibrosis resolution. 
Secondly, I wanted to determine whether inhibition of macrophage phagocytosis in vivo 
during the resolution phase following CCl4 injury, might alter hepatic macrophage subsets 
and consequently affect recovery following cessation of CCl4. Given the complexity of 
macrophage phagocytosis (described in detail in Chapter 1) potentially involving numerous 
molecules and receptors, I used commercially available blocking antibodies against the 
extracellular bridging molecule MFG-E8 or the phagocytic receptor integrin αv. Milk fat 
globule-EGF factor 8 (MFG-E8, lactadherin) is a glycoprotein that is a key extracellular part 
of the phagocytic process, one domain binding to phosphatidylserine on apoptotic cells and 
another to αvβ3 and αvβ5 integrins on the surface of phagocytic cells, thus facilitating 
engulfment and ingestion (Aziz et al., 2011a, Toda et al., 2012). Additionally, recent studies 
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have suggested that MFG-E8 might have a direct anti-inflammatory effect on macrophages 
(Aziz et al., 2011a, Aziz et al., 2011b). Furthermore, in a separate study MFG-E8 has been 
shown to be anti-fibrotic in a pulmonary fibrosis model, by targeting collagen for uptake by 
macrophages (Atabai et al., 2009). Given the importance of phagocytosis in the formation of 
the restorative hepatic macrophage phenotype, MFG-E8 was an attractive candidate 
molecule which could contribute to the generation of this cell type and hence promote 
hepatic fibrosis regression. 
Integrin αv (ITGAV) on the surface of phagocytes in complexes with integrin β3 or β5 is a 
key phagocytic receptor (Savill et al., 1990, Toda et al., 2012, Wu et al., 2005, Ravichandran 
and Lorenz, 2007). Analysis of the microarray data demonstrated significant gene expression 
of ITGAV in both inflammatory and restorative macrophages. Hence, blockade of ITGAV 
could potentially inhibit macrophage phagocytosis and hence alter hepatic macrophage 
subsets and fibrosis resolution. 
Finally, having determined that macrophage liposome ingestion in vitro results in a similar 
change in phenotype to that observed in vivo (Fig 7.5), I aimed to determine the effects of 
liposome administration to mice on hepatic macrophage phenotype and fibrosis resolution. 
AIMS 
 To determine the effect of rosiglitazone administration on hepatic macrophage 
subsets and fibrosis resolution following CCl4 induced injury 
 To determine the effect of antibody blockade of MFG-E8 on hepatic macrophage 
subsets and fibrosis resolution following CCl4 induced injury 
 To determine the effect of antibody blockade of integrin αv (ITGAV) on hepatic 
macrophage subsets and fibrosis resolution following CCl4 induced injury 
 To determine the effect of liposome administration on hepatic macrophage subsets 
and fibrosis resolution following CCl4 induced injury 
RESULTS 
Rosiglitazone administration has no detectable effect on hepatic macrophage subsets or 
resolution of fibrosis following CCl4 injury 
As shown in Fig 8.1A and described in detail in the legend, adult male C57BL/6 mice were 
administered 4 weeks of CCl4 as before. At 24, 48 and 72 hrs following the final CCl4 
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injection mice were given either rosiglitazone (10mg/kg) at a published dose (Genovese et 
al., 2005) or DMSO control. Animals were harvested at 96 hours, as shown. 
Circulating monocytes were assessed by flow cytometry as before. As shown in Fig 8.1B, 
the administration of rosiglitazone showed a trend to reducing both subsets of circulating 
monocytes, that did not reach statistical significance (n=6-8). Hepatic macrophages and 
subsets were identified using flow cytometry on hepatic non-parenchymal cells as before 
(Fig 3.8B, 3.12A and 3.12B). As shown in Fig 8.1C, rosiglitazone administration did not 
change the relative contribution of macrophages to the hepatic leucocyte pool (n=4-8). 
Further analysis showed no change in the proportion of each of the 3 hepatic macrophage 
subsets in response to rosiglitazone (Fig 8.1D), indicating no increase in restorative 
macrophage number with drug treatment.  Finally, as shown in Fig 8.1E, hepatic fibrosis, as 




Figure 8.1 – Rosiglitazone does not affect Hepatic Macrophage Subsets 
Adult male C57BL/6 mice were  injured with 4 weeks of CCl4 followed by administration of 
PPAR-γ agonist rosiglitazone (10mg/kg, IP) or DMSO (vehicle) control 24, 48 and 72 hrs 











 cells) were identified using flow cytometry and 
quantified from mice treated with rosiglitazone or DMSO at time of harvest (96 hrs) (n=6-8). 
(C) Hepatic macrophages were identified by flow cytometry as before and expressed as a % 
of total hepatic CD45 positive cells (n=4-8). (D) Macrophage subsets were identified by flow 
cytometry as before and expressed as a % of total hepatic macrophages (n=4-8). (E) Hepatic 
fibrosis was assessed by PSR staining and morphometric pixel analysis (n=6-8; Expressed 
relative to mean % area for livers from DMSO-treated animals). All data expressed as 







Antibody Blockade of MFG-E8 does not affect hepatic macrophage subsets or 
resolution of fibrosis following CCl4 injury 
To test the role of MFG-E8 in the generation of the restorative hepatic macrophage, I 
administered an Anti-MFG-E8 blocking antibody (or isotype control) at a published dose of 
2mg/kg (Bu et al., 2007), to CCl4-injured mice, 24, 48 and 72 hrs following the final CCl4 
injection with harvest at 96 hours (Fig 8.2A). I then proceeded to determine if this induced 
any changes in macrophage or fibrosis responses. Quantification of circulating monocytes as 
before, showed no difference in the number of either subset in response to the Anti-MFG-E8 
antibody (Fig 8.2B, n=5-6). I proceeded to identify and quantify hepatic macrophages and 
subsets using flow cytometry of digested livers, as before. As shown, no difference was seen 
in the relative contribution of macrophages to the hepatic leucocyte pool (Fig 8.2C, n=5-6). 
Furthermore, the blocking antibody had no effect on relative proportion of each macrophage 
subset (Fig 8.2D, n=5-6). Finally, analysis of liver fibrosis by PSR staining showed no 
significant difference in fibrosis resolution following administration of the MFG-E8 




Figure 8.2 – Anti-MFG-E8 does not affect Hepatic Macrophage Subsets or Fibrosis 
Resolution 
Adult male C57BL/6 mice were  injured with 4 weeks of CCl4 followed by administration of 
Anti-MFG-E8 (2mg/kg i.p.) or Hamster IgG Isotype control antibody 24, 48 and 72 hrs after 











 cells) were identified using flow cytometry and 
quantified from mice treated with Anti-MFG-E8 or Isotype at time of harvest (96 hrs) (n=5-
6). (C) Hepatic macrophages were identified by flow cytometry as before and expressed as a 
% of total hepatic CD45 positive cells (n=5-6). (D) Macrophage subsets were identified by 
flow cytometry as before and expressed as a % of total hepatic macrophages (n=5-6). (E) 
Hepatic fibrosis was assessed by PSR staining and morphometric pixel analysis (n=5-6; 
Expressed relative to mean % area for livers from Isotype-treated animals). All data 







Antibody Blockade of Integrin αv Reduces Hepatic Restorative Macrophages 
I sought to determine whether blockade of the key phagocytic receptor ITGAV might alter 
hepatic macrophage subsets and affect liver fibrosis resolution. I utilised an Anti-ITGAV 
blocking antibody (RMV-7) or isotype control, at a previously published dose (Takahashi et 
al., 2001). Briefly, as shown in Fig 8.3A, adult male C57BL/6 mice were injured with 4 
weeks of CCl4 as before, followed by administration of Anti-ITGAV (200µg/mouse) or 
isotype control 24, 48 and 72 hrs following the final CCl4 injection with harvest at 96 hrs.  
As shown in Fig 8.3B, analysis of circulating monocyte subsets by flow cytometry at the 
time of harvest demonstrated no significant difference in the number of either monocyte 
subset, although there was a trend to a reduced number of Ly-6C
lo
 monocytes following 
treatment with anti-ITGAV (n=5). I proceeded to analyse the hepatic macrophages by flow 
cytometry as previously described. No difference was seen in the contribution of 
macrophages to the hepatic leucocyte pool (Fig 8.3C, n=5). However, as shown in Fig 8.3D, 
analysis of hepatic macrophage subsets demonstrated that Anti-ITGAV treatment did induce 
an alteration, with a significant reduction in the contribution of restorative Ly-6C
lo 
macrophages, whilst resident macrophages increased when compared to treatment with the 
isotype antibody (n=5). Analysis of liver fibrosis with PSR staining, on the other hand, did 
not show any significant difference with ITGAV blockade when compared to isotype control 




Figure 8.3 - Anti-ITGAV reduces the Restorative Macrophage Population 
Adult male C57BL/6 mice were injured with 4 weeks of CCl4 followed by administration of 
Anti-ITGAV or Isotype control (200 µg/mouse i.p.) 24, 48 and 72 hrs after the final CCl4 











 cells) were identified using flow cytometry and quantified from 
mice treated with Anti-ITGAV or Isotype control at time of harvest (96 hrs) (n=5). (C) 
Hepatic macrophages were identified by flow cytometry as before and expressed as a % of 
total hepatic CD45 positive cells (n=5). (D) Macrophage subsets were identified by flow 
cytometry as before and expressed as a % of total hepatic macrophages (n=5). (E) Hepatic 
fibrosis was assessed by PSR staining and morphometric pixel analysis (n=5; Expressed 
relative to mean % area for livers from Isotype-treated animals). All data expressed as 







Administration of Liposomes during Fibrosis Resolution Increases Restorative Hepatic 
Macrophages 
Given that the restorative macrophage phenotype could be partially recapitulated by the 
ingestion of liposomes in vitro (Fig 7.5), I sought to determine whether the administration of 
liposomes to mice could induce a similar change in macrophage phenotype in vivo. 
Adult male C57BL/6 mice were injured with 4 weeks of CCl4 followed by administration of 
200µl of liposomal PBS (or PBS control) 48, 72 and 96 hrs after the final CCl4 injection, 
with harvest at 120 hrs, according to the schedule shown (Fig 8.4A). As shown in Fig 8.4B, 
analysis of circulating monocyte subsets by flow cytometry at the time of harvest 
demonstrated that the administration of liposomes caused a significant increase in the 
number of circulating Ly-6C
lo
 monocytes, whilst no significant change was seen in the 
number of circulating Ly-6C
hi
 monocytes, albeit with a non-significant trend to reduction in 
this population (n=12-14).  
I then proceeded to assess the effect of liposome administration on hepatic macrophages. As 
shown in Fig 8.4C, injection of liposomal PBS increased the relative contribution of 
macrophages to the hepatic leucocyte pool when compared to PBS alone (n=13-14). 
Macrophage subset analysis showed that this increase in hepatic macrophages was 
accompanied by a change in macrophage subsets, with a significant reduction in the 
contribution of Ly-6C
hi
 macrophages and a significant increase in the contribution of Ly-6C
lo
 
macrophages following liposome administration (Fig 8.4D, n=13-14). Importantly, these 
changes were also observed when the absolute number of each macrophage subset was 






Figure 8.4 – Liposomes Increase the Restorative Macrophage Population 
Adult male C57BL/6 mice were injured with 4 weeks of CCl4 followed by administration of 
Lipsomal PBS or PBS control (200 µl/mouse i.v.) 48, 72 and 96 hrs after the final CCl4 dose 











 cells) were identified using flow cytometry and quantified from mice 
treated with Lipsosomal PBS or PBS control at time of harvest (120 hrs) (n=12-14 from 2 
independent experiments). (C) Hepatic macrophages were identified by flow cytometry as 
before and expressed as a % of total hepatic CD45 positive cells (n=13-14 from 2 
independent experiments). (D) Macrophage subsets were identified by flow cytometry as 
before and expressed as a % of total hepatic macrophages (n=13-14 from 2 independent 
experiments). (E)  Changes in hepatic macrophage subset number, identified by flow 
cytometry, following liposomal PBS or PBS administration (Relative to mean total 
macrophage number in PBS-treated livers; n=13-14 from 2 independent experiments). All 







Liposome Administration Accelerates Hepatic Fibrosis Resolution 
Having shown that liposome administration induced a change in hepatic macrophage 
phenotype, I sought to determine whether this could accelerate hepatic fibrosis resolution. As 
previously demonstrated, being post-phagocytic is a key feature of the restorative Ly-6C
lo
 
macrophage subset. I therefore wished to confirm that hepatic macrophages showed 
evidence of liposome ingestion. To this end, liposomes were fluorescently labelled with 
membrane dye CM-DiI, prior to injection according to an identical schedule (Fig 8.4A). 
Hepatic macrophages were identified as before by flow cytometry. The percentage of each 
hepatic macrophage subset which was positive for CM-DiI, indicating ingestion of 
liposomes, was then defined using flow cytometry. As shown in Fig 8.5A , both Ly-6C
lo
 and 
“Resident” hepatic macrophages show a high degree of CM-DiI positivity, demonstrating a 
high level of phagocytosis of liposomes in these populations (n=8). 
I then went on to assess the effect of liposomes on hepatic fibrosis resolution in the same 
model (Fig 8.4A). As shown in Fig 8.5B and C, liposome administration caused a reduction 
in hepatic PSR staining (n=6), indicating that this intervention accelerated the regression of 




Figure 8.5 – Liposome Administration Accelerates Hepatic Fibrosis Resolution 
Liposomal PBS or PBS control were administered to chronically injured C57BL/6 mice 
according to the schedule shown in Fig 8.4A. (A) Percentage of the stated hepatic 
macrophage subset containing fluorescently-labelled (CM-DiI) liposomes assessed by flow 
cytometry (n=8). (B) Fibrosis assessed by PSR staining following liposomal PBS (or PBS 
control) administration (Representative images shown; Scale bar=100μm) (C) Quantification 
of fibrosis by morphometric pixel analysis (Expressed relative to mean % area for liposome-









In this chapter I have sought to utilise the previous data to ascertain if the in vivo hepatic 
macrophage phenotype can be manipulated in the CCl4 model. Ultimately, such studies are 
essential for translational purposes.  
PPAR-γ signalling was an intriguing initial target. As previously demonstrated from the 
pathway analysis of genes upregulated in restorative macrophages, PPAR signalling was one 
of the enriched pathways (Fig 6.3B). It is known that PPAR-γ activation in macrophages 
plays an important role, being responsible for inflammatory gene expression, macrophage 
polarisation and promoting the resolution of inflammation (Bouhlel et al., 2007, Castrillo and 
Tontonoz, 2004, Gautier et al., 2012). Indeed, recent data using macrophage specific PPAR-
γ knockout mice, has demonstrated that macrophage PPAR-γ expression has important anti-
fibrotic properties in the liver (Moran-Salvador et al., 2013). Given the already well 
established clinical use of the PPAR-γ agonists pioglitazone and rosiglitazone in the 
management of diabetes, they would be potentially attractive anti-fibrotic drugs in liver 
fibrosis. Indeed, studies have already shown that pioglitazone may have an anti-fibrotic 
effect in the livers of non-diabetic NAFLD patients (Aithal et al., 2008). However, despite 
these data, there was no obvious effect of rosiglitazone administration on overall 
macrophage number, macrophage subsets or fibrosis regression in my CCl4 model (Fig 8.1). 
Does this mean a genuine lack of effect? I’d suggest that the studies presented here are too 
preliminary to definitively state this. Whilst, I’d used a previously published dose of 
rosiglitazone, further studies are required to confirm that the drug was effective in activating 
PPAR-γ in the livers of mice in vivo at this dose. Secondly, the timing of drug administration 
may be too short to show a demonstrable effect. Future studies involving more protracted 
drug administration during fibrosis resolution would be useful. Thirdly, PPAR-γ activity is 
already evident in the restorative Ly-6C
lo
 hepatic macrophage population in vivo. It is 
feasible that this pathway is already maximally activated in these cells and hence 
administration of a PPAR-γ agonist when this macrophage subset already predominates may 
have little overall effect. Hence, timing is likely to be crucial. Finally, PPAR-γ signalling is 
not specific to macrophages and indeed has effects on HSC activation (Marra et al., 2000) 
and hepatocyte function (Rogue et al., 2011). Thus, systemic treatment with PPAR-γ 
modulating drugs is likely to affect several hepatic cell types, making specific conclusions 
about the effect on macrophages difficult to draw. 
I proceeded to try and inhibit the phagocytic process in vivo to determine whether this might 
alter macrophage phenotype and have consequent effects on hepatic fibrosis. Again, this is a 
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natural progression from my previous data, where I’ve shown that macrophage phagocytosis 
plays a key part in the generation of the restorative macrophage phenotype. I initially 
attempted to inactivate MFG-E8, a key molecule in the phagocytic process, in vivo using a 
blocking antibody (Bu et al., 2007) during fibrosis resolution following CCl4 injury. 
Administration of this antibody had no demonstrable effect on circulating monocyte number, 
hepatic macrophage number, macrophage subsets or hepatic fibrosis resolution. As an 
alternative strategy for inhibiting phagocytosis, I administered the ITGAV blocking antibody 
RMV-7 to mice following CCl4 injury, again at published doses that have been shown to be 
effective in mice in vivo (Takahashi et al., 2001). On this occasion, the ITGAV blocking 
antibody did induce a statistically significant reduction in the Ly-6C
lo 
restorative macrophage 
subset (Fig 8.3D), suggesting that ITGAV activity and hence potentially phagocytosis are 
important for the generation of this macrophage population. However, no effect was seen on 
the overall levels of hepatic fibrosis. Whilst, in both of these blocking studies, published 
doses of antibody were used, further work is required to ascertain if the antibody was 
effective in inhibiting the relevant pathway and indeed inhibiting the phagocytic uptake of 
cell debris in the injured liver. Given that effective phagocytosis is such an innate protective 
immune and that the phagocytic process has such a range of receptors and pathways, it is 
likely that a degree of redundancy exists, such that even with the effective blockade of one 
pathway, effective clearance of cell debris may continue. This may also contribute to the 
overall lack of effect with these blockade strategies. A further caveat to interpretation of 
these data is the pleotropic functions of these molecules. Specifically, ITGAV also has an 
important role in the activation of latent TGF-β (Munger et al., 1999) and hence any global 
inhibition method such as a blocking antibody may also have effects outwith the role in 
phagocytosis. 
The other strategy I employed to try and manipulate in vivo hepatic macrophage phenotype 
in my CCl4 model was the administration of liposomes. As previously discussed, liposome 
uptake by macrophages has been shown to be a phagocytosis event and indeed as shown in 
Fig 7.5, liposome administration to macrophages in vitro induces a macrophage phenotype 
similar to that of the restorative hepatic Ly-6C
lo
 macrophages in vivo. Furthermore, 
liposomes have been widely used in animal models as drug delivery vehicles to 
macrophages, most commonly for liposomal clodronate. Indeed liposomal drug delivery is 
also finding use in human disease (Chang and Yeh, 2012). Proof of principal that liposome 
administration per se can induce changes in macrophage phenotype in vivo with a 
consequent effect on tissue inflammation already exists in a rat model of acute myocardial 
infarction (Harel-Adar et al., 2011) and a model of inflammatory arthritis (Ma et al., 2011). 
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Furthermore, this effect may well be mediated by potentiation of macrophage ERK 
signalling (Ma et al., 2011), a pathway I’ve shown to be important in the matrix degrading 
properties of macrophages following phagocytosis (Fig 7.3). Hence, there is good scientific 
rationale to use liposomes as a means to manipulate hepatic macrophage phenotype in vivo, 
with the aim of enhancing the restorative macrophage population and accelerating fibrosis 
regression. It was therefore relevant to see that the administration of liposomes following 4 
weeks of CCl4 injury in my model, resulted in a striking change in hepatic macrophage 
phenotype, with a reduction in pro-fibrogenic Ly-6C
hi
 cells and an increase in restorative Ly-
6C
lo
 macrophages (Fig 8.4E). Correspondingly, in keeping with this change in macrophage 
phenotype to favour scar resolution, liposome administration resulted in accelerated matrix 
degradation (Fig 8.5B and C). Overall, these findings demonstrate that the induction of 
phagocytosis in macrophages in vivo modifies macrophage phenotype, enhancing the 
restorative Ly-6C
lo





 Administration of the PPAR-γ agonist rosiglitazone to mice following CCl4 injury, 
had no detectable effect on numbers of circulating monocytes or hepatic macrophage 
subsets and no obvious effect on liver fibrosis resolution in a short time frame. 
 Antibody blockade of MFG-E8 in vivo following CCl4 injury had no detectable 
effect on numbers of circulating monocytes or hepatic macrophage subsets and no 
obvious effect on liver fibrosis resolution. 
 Antibody blockade of integrin αv in vivo following CCl4 injury, induced a change in 
hepatic macrophage phenotype with a reduction in restorative Ly-6C
lo
 macrophage 
number, suggesting a role for this key phagocytosis receptor in the generation of this 
population. 
 Antibody blockade of integrin αv in vivo following CCl4 injury had no detectable 
effect on liver fibrosis resolution in a short time frame. 
 Administration of liposomal PBS to mice following CCl4 injury induced a 
phenotypic switch in hepatic macrophages with a reduction in pro-fibrotic Ly-6C
hi
 
macrophage number and an increase in restorative Ly-6C
lo
 hepatic macrophages. 










In this thesis, I have established a reversible murine model of liver fibrosis using CCl4 and 







 macrophage population accumulates in the liver 
and is the main MMP-expressing macrophage subset during maximal fibrosis resolution, is 
necessary for degradation of tissue scar, is derived from infiltrating Ly-6C
hi
 inflammatory 
monocytes, has a distinct pattern of gene expression including matrix degradation and 
phagocytic genes and is characterised by evidence of prior phagocytosis of dying cells. The 
restorative phenotype can be recapitulated in vitro by phagocytosis induced ERK signalling 
and can be induced in vivo by the administration of liposomes which accelerates scar 
resolution. Much of this data has been published (Ramachandran et al., 2012) and Appendix 
2. 
As discussed in detail in Chapter 1, there is a growing body evidence for a role of 
macrophages in inflammation and tissue fibrogenesis, not only in the liver, but also in other 
organs (Wynn and Barron, 2010).  More recently, data is emerging to suggest a functional 
heterogeneity of macrophage subtypes in vivo and a potential role in fibrosis resolution 
(Duffield et al., 2005, Fallowfield et al., 2007, Ramachandran and Iredale, 2009, Gibbons et 
al., 2011). Given that tissue fibrosis is now estimated to contribute to up to 45% of deaths in 
the Western world (Hayden, 2011), a greater understanding of the processes involved is 
essential to develop badly needed anti-fibrotic therapies. The liver, with its well described 
fibrotic response to injury and potential reversibility, is the ideal organ to study the 
mechanisms of fibrogenesis and fibrosis regression (Ramachandran and Iredale, 2012a). 
Hence, I sought to use a reversible murine liver fibrosis model to identify the macrophage 
population responsible for the resolution of fibrosis: termed the restorative macrophage. 
Initially, I needed to establish a robust and reproducible reversible liver fibrosis model. I 
utilised the widely-used CCl4 model in mice. As shown in Fig 3.1 to Fig 3.4, 4 weeks of 
twice weekly CCl4 treatment to male C57BL/6 mice induces significant hepatic fibrosis, 
which peaks 48-72 hours after the final CCl4 injection, followed by fibrosis resolution. 
Importantly for subsequent experiments, this model enabled me to study a pro-fibrogenic 
timepoint (24 hrs after the final CCl4 injection), and a pro-resolution timepoint (72 hrs after 
the final CCl4 injection) at the time of initiation of maximal matrix degradation, when the 
liver is primed for scar breakdown. 
Differential Ly-6C expression has been widely used to identify functionally distinct 
populations of circulating murine monocytes (Gordon and Taylor, 2005, Ingersoll et al., 
2009) and more recently macrophage subpopulations in diseased tissue (Lin et al., 2009, 
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Arnold et al., 2007, Karlmark et al., 2009, Movahedi et al., 2010, Nahrendorf et al., 2007). 
Using this data, I was able to demonstrate that differential Ly-6C expression can be exploited 
to identify the macrophage subset responsible for fibrosis resolution. Specifically, in my 
CCl4 model, a Ly-6C
lo
 monocyte-derived macrophage subset accumulates maximally at the 
critical 72 hr timepoint (Fig 3.9) and represents the main MMP-expressing macrophage 
population in the liver at this time (Fig 3.11). Conversely, at the time of fibrogenesis (24 hrs) 
in this model a Ly-6C
hi
 monocyte-derived macrophage population predominated (Fig 3.9). 
This mirrors another study in the liver where this subset has been shown to be pro-fibrogenic 
(Karlmark et al., 2009). 
As a means of comparison I also sought to use a second model of liver murine liver fibrosis. 
Oral thioacetamide (TAA) induces a fibrotic response in rats (Jeong et al., 2001, Noda et al., 
1996), but has only rarely been described in mice, with no robust data on reversibility. I 
established a murine TAA in male C57BL/6 mice model, demonstrating that significant 
fibrosis is induced by 8 weeks of treatment with cirrhosis by 52 weeks of therapy (Fig 3.6). 
This was a dose-response effect, with only the higher dose of TAA (600mg/l) causing this. 
However, in contrast to the CCl4 model, no fibrosis reversibility was seen following TAA 
injury with recovery times of up to 8 weeks (Fig 3.7). Why this difference in reversibility 
between these 2 models? There are numerous potential explanations. From my data, the 
TAA model lacked the dynamic changes in monocyte-derived macrophages seen in the CCl4 






 subsets was seen during treatment or 
following the cessation of TAA (Fig 3.12). This lack of accumulation of MMP-expressing 
restorative macrophages could explain the absence of matrix degradation I observed. This 
raises a wider question on fibrosis resolution – is tissue inflammation/damage and 
consequent recruitment of inflammatory cells, in particular macrophages, actually a pre-
requisite for fibrosis resolution as well as fibrogenesis? Certainly, one of the features of non-
resolving liver scars is hypocellularity, suggesting the absence of the intimate relationship 
between SAMs and fibrotic matrix may inhibit matrix degradation (Issa et al., 2004). 
Furthermore, a study by Mitchell and colleagues demonstrated that knockout of the 
monocyte chemokine receptor CCR2 in mice inhibits hepatic scar formation in response to 
CCl4 injury but also attenuates scar resolution, indicating that CCR2-dependent monocyte 
recruitment is likely to be a pre-requisite for both fibrogenesis and fibrosis regression 
(Mitchell et al., 2009). This has important potential implications for the development of anti-
fibrotic therapies. Some authors have suggested inhibiting the inflammatory process, in 
particular chemokines, as a potential anti-fibrotic therapy (Sahin et al., 2010, Vielhauer et al., 
2010). However, this may also result in inhibition of fibrosis resolution and given that many 
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patients present with established liver fibrosis, a treatment that can manipulate the immune 
response to promote fibrosis regression is likely to be more useful. The TAA model I have 
described may provide a useful method for testing some of these theories. An interesting 
series of experiments would be to determine whether an established irreversible liver fibrosis 
induced by TAA could be made more reversible by inducing hepatic inflammation and 
monocyte recruitment, for example by giving a single injection of CCl4 or perhaps even 
better by causing hepatic overexpression of CCL2 (MCP-1) by administration of an 
adenoviral vector.  
Clearly, other factors may also contribute to the irreversibility seen with the TAA model. 
The composition of the scar tissue is likely to be different with liver fibrosis in TAA mice 
being rich in elastin (Pellicoro et al., 2011), which may be more resistant to degradation than 
the more typical collagens 1 and 3. The pattern of fibrosis is also different in TAA than CCl4 
injury, with a more biliary distribution evident in response to TAA (Jeong et al., 2001, Noda 
et al., 1996). This anatomical pattern may be more inherently resistant to scar breakdown, 
but also may result in preferential activation of portal myofibroblasts rather than HSCs, 
which may well have a different phenotype (Bosselut et al., 2010). Further light could be 
shed on this by isolating myofibroblasts from TAA and CCl4 livers and comparing their 
phenotype and gene expression profiles. 
Despite the obvious differences between the CCl4 and TAA models, one similarity in terms 





macrophages in response to injury and the progressive reaccumulation following the removal 
of the injurious stimulus (Fig 3.9 and 3.12). In depth study of this population was beyond 
the scope of this thesis. However, it would be intriguing to know the fate of these cells in 
response to injury (e.g. cell death, phenotypic change or migration to draining lymph nodes), 
the means of repopulation and their function during this repopulation phase. Complex 
lineage tracing experiments using inducible macrophage specific Cre mice would be required 
to unpick this, but is essential to our full understanding of the role of macrophages in hepatic 
fibrogenesis and resolution. 
Following the initial characterisation of macrophage dynamics in my reversible CCl4 model, 
I proceeded to obtain more functional data using macrophage depletion. I was able to show 
that in CD11b-DTR mice injured with CCl4, DT administration during the resolution phase 
resulted in selective depletion of the predominant Ly-6C
lo
 macrophage subset and 
consequently prevented fibrosis regression (Fig 4.2 and 4.3). The close correlation between 
the number of hepatic Ly-6C
lo
 macrophages and the degree of fibrosis resolution (Fig 4.4) 
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emphasises their role as the restorative hepatic macrophage. The contrast between this 
CD11b-DTR model and macrophage depletion with liposomal clodronate, where no 
difference in fibrosis regression was observed (Fig 4.6), was striking. This is the first direct 
comparison of depletion, in the same disease model, between the liposomal clodronate and 
CD11b-DTR systems. What is clear from my data, is that liposomal clodronate induces a 
much more global depletion of different subpopulations of hepatic macrophage than CD11b-
DTR (Fig 4.6). Additionally, liposomal clodronate seems to have more off target effects on 
other immune cell populations such as neutrophils or T cells (Fig 4.6). This is not 
withstanding the clear effects of liposome administration in itself (Fig 8.4 and 8.5). Thus, 
macrophage depletion with liposomal clodronate may miss more subtle functional effects, 
particularly when distinct subsets have opposing functions. Furthermore, experiments using 
liposomal clodronate should always also include 2 control arms, one with vehicle alone and 
one with liposomes alone.  
Having identified the restorative hepatic macrophage as the Ly-6C
lo
 monocyte-derived 
population, I sought to characterise this subset further. A major question arising from studies 
regarding the divergent role of macrophages in fibrogenesis and recovery was whether these 
distinct functions were mediated by distinct cell populations or whether cells underwent a 
phenotypic switch in situ (Friedman, 2005, Wynn, 2011). Using a series of adoptive transfer 
and in situ labelling experiments (Fig 5.1 to 5.4), I have shown that the Ly-6Clo population 
derives from Ly-6C
hi 
inflammatory monocytes, a common origin to the pro-fibrogenic Ly-
6C
hi
 macrophages, and indicating that the restorative hepatic macrophage is formed by a 
switch in macrophage function in vivo. Additionally, this switch occurs after a significant 
amount of proliferative activity of these Ly-6C
hi
 macrophages (Fig 5.5), suggesting a 
combination of recruitment and local proliferation is needed to generate the restorative 
macrophage phenotype. These findings are certainly in keeping with the known ability of 
macrophages to change phenotype according to local environmental cues (Mosser and 
Edwards, 2008). My data is also analogous to that described for the role of macrophages in 
muscle regeneration (Arnold et al., 2007). Once again this highlights that a therapeutic 
strategy aimed at global inhibition of macrophage recruitment is unlikely to be entirely 
successful, as this would also diminish restorative macrophages. Hence a more subtle 
approach of trying to promote the formation of the pro-resolution phenotype is likely to be 
needed.  
Having identified that pro-fibrotic Ly-6C
hi
 and pro-resolution Ly-6C
lo
 hepatic macrophages 
derive from a common origin, I proceeded to compare the gene expression profiles of these 2 
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populations to shed further light on the mechanisms of macrophage-induced fibrogenesis and 
fibrosis regression. I analysed these 2 populations using microarray whole trancriptome 
analysis, enabling unbiased comparisons to be made. This has highlighted a number of key 
features of the restorative macrophage subset. In particular, the upregulation of matrix-
degrading MMPs such as MMP-12 and MMP-9, growth factors such as IGF-1, and other 
potentially anti-inflammatory molecules such as CX3CR1 (Karlmark et al., 2010) and CD74 
(Heinrichs et al., 2011) was observed in the Ly-6C
lo
 cells (Fig 6.2). Expression of Arginase-
1 was also increased in the restorative macrophage subset (Fig 6.2). This has recently been 
shown to have an anti-fibrotic role in the liver (Wynn and Barron, 2010).  These microarray 
data also enabled me to identify specific markers of restorative macrophages, which could be 
utilised to identify them in situ in liver tissue using immunohistochemistry for MMP-12 and 
GPNMB. Importantly, I was also able to apply this to human liver tissue and identify 
subpopulations of macrophages which could represent the human restorative macrophage 
(Fig 6.5). This is useful, as the potential to perform multicolour flow cytometry on freshly 
isolated human liver is obviously much more limited. One of the other striking features of 
the restorative macrophage expression profile was the enrichment of genes associated with 
phagocytosis (Fig 6.2 and 6.3). As described in detail in chapter 1, phagocytosis is a key 
function of macrophages in inflammatory environments and has important consequences for 
macrophage phenotype. I therefore wondered whether phagocytosis of dead/dying cells in 
the inflamed liver might be a reason for the change in macrophage phenotype from one 
promoting fibrogenesis (Ly-6C
hi
) to one promoting fibrosis resolution (Ly-6C
lo
). Indeed, I 
was able to confirm definitively that the restorative Ly-6C
lo
 but not the Ly-6C
hi
 hepatic 
macrophage population had ingested apoptotic debris (Fig 6.6). 
In addition to the information about the restorative macrophage, this dataset also provided 
valuable functional insights into the pro-fibrotic Ly-6C
hi
 macrophage subset. It should be 
borne in mind that whilst there is currently very limited characterisation of restorative 
macrophages in other organs, a macrophage population derived from Ly-6C
hi
 monocytes has 
been shown to be pro-fibrogenic in the liver (Karlmark et al., 2009), but also lung (Gibbons 
et al., 2011, Osterholzer et al., 2013) and kidney (Lin et al., 2009). However, the exact 
expression profile of these pro-fibrogenic macrophages had not previously been described. 
Expression of the key pro-fibrogenic cytokine TGF-β with resultant HSC activation has been 
the proposed mechanism of fibrosis promotion by hepatic macrophages (Wynn and Barron, 
2010, Karlmark et al., 2009). Interestingly, I did not find a major difference in TGF-β 
expression between pro-fibrogenic and pro-resolution macrophage populations, arguing 
against this (Fig 6.2). However, pro-fibrotic Ly-6C
hi
 hepatic macrophages did show a 
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significantly higher level of expression of Thrombospondin 1 (Thbs1), a protein which in 
addition to having a role in phagocytosis is an important activator of latent TGF-β (Breitkopf 
et al., 2005, Crawford et al., 1998, Elpek et al., 2008, El-Youssef et al., 1999). Whether, this 
is an important functional observation linking hepatic macrophages and fibrogenesis should 
be further studied, ideally using macrophage-specific Thbs1 knockout mice. Ly-6C
hi
 hepatic 
macrophages also expressed other potentially pro-fibrogenic mediators. For example, Il-1β 
expression was higher in Ly-6C
hi
 macrophages (Fig 6.4), a cytokine which in addition to 
being pro-inflammatory has been shown to have a pro-fibrogenic role in the liver (Gieling et 
al., 2009), potentially via promoting HSC survival in an NF-κB dependent manner (Pradere 
et al., 2013). Additionally, Ly-6C
hi
 macrophages expressed higher levels of a number of 
chemokines, including CCL2 and CXCL10 (Fig 6.2 and 6.4). CCL2, in particular, has been 
shown to be pro-fibrotic in the liver (Imamura et al., 2005) and is likely to contribute to 
further recruitment of inflammatory monocytes and also have direct effects on hepatic 
stellate cell chemotaxis (Friedman, 2008). CXCL10 has also been shown to be a pro-
fibrogenic chemokine in the liver (Hintermann et al., 2010). Chitinase 3-like 3 (Chi3l3 or 
YM-1) was another gene that was strikingly upregulated in the pro-fibrotic macrophage 
subset (Fig 6.2 ad 6.4) and indeed served as a marker for this population in 
immunohistochemical studies (Fig 6.5). Chi3l3 has also been shown to be a marker of the 
pro-fibrogenic marcrophage population in the lung (Gibbons et al., 2011). The exact function 
of Chi3l3 remains unknown, but chitinases themselves have been suggested to have a pro-
fibrogenic function (Wynn and Barron, 2010) and indeed a human chitinase YKL-40 has 
been suggested as a serum marker of liver fibrosis (Johansen et al., 2000). Whether Chi3l3 is 
simply a marker of the pro-fibrotic hepatic macrophage or whether it has a functional role 
could be better defined using knockout mice.  
The other thing that is clear from my extensive microarray dataset is that these in vivo 
hepatic macrophage subsets do not fit into the traditional M1/M2 macrophage paradigm (Fig 
6.2). Whilst this has been a useful nomenclature to help understanding of the potential for 
macrophage polarisation, it clearly cannot represent the complex in vivo phenotypes 
observed and hence, should be avoided where possible, with a greater focus given to the 
functional role of the specific population. 
Overall, these data enable development of a greater understanding of the functional role of 
liver macrophages in hepatic fibrogenesis and fibrosis resolution, summarised in the 
schematic diagram is shown in Fig 9.1. 
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Having characterised the pro-fibrotic and restorative hepatic macrophage subsets, I then 
wished to utilise these data to try and determine what causes the Ly-6C
hi
 macrophage 
population to change phenotype in vivo to develop pro-resolution features. Phagocytosis 
seems to play a major role in this switch and I was, hence able to model this in vitro 
(Chapter 7). Taking this 1 step further, my preliminary data suggests that phagocytosis-
induced ERK signalling may well mediate the increase in matrix degrading enzymes 
expressed by restorative macrophages (Fig 7.3). If this could be confirmed in vivo, 
potentially using macrophage specific transgenic targeting or ERK inhibitors delivered in a 
macrophage specific manner perhaps via liposomes, this could offer a new means of 
manipulating in vivo macrophage phenotype. 
I was, however, able to utilise my data showing that phagocytosis induces restorative 
macrophage phenotype to develop a novel therapeutic strategy. By administering liposomes 
to mice following CCl4 injury, I was able to enhance the macrophage phenotypic switch in 
vivo, resulting in an increase in restorative hepatic macrophage number and reduction in pro-
fibrotic macrophages (Fig 8.4) and hence accelerate fibrosis resolution (Fig 8.5). It would be 
intriguing to replicate these experiments in other models of liver fibrosis or indeed fibrosis in 
other organs to determine whether this could be developed as a genuine translational 
therapeutic strategy. An alternative would be to feed liposomes to macrophages in vitro to 
promote a matrix degrading properties and then to use these modified macrophages as a cell 
therapy. 
It would be more readily translational if we could identify the specific pathway that links 
macrophage phagocytosis and the matrix degrading phenotype. Hopefully, this would yield a 
more druggable target to promote the phenotypic switch in macrophages and enhance 
fibrosis resolution. PPAR-γ was a potentially attractive pathway given the existence of drugs 
already in widespread clinical use. Unfortunately, my data did not demonstrate a significant 
effect of PPAR-γ agonism on macrophage phenotype or fibrosis regression (Fig 8.1). 
However, as described in Chapter 8, this may be experimental and certainly merits further 
study. I did show that blockade of integrin αv does change the hepatic macrophage phenotype 
in vivo, albeit with no demonstrable effect on fibrosis regression in my initial studies (Fig 
8.3). This again could be studied further, potentially using LysM-Cre mice crossed with mice 
with a floxed ITGAV gene. However, this highlights one of the key experimental problems 
in studying the role of specific pathways in fibrosis resolution. Namely, that fibrosis is a 
dynamic process and using transgenic mice with a relevant gene knocked out will result in a 
different level of peak inflammation/fibrosis following injury. This makes reliable 
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interpretation of the resolution phase almost impossible. Furthermore, global knockouts of 
molecules such as ITGAV or PPAR-γ will clearly have effects on cell types other than 
macrophages. Hence, what is badly needed is a series of inducible macrophage-specific cre 
mice, whereby tissue injury and fibrosis can be caused and then the gene of interest deleted 
solely in macrophages during the resolution phase, avoiding the confounding effects of 
differences in peak fibrosis. One such mouse line, Csf1r-Mer-iCre-Mer mice which enable 
inducible Cre expression in Csf1r-expressing monocytes in response to tamoxifen 
administration has recently been used to knockout Vegf expression in monocytes in vivo 
(Qian et al., 2011). Such mice could also be useful for more in depth lineage tracing 
experiments to study the fate of macrophages during fibrosis resolution. 
How does the phenotype of the hepatic restorative macrophage compare to those described 
in the literature? In the context of murine peritoneal inflammation, a pro-resolution 
macrophage population has been identified (Bystrom et al., 2008). Analogous to my 
restorative macrophage subset, these macrophages show lower levels of expression of pro-
inflammatory cytokines and chemokines than their pro-inflammatory counterparts, and 
importantly do not conform to the M1/M2 paradigm but rather represent hybrid cells 
(Bystrom et al., 2008). In muscle injury, the macrophage population responsible for 
promoting regeneration upregulates PPAR-γ (Arnold et al., 2007). However, extensive 
datasets on the phenotype of macrophages responsible for the resolution of tissue injury, 
such as that presented in thesis, do not currently exist for other organs. Further work 
characterising such populations would enable comparison to the liver and identification of 
pathways which might be targetable in several diseases.  
What is the relevance of my data to human disease? I had deliberately focussed my attention 
on an early CCl4-induced fibrosis in mice, which resolves rapidly. This was convenient as it 
enabled in depth analysis of macrophage dynamics on a day-by-day basis, and has provided 
robust and reproducible data. Reassuringly, I was also able to identify a subset of 
macrophages in human cirrhotic liver which expressed the same markers (MMP-12 and 
GPNMB) as the murine restorative macrophages. However, clearly much more work is 
required to translate my murine data to human disease, where liver fibrosis is generally 
formed over many years. Importantly, we do now have convincing evidence that human liver 
fibrosis is also reversible (Ramachandran and Iredale, 2009). Furthermore, our understanding 
of the heterogeneity of macrophages in the cirrhotic human liver is ever improving. In 
human livers, similar to my mouse model, 3 populations of macrophages could be identified 
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subset accumulating maximally in the fibrotic/cirrhotic 
livers (Zimmermann et al., 2010). Interestingly, in my model, pro-inflammatory Ly-6C
hi
 
macrophages express higher levels of CD14 whilst restorative Ly-6C
lo
 macrophages express 
higher levels of CD16/32, suggesting some similarities to the human data (Fig 6.2B). In a 
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 counterparts, which is more 
akin to Ly-6C
hi
 macrophages in my model. In order to define these similarities more closely, 
further studies are required, potentially involving isolation of human hepatic macrophage 
subsets and microarray analysis with comparison to the gene expression profiles in my 
model. Even more useful would be to perform this study in human livers where fibrosis 
remodelling is actively occurring, for example in patients with chronic viral hepatitis who 
have received treatment or patients with alcohol-related liver disease who are now abstinent. 
Such studies would identification of common pathways in macrophages between human 
disease and murine models and are essential for the development of therapies which can 







Figure 9.1 – Summary of the Proposed Role of Macrophages in Hepatic Fibrogenesis 
and Fibrosis Regression 
Schematic showing the proposed role of macrophages in hepatic fibrogenesis and fibrosis 
regression, incorporating the data presented in this thesis. In response to hepatic injury, 
inflammatory monocytes are recruited to the liver. These proliferate in situ and form pro-
fibrotic Ly-6C
hi
 macrophages in the liver, which show a number of features which can 
enhance fibrogenesis. Ly-6C
hi
 macrophages express high levels of thrombospondin-1, which 
can activate latent TGF-β, and hence promote transdifferentiation of quiescent hepatic 
stellate cells (HSCs) into a myofibroblast phenotype. These activated myofibroblasts 
proliferate and secrete ECM (resulting in scar formation) and TIMP-1, which inhibits both 
matrix-degradation by MMPs and HSC apoptosis. Hepatic Ly-6C
hi
 macrophages also 
express inflammatory cytokines IL-1β and TNF-α, which in addition to driving hepatic 
inflammation, promote myofibroblast survival. Pro-fibrotic macrophages produce high levels 
of chemokines such as CCL2 and CXCL10 which can further enhance recruitment of 
monocytes and other immune cells. Other molecules such as Chi3l3 show a high expression 
in Ly-6C
hi
 macrophages, but the exact function in fibrogenesis remains unknown. Within the 
liver these pro-fibrogenic macrophages then change phenotype, at least partly in response to 
phagocytosis of cellular debris and macrophage ERK signalling. This results in the 
generation of Ly-6C
lo
 restorative hepatic macrophages, which mediate fibrosis regression. 
These restorative macrophages upregulate opsonins and phagocytosis receptors, enhancing 
the clearance of cellular debris, and hence promoting the generation of further restorative 
macrophages. Ly-6C
lo
 macrophages downregulate thrombospondin-1 and pro-inflammatory 
cytokine expression, promoting myofibroblast apoptosis. They also upregulate matrix 
degrading enzymes such as MMP-12 and MMP-9, which in combination with falling TIMP-
1 levels, results in increased hepatic matrix degrading activity and hence scar degradation. A 
number of other properties of the restorative macrophage are also shown, including 
expression of GPNMB, Arginase-1, anti-inflammatory receptors, activation of PPAR 
signalling and production of growth factors such as IGF-1 which may promote hepatocyte 
regeneration. The exact functional role of these pathways in macrophages remains to be 
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APPENDIX 1 – TABLE OF GENE NAMES 
Abbreviation Gene Name 
Plau Plasminogen activator, urokinase 
Mmp13 matrix metallopeptidase 13 
Mmp2 matrix metallopeptidase 2 
Mmp9 matrix metallopeptidase 9 
Mmp12 matrix metallopeptidase 12 
Hgf hepatocyte growth factor 
Igf1 insulin-like growth factor 1 
Mif macrophage migration inhibitory factor 
Cd74 CD74 antigen (invariant polypeptide of major histocompatibility 
complex, class II antigen-associated) 
Cx3cr1 chemokine (C-X3-C motif) receptor 1 
Ccr2 chemokine (C-C motif) receptor 2 
Ccr1 chemokine (C-C motif) receptor 1 
Sell selectin, lymphocyte 
Thbs1 thrombospondin 1 
Tgf-β1 transforming growth factor, beta 1 
Cxcl10 chemokine (C-X-C motif) ligand 10 (IP10) 
Cxcl3 chemokine (C-X-C motif) ligand 3 
Cxcl2 chemokine (C-X-C motif) ligand 2 (MIP-2) 
Ccl4 chemokine (C-C motif) ligand 4 (MIP-1B) 
Ccl3 chemokine (C-C motif) ligand 3 (MIP-1a) 
Ccl2 chemokine (C-C motif) ligand 2 (MCP-1) 
Il-10 interleukin 10 
Il-12β interleukin 12b 
Il-12α interleukin 12a 
Il-6 interleukin 6 
Il-1β interleukin 1 beta 
Tnf-α tumor necrosis factor 
Scarb1 scavenger receptor class B, member 1 
Ech1 enoyl coenzyme A hydratase 1, peroxisomal 
Abca1 ATP-binding cassette, sub-family A (ABC1), member 1 
Lpl lipoprotein lipase 
Cd36 CD36 antigen (Scarb3) 
Marco macrophage receptor with collagenous structure 
Trem2 triggering receptor expressed on myeloid cells 2 
Axl AXL receptor tyrosine kinase 
Mertk c-mer proto-oncogene tyrosine kinase 
Gpnmb glycoprotein (transmembrane) nmb 
Cd81 CD81 antigen 
Cd5l CD5 antigen-like 
Fcrls Fc receptor-like S, scavenger receptor 
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Mfge8 milk fat globule-EGF factor 8 protein 
Gas6 growth arrest specific 6 
C1qb complement component 1, q subcomponent, beta polypeptide 
C1qa complement component 1, q subcomponent, alpha polypeptide 
Mrc1 mannose receptor, C type 1 
Arg1 arginase, liver 
Retnla resistin like alpha 
Kdm6b KDM1 lysine (K)-specific demethylase 6B 
Chi3l3 chitinase-like 3 
Il1rn interleukin 1 receptor antagonist 
Ciita class II transactivator 
Cd32 Fc receptor, IgG, low affinity IIb 
Cd16 Fc receptor, IgG, low affinity III 
Serpine1 serine (or cysteine) peptidase inhibitor, clade E, member 1 
Cd86 CD86 antigen 
Cd80 CD80 antigen 
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Differential Ly-6C expression identifies the recruited
macrophage phenotype, which orchestrates the
regression of murine liver fibrosis
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Although macrophages are widely recognized to have a profibrotic
role in inflammation, we have used a highly tractable CCl4-induced
model of reversible hepatic fibrosis to identify and characterize the
macrophage phenotype responsible for tissue remodeling: the hith-
erto elusive restorative macrophage. This CD11Bhi F4/80int Ly-6Clo
macrophage subset was most abundant in livers during maximal fi-
brosis resolution and represented the principle matrix metalloprotei-
nase (MMP) -expressing subset. Depletion of this population in
CD11B promoter–diphtheria toxin receptor (CD11B-DTR) transgenic
mice caused a failure of scar remodeling. Adoptive transfer and
in situ labeling experiments showed that these restorative macro-
phages derive from recruited Ly-6Chi monocytes, a common origin
with profibrotic Ly-6Chi macrophages, indicative of a phenotypic
switch in vivo conferring proresolution properties. Microarray pro-
filing of the Ly-6Clo subset, compared with Ly-6Chi macrophages,
showed a phenotype outside the M1/M2 classification, with
increased expression of MMPs, growth factors, and phagocyto-
sis-related genes, including Mmp9, Mmp12, insulin-like growth
factor 1 (Igf1), and Glycoprotein (transmembrane) nmb (Gpnmb).
Confocal microscopy confirmed the postphagocytic nature of re-
storative macrophages. Furthermore, the restorative macrophage
phenotype was recapitulated in vitro by the phagocytosis of cel-
lular debris with associated activation of the ERK signaling cas-
cade. Critically, induced phagocytic behavior in vivo, through
administration of liposomes, increased restorative macrophage
number and accelerated fibrosis resolution, offering a therapeutic
strategy to this orphan pathological process.
Kupffer Cell | collagen | degradation | myofibroblast | proliferation
As the generic and common pathological endpoint to chronicinjury, fibrosis has been estimated to contribute to 45% of
all deaths in industrialized nations (1, 2). Currently, no direct
antifibrotic therapeutic interventions exist. Long thought of as
inexorably progressive, recent evidence, particularly in the liver
(3) but also the kidney (4), lung (5, 6), and heart (7), indicates
that some reversibility exists, even in advanced disease. There-
fore, a more detailed understanding of the specific mechanisms
governing fibrosis regression will likely inform therapeutic
approaches.
Macrophages have long been implicated in promoting tissue fi-
brosis (8–10). However, it has recently been shown that they also
play a pivotal role in fibrosis regression (6, 11), in part through ex-
pression of matrix-degrading metalloproteinase enzymes (MMPs)
(12). Macrophages are capable of distinct activation states and
functions, which in vitro, can be broadly classified asM1 (classical)
or M2 (alternative) (13, 14). It is generally postulated that M1
macrophages are proinflammatory, whereas M2 macrophages are
responsible for immunomodulation and wound-healing responses
(14). However, it is increasingly clear that this binary classification
does not address the more complex heterogeneity in vivo, where
macrophages adopt distinct phenotypes and even switch between
phenotypes in response to the myriad of stimuli to which they are
exposed (13). These in vivo macrophage phenotypes are impos-
sible to recapitulate exactly in tissue culture models, emphasizing
the importance of the characterization of macrophages on the
basis of function (13).
Ly-6C is a cell surface glycoprotein that is widely used to
identify functionally discrete murine circulating monocyte pop-
ulations: Ly-6Chi monocytes (analogous to CD14hi CD16lo human
monocytes) are recruited early to inflammatory environments
and thought to be proinflammatory, whereas Ly-6Clo monocytes
(analogous to CD14lo CD16hi human monocytes) are a more
patrolling cell type and can replenish resident tissue macrophages
(15, 16). Differential Ly-6C expression in diseased tissues has
identified functionally distinct macrophage populations (17–20).
Indeed, an Ly-6Chi intrahepatic macrophage population, derived
from recruitment of circulating Ly-6Chi monocytes, is critical for
fibrogenesis (21). However, the nature, origin, and phenotype of
the macrophage subset responsible for mediating fibrosis reso-
lution have not been defined.
In this study, we have exploited differential Ly-6C expression
in a tractable and reproducible model of reversible murine he-
patic fibrosis to identify the specific macrophage population re-
sponsible for fibrosis resolution: the restorative macrophage. We
have gone on to characterize this cell, and we have shown cate-
gorically that it is derived from recruited inflammatory mono-
cytes after a phenotypic switch mediated by the ingestion of
cellular debris and that it represents a newly identified phenotype
distinct from the M1/M2 paradigm. Finally, we have established
this mechanism to manipulate macrophage phenotype in vivo
and accelerate fibrosis resolution.
Author contributions: P.R., A.P., M.A.V., L.B., S.N.H., S.J.F., and J.P.I. designed research;
P.R., A.P., M.A.V., L.B., R.L.A., A.A., S.N.H., V.K.S., A.C., T.T.G.-W., and M.J.W. performed
research; N.v.R. contributed new reagents/analytic tools; P.R., A.P., D.R.D., and J.R.M.
analyzed data; and P.R., J.A.F., S.J.F., and J.P.I. wrote the paper.
The authors declare no conflict of interest.
This article is a PNAS Direct Submission.
Freely available online through the PNAS open access option.
Data deposition: The microarray data reported in the paper have been deposited in the
ArrayExpress database, www.ebi.ac.uk/arrayexpress (accession no. E-MEXP-3177).
1To whom correspondence should be addressed. E-mail: john.iredale@ed.ac.uk.
See Author Summary on page 18649 (volume 109, number 46).
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.
1073/pnas.1119964109/-/DCSupplemental.
E3186–E3195 | PNAS | Published online October 24, 2012 www.pnas.org/cgi/doi/10.1073/pnas.1119964109
Results
Experimental Liver Fibrosis Shows Distinct Phases of Fibrogenesis and
Resolution. We established a model of liver fibrosis reversal from
which macrophage populations could be isolated on a day-to-day
basis. C57BL/6 mice were administered two times weekly i.p.
carbon tetrachloride (CCl4) for 4 wk followed by tissue harvests
24, 48, 72, 96, 168, and 256 h after the final CCl4 injection
(Fig. 1A). Comparison was made with age-matched uninjured
(control) animals. Hepatic fibrosis and myofibroblast activation
were assessed by immunohistochemistry and morphometric
analysis of picrosirius red (PSR), collagen 1, collagen 3, and
α-smooth muscle actin (α-SMA). Liver fibrosis and myofibroblast
activation (α-SMA) peaked at 48–72 h, identifying 24 h as a time
of active fibrogenesis, whereas maximal scar resolution and re-
duction in myofibroblast area occurred between 72 and 96 h and
was followed by a more protracted regression of the residual
fibrosis (96–256 h) (Fig. 1 B and C). Scar resolution occurred
after reduction in overall hepatic damage as assessed by serum
alanine aminotransferase (ALT) and aspartate aminotransferase
(AST) levels (Fig. 1D). Additionally, at the initiation of scar
resolution, there was a significant reduction in hepatic levels of
Il-1β, Ccl2, Ccl3, and Cxcl2, suggesting an overall change in
macrophage phenotype (Fig. 1E). As we have previously shown
(3), loss of liver Timp-1 at a gene and protein level preceded
fibrosis regression (Fig. S1 A and B).
Ly-6Clo Monocyte-Derived Macrophages Predominate During Maximal
Fibrosis Resolution and Represent the Principle MMP-Expressing Subset.
Having identified the time of early and maximal fibrosis resolu-
tion (72 h), we determined whether there were associated
changes in specific hepatic macrophage subsets. Total hepatic
macrophages were identified on flow cytometry as viable CD45+
Ly-6G− NK1.1− CD3− B220− CD11B+ F4/80+ cells from the
nonparenchymal cell fraction of digested livers (Fig. S2 A–E).
Importantly, coinciding with maximal fibrosis resolution, total
hepatic macrophage number peaked at 72 h (Fig. 2A), and
macrophages closely associated with hepatic scars topographi-
cally (Fig. 2B).
Flow cytometric analysis of hepatic macrophages enabled
identification of distinct subsets. F4/80hi CD11Bintermediate mac-
rophages predominated in the control (uninjured) liver and rep-
resent the resident Kupffer cell population (22) (Fig. 2C). The
proportion of resident macrophages was reduced during active
inflammation/fibrogenesis (24 h) and progressively increased
during resolution (Fig. 2 C and E). The CD11Bhi F4/80intermediate
subset represents a recruited monocyte-derived macrophage
population (22). Analysis of Ly-6C expression on this subset
identified two clearly distinct hepatic recruited macrophage pop-
ulations: Ly-6Chi and Ly-6Clo (Fig. 2D). Dynamic changes in these
macrophage populations were seen during fibrogenesis and reso-
lution (Fig. 2 D and E). Whereas during fibrogenesis (24 h), Ly-
6Chi (profibrotic) macrophages were the predominant subset (21)
(Fig. 2E), at maximal scar resolution (72 h), when macrophage
number peaked, there was a reduction in the Ly-6Chi population
and a dramatic and significant increase in Ly-6Clo macrophages,
which became the dominant population (Fig. 2E). Overall, these
changes were also evident when absolute macrophage numbers
were quantified (Fig. 2F). Therefore, Ly-6Clo monocyte-derived
macrophages at the time of maximal scar resolution represented
the most numerous macrophage population seen throughout the
injury and recovery phases (4.13 ± 0.5-fold more than the total
number of macrophages in the undamaged liver).
During late resolution (168 h), the relative proportions of mac-
rophage subsets returned to control liver, although there re-
mained an increase in the proportion of the Ly-6Clo subset (Fig.
2E).We have previously shown that macrophageMMP expression
is critical for fibrosis regression (12). To identify the principle
hepaticMMP-expressingmacrophage subset, we used a pan-MMP
substrate (MMPsense), which becomes fluorescent after cleavage
by activeMMPs in vivo (23), enabling us to identify a population of
MMPsense-positive hepatic macrophages by flow cytometry (Fig.
Fig. 1. Experimental liver fibrosis shows distinct phases of fibrogenesis and
resolution. (A) Schematic representation of the model of reversible hepatic
fibrosis in C57BL/6 mice by 4 wk of two times per week i.p. CCl4 followed by
harvest at serial time points after the final injection. Comparisons were
made with control (uninjured) animals. (B and C) Histological characteriza-
tion of hepatic fibrosis and myofibroblast activation by PSR, collagen 1,
collagen 3, and α-SMA immunohistochemistry. (B) Representative images
are shown for control animals and each time point. (Scale bar: 100 μm.) (C)
Quantification of histological changes by morphometric pixel analysis ex-
pressed relative to mean percent area of control animals (n = 4 per time
point; representative of three independent experiments). (D) Serum ALT and
AST levels in control mice and at stated time point after the final CCl4 dose
(n = 5–6 per time point from two independent experiments). (E) Whole-liver
protein levels of Il-1β, Ccl2, Ccl3, and Cxcl2 measured by multiplex cytokine
assay expressed relative to mean protein concentration at the 24-h time
point for each (n = 7–9 per time point from two independent experiments).
All data shown as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001.

















2G). Subset analysis of these cells during both fibrogenesis (24 h)
and maximal matrix degradation (72 h) showed that the pre-
dominant active MMP-expressing macrophage population at both
time points was the Ly-6Clo macrophage (Fig. 2H). Therefore, Ly-
6Clo monocyte-derived macrophages accumulate maximally dur-
ing the most rapid phase of fibrosis resolution. Furthermore, they
represent the principle MMP-expressing population during both
fibrogenesis and fibrosis regression.
Depletion of CD11B-Positive Macrophages Defines Ly-6Clo Cells as
Being Critical for Scar Resolution. To define the functional role of
distinct macrophage subsets in mediating scar resolution, a well-
described selective in vivo macrophage depletion strategy was
used (11). CD11B promoter - diphtheria toxin receptor (CD11B-
DTR) transgenic mice were given CCl4 for 4 wk. To ensure
maximal macrophage depletion throughout the rapid phase of
scar resolution, i.v. diphtheria toxin (DT) (or PBS control) was
administered 48, 72, and 96 h after the final CCl4 injection fol-
lowed by harvest at 120 h (Fig. 3A). In concordance with previous
data (17), administration of DT was effective in depleting both
populations of circulating monocytes (Ly-6Chi and Ly-6Clo) (Fig.
S3 A and B). The degree of depletion was more profound for the
Ly-6Clo monocytes in keeping with them being a more mature cell
type forming from differentiation of Ly-6Chi monocytes (15) and
thus, taking longer to replenish after depletion (24).
We proceeded to analyze hepatic macrophage subsets in
CD11B-DTR mice (Fig. 3 B and C). Importantly, administration
of DT during maximal fibrosis resolution, when Ly-6Clo intra-
hepatic macrophages predominate, induced significant depletion
of this subset until harvest, causing a 76.7 ± 3.16% reduction in
relative number at 120 h (Fig. 3 B and C). No depletion of the
smaller population of hepatic Ly-6Chi macrophages was seen,
whereas there was a minor increase in the resident macrophage
number (Fig. 3C). For comparison, we depleted macrophages
during the inflammatory/fibrogenic phase when both Ly-6Chi and
Ly-6Clo hepatic macrophages are present in large numbers. DT
was administered to CD11B-DTR mice 8 h after final CCl4, with
harvest at 24 h. Using this strategy, we observed a more general
depletion of both Ly-6Chi and Ly-6Clo monocyte-derived mac-
rophage subsets (Fig. S3C). Thus, timing depletion for when an
individual population predominates is critical for selectivity.
What is also apparent from these data is that the Ly-6Clo hepatic
macrophage subset is more susceptible to depletion after DT
than the Ly-6Chi subset. This result is likely to reflect the higher
level of CD11B expression in Ly-6Clo macrophages than the Ly-
6Chi subset (Fig. S3D). Importantly, DT administration during
fibrosis regression did not induce a change in the number of
hepatic neutrophils or CD3-positive cells (Fig. S3 E and F).
Furthermore, this depletion strategy caused persistent fibrosis,
indicating a failure to remodel the hepatic scar (Fig. 3 D and E).
No difference was detected in the α-SMA area after macrophage
depletion, suggesting that the observed phenotype was a result of
reduced matrix degradation rather than increased myofibroblast
activation (Fig. 3 D and E). To confirm the specificity of these
findings, we administered DT (or PBS control) to WT mice
according to the same schedule (Fig. 3A). DT administration to
WT mice had no effect on macrophage subsets or hepatic fibrosis
(Fig. S3 G and H). To further show the specific effect of hepatic
Ly-6Clo macrophages on fibrosis regression, we identified a sta-
tistically significant inverse correlation between the number of
Ly-6Clo macrophages and the degree of fibrosis (Fig. 3F), indi-
cating that the degree of depletion of this subset directly relates
to the amount of residual scar. Critically, no significant correla-
tions were seen between the number of Ly-6Chi or resident
macrophages and the degree of fibrosis (Fig. S3 I and J).
These findings indicate that Ly-6Clo macrophages are critical
for the resolution of hepatic fibrosis and the restoration of normal
tissue architecture. Furthermore, given the temporal and nu-
merical association of the Ly-6Clo subset with the time of maximal
scar degradation (Fig. 2 D–F) and the fact that they are the
principle MMP-expressing population (Fig. 2H), we postulated
that these represent the elusive restorative macrophages.
Fig. 2. Ly-6Clo macrophages predominate during maximal fibrosis resolu-
tion and represent the principle MMP expressing subset. (A–G) Analysis of
hepatic macrophages at 24 (inflammation/fibrogenesis), 72 (early and max-
imal scar resolution), and 168 h (late resolution) after the final CCl4 injection.
Comparison was made to control (uninjured) mice. (A) Total hepatic mac-
rophage number quantified by flow cytometry expressed relative to the
mean number of macrophages in control liver (n = 8–12 per time point from
two independent experiments). (B) F4/80 immunohistochemistry indicates
that macrophages localize around areas of scar at 72 h. (Scale bar: 100 μm.)
(C) F4/80hi CD11Bint resident Kupffer cells during injury and resolution
(representative percentages indicate F4/80hi CD11Bint cells as a proportion of
total macrophages). (D) Subset analysis of CD11Bhi F4/80int monocyte-de-
rived macrophages on the basis of differential Ly-6C expression identifies
two distinct populations: Ly-6Chi and Ly-6Clo with dynamic changes during
injury and resolution (representative percentages indicate each subset as
a proportion of total hepatic macrophages). (E) Quantification of Ly-6Chi, Ly-
6Clo, and resident macrophage subsets as a proportion of total hepatic
macrophage number (n = 10–17 per time point from four independent
experiments). (F) Relative number per liver of each macrophage subset at
each time point expressed relative to mean total macrophage number in
control liver (n = 12–17 per time point from four independent experiments).
(G and H) After 4 wk of CCl4, mice were given fluorescent MMP substrate
(MMPsense) or vehicle control at 0 or 48 h with harvest at 24 or 72 h, re-
spectively. (G) Identification of MMPsense-positive macrophages at 24 and
72 h by flow cytometry. (H) Macrophage subset analysis of MMPsense-pos-
itive macrophage population at 24 and 72 h (n = 3–4). All data shown as
mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001. Representative flow
cytometry plots, histograms, and images are shown.
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CD11c+ dendritic cells (DCs) have been associated with res-
olution of liver injury (25, 26) and share a number of cell surface
markers with macrophages (27). The restorative macrophage
subset at 72 h expressed only intermediate levels of CD11c (Fig.
S4A). Furthermore, administration of DT to chronically injured
CD11c-DOG mice at a dose known to deplete hepatic DCs (28)
had no effect on the identified hepatic macrophage subsets (Fig.
S4 B and C), indicating no significant contribution of hepatic DCs
to these populations.
Ly-6Clo Macrophages Derive from an in Situ Phenotypic Switch of
Recruited Ly-6Chi Monocytes. The profibrotic Ly-6Chi macrophage
subset has been shown to derive from a Chemokine (C-C motif)
receptor 2 (CCR2)-dependent recruitment of circulating Ly-6Chi
monocytes (21). Given that hepatic Ly-6Clo macrophages are also
monocyte-derived (Fig. 2D), restorative macrophages must have
an origin from recruited Ly-6Chi or Ly-6Clo monocytes. Blood
analysis showed that, during active fibrogenesis (24 h), there was
an increased number of both populations of circulating mono-
cytes, whereas during maximal resolution (72 h), only the Ly-6Chi
monocytes remained elevated (Fig. S5 A–C).
To determine which of the circulating monocyte populations
contributed to the formation of the restorative macrophages,
adoptive transfer and in vivo labeling experiments were per-
formed. For adoptive transfer, hepatic fibrosis was induced in
C57BL/6 mice (CD45.2+); 4 h after the final CCl4 injection, we
injected 9 × 105 FACS-sorted bone marrow-derived CD45.1+ Ly-
6Chi monocytes (Ly-6G− CD115+ CD11B+ Ly-6Chi cells) (Fig.
S5D) or vehicle control through the tail vein, with harvests at 24,
72, and 168 h (Fig. 4A). Adoptively transferred CD45.1+ Ly-6Chi
monocytes could be detected in livers during active fibrogenesis
(24 h) and early resolution (72 h) but not during late resolution
(Fig. 4B). Even at 24 h, these monocytes had differentiated into
Ly-6Clo macrophages (Fig. 4 C–E). This population remained the
predominant macrophage population formed from the adoptively
transferred monocytes at 72 h (Fig. 4 C–E). To determine the
relative contribution of Ly-6Clo monocytes to the hepatic mac-
rophage subsets, we used a well-validated in vivo labeling tech-
nique (29, 30). After chronic injury with 4 wk of CCl4, mice were
given 200 μL fluorescent latex beads (which selectively label cir-
culating Ly-6Clo monocytes) through the tail vein 4 h after the
final CCl4 injection. Animals were harvested at 24, 72, and 168 h
(Fig. 4F). This technique caused selective labeling of circulating
Ly-6Clo monocytes (Fig. S5 E and F) as previously shown (29, 30).
Latex-positive cells could not be identified in livers at 24 or 72 h,
despite concurrent positive circulating Ly-6Clo monocytes (Fig.
4G). However, a population of intrahepatic latex-positive cells
emerged during late resolution (168 h) (Fig. 4H), predominantly in
the resident macrophage population (Fig. 4 H and I).
Recent work has also shown a key role for local proliferation in
the accumulation of macrophages during chronic inflammation
(31). Given the dramatic increase in the number of Ly-6Clo mac-
rophages at maximal resolution (Fig. 2F), we determined the
contribution of local macrophage proliferation to this population.
Using flow cytometric Ki-67 staining on hepatic nonparenchymal
cells after 4 wk of CCl4, we could identify proliferative hepatic
macrophages (Fig. 4J). Interestingly, the recruited proinflam-
matory Ly-6Chi macrophage population represented the most
proliferative macrophage subset at 24, 72, and 120 h after the final
CCl4 injection (Fig. 4K). The fact that the number of Ly-6C
hi
macrophages rapidly declines (Fig. 2 E and F) in the context of
active proliferation emphasizes that this population undergoes a
switch in phenotype in vivo.
These data show that restorative Ly-6Clo macrophages derive
from circulating Ly-6Chi monocytes, a common origin to profi-
brotic macrophages, and that an in vivo phenotypic switch leads
to fibrosis-modifying capabilities. Furthermore, Ly-6Clo mono-
cytes make no contribution to the proresolution population but
contribute to repopulating the resident macrophage pool during
late resolution.
Ly-6Clo Macrophages Show a Characteristic Gene Expression Profile
Favoring Scar Resolution. Having identified that Ly-6Clo macro-
phages, derived from a phenotypic switch of Ly-6Chi monocytes,
are critical for regression of hepatic fibrosis, we sought to define
the mediators produced by this newly identified macrophage
subset that confer its restorative properties. Affymetrix mouse
gene microarrays were performed on FACS-sorted restorative 72-
h Ly-6Clo macrophages and compared with the profibrotic 24-h
Ly-6Chi macrophages given their common origin, distinct func-
tional roles, and relative predominance at critical time points in
Fig. 3. Depletion of CD11B-positive macrophages defines Ly-6Clo cells as
being critical for scar resolution. (A) Schematic representation of model of
macrophage depletion during fibrosis resolution in CD11B-DTR mice by ad-
ministration of DT (or PBS control). (B) Flow cytometry data from livers of
PBS and DT-treated mice gated on viable CD45+ Ly-6G− CD11Bhi F4/80int
hepatic macrophages (representative percentages of each subset as a pro-
portion of total macrophage number shown). (C) Quantification of relative
number of each macrophage subset expressed relative to mean total mac-
rophage number in PBS-treated livers (n = 11–13 from two independent
experiments). (D) Representative PSR staining and immunohistochemistry
of collagen 1, collagen 3, and α-SMA after macrophage depletion or control.
(Scale bar: 100 μm.) (E) Quantification of histological changes by pixel
analysis expressed relative to mean percent area in PBS-treated liver (n = 10–
12 from two independent experiments). (F) Correlation of degree of fibrosis
assessed by PSR, collagen 1, and collagen 3 area with the relative number of
Ly-6Clo macrophages (n = 22 from two independent experiments). All data
shown as mean ± SEM. *P < 0.05, ***P < 0.001. NS, nonsignificant. Repre-
sentative flow cytometry plots and images are shown.

















the fibrogenesis resolution model. Specific microarray hits were
confirmed by quantitative PCR.
A number of differentially regulated genes were identified, and
the full list is available in Tables S1 and S2. In keeping with the
critical role of macrophage MMP expression in fibrosis resolu-
tion (12), the switch to a proresolution macrophage phenotype
was associated with an up-regulation of MMPs (Fig. 5A). Fur-
thermore, a number of proinflammatory cytokines and chemo-
kines were down-regulated, and concurrently, genes associated
with an antiinflammatory macrophage program [e.g. Chemokine
(C-X3-C) receptor 1 (CX3CR1)] (32) or antifibrotic effects (e.g.
Macrophage migration inhibitory factor (MIF) and CD74) (33)
were increased (Fig. 5A). Expression of TGF-β, the archetypal
profibrotic cytokine, was reduced in the restorative macrophage
population along with Thrombospondin-1 (Thbs1), a potent
activator of latent TGF-β (34). We also identified additional pro-
resolution mechanisms, such as a strong increase in expression of
insulin-like growth factor 1 (Igf1), which has been implicated as
being antifibrotic (35) (Fig. 5A). Thus, the switch to a restorative
macrophage phenotype confers a number of proresolution fea-
tures, highlighting the importance of a cellular mechanism for
tissue fibrosis regression.
We performed pathway enrichment analysis on the differen-
tially regulated genes from the two macrophage populations using
the DAVID bioinformatics tool (36, 37). The proinflammatory
macrophage population was enriched for pathways, including
response to wounding, coagulation cascade, and chemotaxis (Fig.
S6A), which are important for fibrogenesis (38, 39). Analysis of the
restorative macrophages showed enrichment for pathways, such as
lysosomes, endocytosis, scavenger receptors, and antigen pre-
sentation, which are implicated in phagocytosis (Fig. S6B).
We also identified enhancement of pathways implicated in fatty
acid metabolism and peroxisome proliferator activated receptor
(PPAR) signaling (Fig. S6B). The enrichment of phagocytosis-
related genes was confirmed individually, where a number of
opsonins, receptors, and genes involved in the recognition, bind-
ing, and clearance of apoptotic cells were up-regulated in the re-
storative macrophage population (Fig. 5B). Similarly, a number of
PPAR-γ target genes was up-regulated in these proresolution
macrophages (Fig. 5B). We also assessed the degree of expression
of a number of previously described M1 and M2 macrophage
markers to determine how hepatic inflammatory and restorative
macrophages fit into the traditional paradigm (Fig. 5 A and B).
Although Ly-6Clo restorative macrophages show increased ex-
pression of some M2 genes, such as Macrophage Mannose
receptor 1 (Mrc1), Arginase-1 (Arg1), and Retnla (Fizz-1), they
also down-regulate other characteristic M2 genes, including
Chi3l3 (YM-1), Il-1 receptor antagonist (Il1rn), Kdm6b (Jmjd3),
Ccl24, Il-10, and TGF-β (14, 40). Simultaneously, these Ly-6Clo
macrophages up-regulate traditional M1 genes, such as Ciita
(MHC class II transactivator), CD16, CD32, and Serpine1 (plas-
minogen activator inhibitor type 1) (14, 40, 41). Therefore, these
hepatic macrophage populations do not fit into the M1/M2 clas-
sification and represent newly identified macrophage phenotypes
(Fig. 5B).
We proceeded to confirm a number of the gene expression
changes at a protein level using flow cytometry (Fig. 5C). Ad-
ditionally, by administering MMPsense 24 h before harvest, we
showed that the switch from inflammatory to restorative mac-
rophage phenotype resulted in an increase in active MMP ex-
pression (Fig. 5C). Our microarray data also enabled us to
identify the functionally distinct macrophage subsets in situ
using immunohistochemistry for Chi3l3, MMP-12, and Glyco-
protein (transmembrane) nmb (Gpnmb) (Fig. 5D). We con-
firmed the specificity of these markers in our CD11B-DTR
depletion model, where the administration of DT causes a sig-
nificant reduction in the number of MMP-12–positive cells
histologically (Fig. S6C), whereas there was no significant dif-
ference in the number of Chi3l3-positive cells (Fig. S6D), mir-
roring the changes seen on flow cytometry (Fig. 3 B and C). We
went on to show the presence of similar MMP-12– and GPNMB-
expressing cells associated with scars in cirrhotic human livers
(Fig. 5D) and have identified them as a subpopulation of human
CD68-positive macrophages (Fig. S6 E and F).
Fig. 4. Ly-6Clo hepatic macrophages derive
from recruited Ly-6Chi monocytes. (A) Schematic
representation of the model of adoptive trans-
fer of CD45.1+ Ly-6Chi monocytes (or vehicle
control) into C57BL/6 mice (CD45.2+) 4 h after
the final CCl4 injection, with livers harvested at
24, 72, and 168 h. (B) Identification of injected
CD45.1+ cells in digested livers at 24 and 72 h
time points (gating on viable CD45.2− cells).
(C) Hepatic CD45.1+ cells have predominantly
differentiated into CD11Bhi F4/80int monocyte-
derived macrophages. (D) CD45.1+ monocytes
have largely formed the restorative Ly-6Clo
macrophage subset. (E) Quantification of the
proportion of identified CD45.1+ hepatic mac-
rophages forming each of the macrophage
subsets (n = 3 per time point). (F) Schematic
representation of the model of in situ labeling
of circulating Ly-6Clo monocytes by injection of
fluorescent latex beads (or vehicle control) 4 h
after the final CCl4 injection. (G) Latex-positive
macrophages are identified in the liver only at
168 h (gating on viable CD45+ Ly-6G− hepatic
macrophages). (H) Latex-positive cells have
formed the resident CD11bint F4/80hi macro-
phage population. (I) Quantification of the pro-
portion of latex-positive cells forming each of the
hepatic macrophage subsets at 168 h (expressed
as a percent of latex-positive cells; n = 4). (J and
K) Ki-67 staining of hepatic macrophages 24, 72,
and 120 h after final CCl4 dose after 4 wk of injury. (J) Ki-67–positive macrophages identified by flow cytometry. (K) Percentage of the stated macrophage subset
at the indicated time point identified as Ki-67–positive (n = 3–6). All data shown as mean ± SEM. *P < 0.05, ***P < 0.001. Representative flow cytometry plots and
proportions are shown.
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These data indicate that the phenotypic switch to the restorative
macrophage population results in a loss of proinflammatory gene
expression, increased expression of matrix-degrading enzymes,
and enrichment of phagocytosis-related genes. Furthermore, the
identified macrophage phenotypes fall outside the M1/M2 para-
digm, highlighting the limitations of this classification in an in
vivo setting.
Restorative Ly-6Clo Macrophages Are Postphagocytic. Having iden-
tified up-regulation of phagocytosis-related pathways, we de-
termined if restorative macrophages were postphagocytic. It is
recognized that ingestion of cellular debris can influence mac-
rophage phenotype (42). Furthermore, the switch to fibrosis res-
olution in our model followed a reduction in hepatocyte death as
assessed by serum ALT and AST (Fig. 1D), indicating that the
increase in the restorative Ly-6Clo population (Fig. 2 E and F)
occurred after the clearance of cellular debris.
Flow cytometric and immunohistochemical analysis showed
that, compared with the proinflammatory 24-h Ly-6Chi macro-
phages, restorative 72-h Ly-6Clo macrophages were larger [for-
ward scatter area (FSC-A)], were more complex [side scatter
area (SSC-A)], and showed features of being postingestion (Fig.
6 A and B). We FACS sorted these two macrophage subsets and
TUNEL stained each to quantify the presence of intra- or ex-
tracellular apoptotic debris using confocal microscopy (Fig. 6C).
No difference was seen in the percentage of each macrophage
subset associated with TUNEL-positive debris (Fig. 6D). How-
ever, in the proinflammatory macrophages, apoptotic debris was
predominantly bound to the cell surface, whereas in the re-
storative macrophage subset, the debris had been ingested (Fig.
6 C and E), confirming the postphagocytic phenotype of the Ly-
6Clo macrophage population. These findings are consistent with
the known ability of monocytes to bind apoptotic debris, but a
delayed capacity to ingest until differentiation into a more ma-
ture macrophage subtype has occurred (43, 44).
Macrophage Phagocytosis in Vitro Induces a Matrix-Degrading
Phenotype Through ERK Signaling. Having identified evidence of
prior phagocytosis as a key feature of the restorative macrophage
population, we sought to model this phenotype in vitro. Given
that the predominant cellular debris in the CCl4 model is hepa-
tocyte-derived, we determined whether ingestion of hepatocyte
debris might induce a similar change in macrophage phenotype.
Primary bone marrow-derived macrophages (BMDMs), widely
used to study macrophage biology in vitro (45), were cultured in
the presence and absence of cell debris generated from strain-
matched primary murine hepatocytes. Macrophage morphology
changed significantly after coculture in keeping with ingestion of
hepatocyte debris (Fig. 7A). Hepatocyte debris alone did not at-
tach to the wells. After ingestion, BMDMs up-regulated Mmp12,
Mmp9, and Igf1 and down-regulated Thbs1 and Chi3l3 (Fig. 7B),
mirroring the phenotypic switch seen in vivo (Fig. 5 A and B).
To confirm the active secretion of MMPs and determine if this
effect was a general effect of phagocytosis on macrophages in-
dependent of the type of debris, we used the well-described model
of phagocytosis of apoptotic thymocytes (46). Culture super-
natants from BMDMs fed with apoptotic thymocytes for 12 h
showed a robust increase in active MMP-9 and MMP-12 secretion
detected by gelatin zymography and Western blotting, respectively
(Fig. 7 C and D).
We then sought todeterminewhich signalingpathwaysmight link
macrophage phagocytosis with the increase in matrix-degrading
activity. MAPK signaling, specifically the ERK and p38 cascades,
is activated in macrophages after phagocytosis, and it has been
reported to regulate a number of macrophage responses (47, 48).
Using immunohistochemistry, we could identify nuclear phos-
Fig. 5. Ly-6Clo macrophages show a gene expression
profile favoring scar resolution. (A and B) Microarray
analysis of inflammatory Ly-6Chi and restorative Ly-
6Clo hepatic macrophage populations isolated by
FACS sorting from livers 24 and 72 h after the final
CCl4 injection, respectively. (A) Differential regula-
tion of cytokines, chemokines, chemokine receptors,
growth factors, and matrix-degrading enzymes be-
tween the inflammatory and restorativemacrophage
populations (expressed as fold change between the
two macrophage subsets). (B) Differential expression
of opsonins, phagocytosis-related genes, PPAR-γ tar-
get genes, and macrophage phenotype markers (M1,
classical; M2, alternative) between the macrophage
subsets on microarray (expressed as fold change be-
tween the two macrophage populations). All micro-
array data based on n = 3 per group taken from two
independent experiments. *P < 0.05, **P < 0.01,
***P < 0.001. (C) Flow cytometric analysis comparing
expression of stated marker between inflammatory
Ly-6Chi and restorative Ly-6Clo hepatic macrophages.
MMPsense was administered 24 h before the time
of harvest to compare MMP activity between mac-
rophage subsets expressed relative to average MFI
for inflammatory macrophage subset (n = 3–6). MFI,
mean fluorescence intensity. *P < 0.05, **P < 0.01. (D)
Immunohistochemistry for genes differentially regu-
lated on microarray in murine liver at 24 and 72 h
time points and cirrhotic human liver (representative
images shown). (Scale bars: 100 μm.)

















pho-ERK staining in macrophages at the 72-h time point (Fig.
7E), indicating activation of the ERK signaling pathway in scar-
associated macrophages during maximal fibrosis resolution. To
show a functional role for ERK signaling in the observed macro-
phage phenotype, we administered the specific ERK kinase [mi-
togen-activated protein kinase kinase 1 and 2 (MEK1/2)] inhibitor
PD98059 (50 μM) or vehicle control to BMDMs at published doses
(49, 50) for 1 h before and during feeding with hepatocyte debris in
vitro. Administration of PD98059 significantly inhibited macro-
phage up-regulation ofMmp9,Mmp12, and Igf1 in response to the
ingestion of hepatocyte debris (Fig. 7F). Furthermore, casein
zymography on culture supernatants showed that ERK inhibition
abrogated the increase in active MMP-9 and MMP-12 secretion
observed after phagocytosis (Fig. 7G), indicating a critical role for
MEK1/2 activation in the increased matrix-degrading activity in
macrophages in response to phagocytosis. MEK1/2 inhibition
had no effect on the down-regulation of Thbs1 and Chi3l3 in
response to phagocytosis (Fig. S7A), suggesting that cross-talk
between signaling pathways is required for generating the
complex overall phenotype of the restorative macrophage. We
confirmed the role of MEK1/2 in macrophage Mmp12 up-regu-
lation in response to phagocytosis using a second specific inhibitor
UO126 (20 μM) (Fig. S7B). Administration of a p38 MAPK in-
hibitor (SB203580; 10 μM) at a published dose (51) had no effect
on macrophage expression of Mmp9, Mmp12, or Igf1 in response
to phagocytosis (Fig. S7C).
These data show that the matrix-degrading phenotype of the
proresolution macrophage can be modeled in vitro by the
phagocytosis of cellular debris, and this phenotypic switch is, at
least in part, mediated by phagocytosis-related MEK1/2 activa-
tion and ERK signaling in macrophages.
Induction of Phagocytic Behavior Using Liposomes Enhances the
Restorative Macrophage Phenotype in Vivo and Accelerates Fibrosis
Resolution. Having conclusively identified macrophage phagocy-
tosis as a key determinant of the proresolution matrix-degrading
phenotype, we wished to use this information to manipulate
Fig. 6. Restorative Ly-6Clo macrophages are postphagocytic. Comparison of
inflammatory (24 h Ly-6Chi) and restorative (72 h Ly-6Clo) macrophage sub-
sets after 4 wk of CCl4. (A) Size [forward scatter area (FSC-A)] and complexity
[side scatter area (SSC-A)] of macrophage subsets assessed by flow cytometry
expressed relative to average MFI for inflammatory macrophages (n = 13
from three independent experiments). (B) F4/80 immunohistochemistry shows
larger scar-associated macrophages at 72 h. (Scale bar: 50 μm.) (C–E) TUNEL
staining and confocal microscopy of FACS-sorted subsets. (C) Stained DAPI,
TUNEL, F4/80, andmerged image for macrophage subsets. (Scale bars: 10 μm.)
Arrowheads, cell-surface debris; arrows, ingested debris. (D) Percentage of
each subset associated with TUNEL-positive nuclei by cell counting (n = 3–4).
(E ) Percentage of TUNEL-associated macrophages with ingested or cell-
surface debris (n = 3–4). Data shown as mean ± SEM. *P < 0.05, **P < 0.01,
***P < 0.001. NS, nonsignificant. Representative images are shown.
Fig. 7. Macrophage phagocytosis in vitro induces a matrix-degrading phe-
notype through ERK signaling. (A and B) Coculture of BMDMs with hepa-
tocyte debris. (A) Changes in macrophage morphology on phase-contrast
microscopy. Hepatocyte debris alone was nonadherent. (B) Changes in
macrophage gene expression after coculture expressed relative to mean
expression of macrophages alone (n = 11–12 from two independent
experiments). (C and D) Coculture of BMDMs with apoptotic thymocytes. (C)
Gelatin zymography of culture supernatants equalized for protein content
showing active MMP-9 (representative zymogram from n = 4 from two in-
dependent experiments). (D) Western blot for MMP-12 on culture super-
natants equalized for protein content (representative blot from n = 4 from
two independent experiments). (E) Dual immunofluorescence for F4/80 and
phospho-ERK in mouse liver 72 h after final CCl4 dose after 4 wk of injury.
Arrows, nuclear pERK and F4/80 dual positive cells. (Scale bars: 10 μm.) (F and
G). Culture of BMDMs ± MEK1/2 inhibitor (PD98059; 50 μM) ± hepatocyte
debris. (F) Changes in macrophage gene expression after coculture ex-
pressed relative to mean expression of macrophages alone (n = 6). (G) Casein
zymography of culture supernatants equalized for protein content showing
active MMP-9 and MMP-12 (representative zymogram from n = 3 shown).
Data shown as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001. Repre-
sentative images are shown.
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macrophage phenotype in vivo with a therapeutic benefit in ac-
celerating fibrosis resolution. The systemic administration of
cellular debris is likely to have significant confounding off-target
effects. Liposome uptake by macrophages represents a genuine
phagocytosis event (52), and it has been widely used to target
macrophages in vivo. Furthermore, recent studies have shown
that liposome administration can alter macrophage phenotype in
vivo in part by induction of ERK signaling after ingestion (53,
54). We proceeded to feed BMDMs with liposomes in vitro,
which induced a change in macrophage phenotype (Fig. 8A)
analogous to the change that we observed in vivo (Fig. 5 A and
B) and similar to the tissue culture models after the ingestion of
cellular debris (Fig. 7B). Thus, ingestion of liposomes models the
phagocytosis of cellular debris and the generation of restorative
macrophages. We went on to administer liposomes (or vehicle
control) to chronically injured mice during maximal fibrosis
resolution for 48, 72, and 96 h after the final CCl4 injection, with
harvest at 120 h (Fig. 8B). In keeping with an induction of
phagocytic behavior, liposome administration caused a reduction
in proinflammatory Ly-6Chi macrophages and an increase in re-
storative Ly-6Clo hepatic macrophages during fibrosis resolution
(Fig. 8C). Liposomes, when fluorescently labeled, were rarely
detected in Ly-6Chi macrophages but frequently seen in Ly-6Clo
macrophages, indicative of a postphagocytic phenotype (Fig. 8D).
Critically, this manipulation accelerated the regression of liver
fibrosis (Fig. 8 E and F), indicating that, by inducing phagocy-
tosis, macrophages could be switched to a phenotype promoting
fibrosis resolution in vivo.
Discussion
In a murine model of reversible hepatic fibrosis, we have used
differential Ly-6C expression to identify and characterize the
hitherto elusive restorative macrophage. This Ly-6Clo CD11Bhi
F4/80int macrophage population accumulates in the liver, and it
is the main MMP-expressing macrophage subset during maximal
fibrosis resolution, is necessary for degradation of tissue scar, is
derived from infiltrating Ly-6Chi inflammatory monocytes, has
a distinct pattern of gene expression, including matrix degrada-
tion and phagocytic and growth factors, and is characterized by
evidence of prior phagocytosis of dying cells. The restorative
phenotype can be recapitulated in vitro by phagocytosis-induced
ERK signaling and can be induced in vivo by the administration
of liposomes, which accelerates scar resolution.
Although evidence for a central role for macrophages in in-
flammation and tissue fibrogenesis has been described across
organ systems (8), data have recently emerged to suggest a
functional heterogeneity of subtypes in vivo and a role in fibrosis
resolution (3, 6, 11, 12). Differential Ly-6C expression has been
widely used to identify functionally distinct populations of cir-
culating murine monocytes (15, 16) and macrophage populations
in pathology (17–21). Our data show that Ly-6C expression can
be exploited to identify the macrophage subset responsible for
fibrosis resolution. Key questions arising from studies regarding
the divergent role of macrophages in fibrogenesis and recovery
were whether these distinct functions were mediated by resident
or recruited cells and whether those cells underwent a pheno-
typic switch in situ (55, 56). Herein, we have shown conclusively
that the proresolution Ly-6Clo macrophage population derives
from recruited Ly-6Chi monocytes, a common origin to the pro-
fibrotic Ly-6Chi macrophage, indicating a switch in macrophage
function in vivo. This finding is in keeping with the known ability
of monocytes and macrophages to change phenotype in situ
depending on local environmental cues (13). These findings have
implications for development of antifibrotic therapies, where
targeting inflammatory monocyte recruitment might adversely
impact on the population of restorative Ly-6Clo macrophages (39,
57). This finding provides an explanation for the apparently
counterintuitive observation made in the work by Mitchell et al.
(58): that decreased CCR2-dependent recruitment of Ly-6Chi
monocytes retards fibrosis resolution (58). A more detailed study
of the signals controlling macrophage dynamics and phenotype
during fibrosis resolution now depends on the development of
monocyte/macrophage-specific chemokine receptor KO trans-
genic mice, in which key genes can be inducibly deleted without
the confounding variable of differences in peak fibrosis that
complicates noninducible transgenic models.
The contribution of local macrophage proliferation during
hepatic fibrogenesis or fibrosis resolution has not previously been
defined. We have shown a high level of proliferation of proin-
flammatory hepatic Ly-6Chi monoctyte-derived macrophages,
suggesting that a combination of recruitment and local pro-
liferation is required for the generation of restorative Ly-6Clo
macrophages. This finding initially seems to contrast with find-
ings in work by Jenkins et al. (31), where resident F4/80hi pleural
macrophages proliferated during chronic parasitic infection.
However, using classical inflammatory stimuli, the work by Jen-
kins et al. (31) also showed the capacity of recruited monocyte-
derived macrophages to proliferate in the context of Il-4 stimu-
lation (31). Our work is, therefore, complementary to this study,
highlighting that the relative contribution of recruitment and
Fig. 8. Induction of phagocytic behavior using liposomes enhances the re-
storative macrophage phenotype in vivo and accelerates fibrosis resolution.
(A) Changes in macrophage gene expression after in vitro feeding with lip-
osomes expressed relative to mean expression of unfed macrophages (n = 6).
(B) Schematic representation of the model of liposome (or vehicle) adminis-
tration during resolution phase after 4 wk of CCl4 injury. (C) Changes in he-
paticmacrophage subsets after liposome administration relative tomean total
macrophage number in vehicle-treated livers (n = 13–14). (D) Percentage of
each hepatic macrophage subset containing fluorescently labeled liposomes
assessed by flow cytometry (n = 8). (E) Fibrosis assessed by PSR staining after
liposome (or vehicle) administration. Representative images are shown. (Scale
bar: 100 μm.) (F) Quantification of fibrosis by morphometric pixel analysis
expressed relative to mean percent area for liposome-treated liver (n = 6).
Data shown as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001.

















local proliferation to tissue macrophage expansion during in-
flammation is critically dependent on the nature of injury and
organ involved. Investigators should consider this information in
future studies on macrophage dynamics.
A major difficulty in studying macrophage heterogeneity in
vivo is the lack of defined specific markers for functionally dis-
tinct populations, necessitating the use of flow cytometry on
freshly isolated tissue to recognize subsets. Thus, existing strat-
egies for macrophage depletion are unable to specifically select
for functionally distinct subsets. In this work, we used the widely
used CD11B-DTR system (11, 17). This transgenic strategy
shows selectivity for CD11Bhi F4/80lo monocytes and monocyte-
derived macrophages compared with CD11Blo F4/80hi resident
tissue macrophages. We have gone on to show that specific de-
pletion of subsets of CD11Bhi F4/80lo cells is critically dependent
on timing. Furthermore, our data indicate an increased suscep-
tibility of Ly-6Clo macrophages to depletion with DT, which is
likely to be a result of higher levels of CD11B expression in this
population. We have discovered a number of genes that are
differentially expressed by the functionally distinct populations.
These findings could inform transgenic studies, where individual
macrophage subsets could be specifically depleted or labeled in
vivo. Using these data, we could identify distinct macrophages in
situ using immunohistochemistry, enabling more easy translation
to studying human tissue. Our findings are based on the highly
tractable and predictable CCl4 model of reversible hepatic fi-
brosis. To study macrophage dynamics and phenotype on a day-
by-day basis, we deliberately focused on an early fibrosis, which
resolves rapidly and completely. A future goal is the more de-
tailed analysis of hepatic macrophage subsets in cirrhotic human
liver to identify analogous populations to those populations de-
scribed in this study; until this analysis is undertaken, extrapo-
lation of our findings to human models must be guarded.
The data presented also show that the switch to a proresolution
macrophage population confers a number of potential antifibrotic
properties. Principally, there is a change from expression of pro-
inflammatory cytokines, chemokines, and profibrotic genes, such
as thrombospondin-1 (34), to a profile incorporating genes re-
sponsible for scar degradation, such as Mmp12 and Mmp9, genes
critical for the clearance of cellular debris, and a number of po-
tential antifibrotic pathways, such as Igf1 (35) and CD74/MIF (33).
Furthermore, our data expose the limitations of categorizing
macrophage populations from an in vivo setting into the widely
used but restrictive M1/M2 paradigm. Moving forward, we
suggest that a more functional classification of macrophage
subsets should be used to better represent their biology.
Phagocytosis can elicit significant effects on macrophage phe-
notype and function (19, 42). By showing that the proresolution
macrophage phenotype can be promoted by ingestion of debris
and that the increase in matrix-degrading activity is mediated by
phagocytosis-induced ERK signaling, we have identified a poten-
tial therapeutic approach to manipulate these cells in situ. Cru-
cially, our data showing that the in vivo phenotypic switch can be
induced through phagocytosis of administered liposomes with a
beneficial effect on fibrosis resolution identify a possible trans-
lational strategy for the treatment of tissue fibrosis. An attractive
alternative therapeutic strategy would be the use of macrophages
modified in vitro by feeding with liposomes to generate pro-
resolution features as a cell therapy to induce fibrosis regression.
This use would require modification of the macrophages to en-
sure adequate trafficking to the fibrotic liver after peripheral in-
jection, but it remains an intriguing area for additional study.
In conclusion, we have identified and characterized a specific
macrophage phenotype responsible for the resolution of tissue
fibrosis. In addition to the value in studying macrophage biology,
this study has important implications for fibrosis research and the
future development of antifibrotic therapies aimed at targeting
macrophages in vivo.
Materials and Methods
Mice. C57BL/6 mice (CD45.2+) were purchased from Harlan. CD11B-DTR mice,
originally obtained from R. Lang, Children’s Hospital Research Foundation,
Cincinnati, OH and as previously described (11), were maintained as heter-
ozygotes on a C57BL/6 background. CD45.1+ C57BL/6 mice (59) were pro-
vided by S. M. Anderton, University of Edinburgh. CD11C-DOG mice (28)
were provided by A. S. MacDonald, University of Edinburgh. Mice were bred
under specific pathogen-free conditions at the University of Edinburgh. All
experiments had local ethical approval and were conducted under UK Home
Office Legislation.
Liver Fibrosis Models. Adult male mice at least 6 wk of age were used. Hepatic
fibrosis was induced by two times per week i.p. CCl4 (0.4 μL/g; Sigma) diluted
1:3 in olive oil (Sigma) for 4 wk (nine injections). Animals were culled at
stated time points after the final CCl4 injection. For depletion studies, DT (10
ng/g in PBS; List Biological Laboratories) or PBS control was administered to
fibrotic CD11B-DTR or WT mice i.v. through the tail vein at the stated time
points. DC depletion in fibrotic CD11C-DOG mice was performed by ad-
ministration of DT (12 ng/g) or PBS control i.p. at the stated time points.
Adoptive transfer experiments were performed through the tail vein at
stated time points using (i) 9 × 105 FACS-sorted CD45.1+ Ly-6Chi monocytes
from bone marrow in RPMI 1640 or vehicle control; (ii) 250 μL fluorescent latex
beads [0.5 μm Fluoresbrite polychromatic red microspheres; 2.5% solids (wt/
vol) diluted 1:25 in PBS for injection; Polysciences Inc] or vehicle control; and
(iii) 250 μL liposomes (60) (provided by N.v.R.), CM-DiI–labeled (Invitrogen)
liposomes (labeled according to the manufacturer’s protocol), or PBS control.
Flow Cytometry and FACS Sorting. Flow cytometry (using BD LSR Fortessa II) and
FACS sorting (using BD FACSAria II) were performed on hepatic nonparen-
chymal cells containing the total hepatic leukocyte population (SI Materials
and Methods). FACS sorting routinely yielded cell purity levels of over 95%.
Detection of in Vivo MMP Activity. To detect in vivo MMP activity, 2 nmol
MMPsense 680 (Perkin-Elmer) (or vehicle control) were administered to ani-
mals through the tail vein 24 h before harvest according to the manufacturer’s
protocol. Hepatic macrophages were identified using flow cytometry fol-
lowed by identification of MMPsense-positive macrophages with excitation
laser at 635 nm (23).
Microarray Analysis. Fifty nanograms RNA from FACS-sorted cells was pro-
cessed using the Ovation Pico WTA system (NuGen) according to the man-
ufacturer’s protocol (n = 3 per group). Processed RNAs were hybridized to
Affymetrix GeneChip Mouse Gene 1.0 ST Arrays. RNA/microarray processing
was carried out by ARK Genomics (Roslin Institute). Data analysis was
performed as described (SI Materials and Methods). Fold change > 2 with
adjusted P < 0.05 was considered significant for individual gene changes.
Gene ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathway enrichment analysis was done with the DAVID tool (36, 37) on
genes that were significantly differentially expressed. Microarray data
are available in the ArrayExpress database (www.ebi.ac.uk/arrayexpress)
under accession number E-MEXP-3177.
In Vitro Phagocytosis Assay. BMDMs, primary murine hepatocyte debris, and
apoptotic thymocytes were prepared as described (SI Materials and Meth-
ods); 2 × 105 BMDMs were seeded per well in 12-well plates followed by the
addition of 5 × 105 washed dead hepatocytes (or control medium) and 1 ×
106 washed dead thymocytes or liposomes at 1:10 dilution by volume (or PBS
control) cultured for 16 h (or 12 h for thymocytes) at 37 °C 5% (vol/vol) CO2
in DMEM/F12 Glutamax (Gibco) medium with 10% FCS. Where stated,
inhibitors PD98059 (50 μM; Cayman Chemical), UO126 (20 μM; New England
Biolabs), SB203580 (10 μM; Cayman Chemical), or DMSO control were added
to the plated BMDMs for 1 h before and maintained throughout the 16-h
incubation with hepatocyte debris. Supernatants were then harvested and
stored at −80 °C, noningested hepatocytes or liposomes were removed by
vigorous washing three times with PBS, and residual adherent macrophages
were used for additional analysis. In control wells containing hepatocyte
debris alone, no adherent cells were detected.
Statistical Analysis. All data are expressed as mean ± SEM. Statistical analysis
was performed using GraphPad Prism 5 software. Statistical evaluation of
multiple groups was performed using a one-way ANOVA with posthoc Tukey
test. Statistical evaluation of two groups was performed using Student t test
or Mann–Whitney test if data were not normally distributed. A value of P <
0.05 was considered statistically significant.
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Additional Methods. Additional methods are shown in SI Materials and
Methods.
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SI Materials and Methods
Hepatic Nonparenchymal Cell Isolation. Isolation of hepatic non-
parenchymal cell (NPC) fraction was performed using a modi-
fied MACS protocol (http://www.miltenyibiotec.com/download/
protocols_gentlemacs_en/1105/gentleMACS-Liver-04.pdf) from
Miltenyi Biotech. Briefly, mouse livers in situ were perfused with
10 mL 0.9% NaCl solution through the inferior vena cava fol-
lowed by cutting of the portal vein to remove circulating cells.
Livers were then harvested and weighed; either the whole liver or
the right lobe was homogenized using a scalpel and digested in
RPMI 1640 containing Collagenase B (1.6 mg/mL; Roche) and
DNase I (100 μg/mL; Roche) for 45 min at 37 °C. Digested livers
were passed through 40-μm cell strainers, and enzymes were in-
activated by the addition of RPMI 1640 with 10% FCS. Con-
taminating hepatocytes were removed by two-time centrifugation
at 50,000 × g for 5 min followed by red cell lysis with lysis buffer
(0.15 M NH4Cl, 10 mM KHCO3, 0.1 mM EDTA in H2O) for
5 min on ice. The remaining nonparenchymal cell fraction con-
taining hepatic macrophages was then harvested by centrifugation
at 300,000 × g for 10 min, counted, and used for flow cytometry
and FACS sorting.
Flow Cytometry and FACS Sorting. Nonspecific antibody binding
was blocked by incubating cells with 10%mouse serum for 20 min
at 4 °C followed by incubation with combinations of primary an-
tibodies (each used at 1/100 dilution unless stated) for 30 min at
4 °C. The following preconjugated antibodies were used: CD11B
(clone M1/70; Ebioscience), CD11C (clone N418; Ebioscience),
Ly-6C (clone HK1.4; Ebioscience), CD45.2 (clone 104; Ebio-
science), CD45.1 (clone A20; Ebioscience), CD115 (clone AFS98;
Ebioscience), CD36 (clone 72–1; Ebioscience), F4/80 (dilution
1:50; clone BM8; Invitrogen), Ly-6G (clone 1A8; Biolegend), CD3
(clone 17A2; Biolegend), NK1.1 (clone PK136; Biolegend), B220
(clone RA3-6B2; Biolegend), CD14 (clone Sa14-2; Biolegend),
CD16/32 (dilution 1:200; clone 93; Biolegend), CD80 (clone 16–
10A1; Biolegend), CD86 (clone GL-1; Biolegend), and CD81
(clone Eat-1; Biolegend). Cell viability was assessed with Propi-
dium Iodide (Sigma) or Fixable Viability Dye eFluor780 (Ebio-
science) according to manufacturers’ protocols. Ki-67 staining for
flow cytometric analysis was performed as described (1) using the
Ki-67 staining kit (clone B56; BD) and the Fix and Perm Kit
(Ebioscience). After antibody staining, samples were either ana-
lyzed immediately or fixed with 10% buffered formalin. Data were
analyzed using FlowJo7.5 software (Treestar).
Hepatic macrophages were defined as viable CD45+ Ly-6G−
CD3− NK1.1− B220− CD11B+ F4/80+ cells from NPC fraction of
digested livers and used to identify macrophage subsets. Subsets
were expressed as proportions of total hepatic macrophages or
CD45+ cells. Quantification of absolute numbers of cells per liver
was performed by expressing each subset as a proportion of NPCs,
counting total number of NPCs in the digested portion of liver,
calculating the total number of NPCs in the whole liver by weight
differential, and thus, calculating the total number of each subset.
Where stated, these values were expressed relative to the mean of
the control liver, which was assigned a value of one.
Circulating monocytes (from whole blood diluted 1:1 in 4.8%
sodium citrate buffer) were stained and fixed using BD FACSlyse
(BD)before analysis.Monocyteswere identifiedasCD45+CD115+
CD11B+ Ly-6G− Ly-6Chi and Ly-6Clo cells from whole blood and
expressed as a percentage of total peripheral mononuclear cells or
a number of cells per 1 mL blood using counting beads.
FACS-sorted viable CD45.1+ Ly-6G− CD115+ CD11B+ Ly-
6Chi monocytes from whole bone marrow were used for adoptive
transfer experiments.
Microarray Data Analysis.Data were extracted through the GCOS
software, and CEL files were used for additional data processing.
CEL files were imported into Bioconductor (2), normalized by
robust multi-array average (RMA) in the Oligo (http://www.
bioconductor.org/packages/2.0/bioc/html/oligo.html) module,
and statistically analyzed with the Limma (3).
RNA Extraction and Quantitative RT-PCR. For whole liver, the cau-
date lobe was snap frozen in liquid nitrogen and stored at −80 °C.
RNAwas extracted using TRIzol reagent (Invitrogen) and RNeasy
mini columns (Qiagen) according to the manufacturer’s protocol,
followed by quantification using the Nanodrop Spectrophotometer
(Thermo Scientific); 1 μg RNA was reverse-transcribed using Su-
perScript III (Invitrogen) according to the manufacturer’s pro-
tocol. Gene expression was calculated using the ΔΔCT method
relative to housekeeping gene 18S.
For FACS-sorted cells, RNA was extracted using the RNeasy
Micro Plus Kit (Qiagen) according to themanufacturer’s protocol;
10 ng RNA were reverse-transcribed and amplified using the
Whole Transcriptome Kit (Qiagen). Gene expression was calcu-
lated using the ΔΔCT method relative to housekeeping gene β2M.
For the in vitro phagocytosis assay, RNAwas extracted using the
Rneasy Micro Plus Kit (Qiagen), and 100 ng RNA were reverse-
transcribed using SuperScript III (Invitrogen). Gene expression
was calculated using the ΔΔCT method relative to housekeeping
gene β2M.
Where stated, relative gene expression was calculated by nor-
malizing to the mean expression of one group, which was assigned
a value of one.
The following primer sets were purchased—18S, B2M, Chi3l3,
Chemokine (C-Cmotif) receptor 2 (Ccr2), and Chemokine (C-X3-
C) receptor 1 (Cx3cr1) from Applied Biosystems and insulin-like
growth factor 1 (Igf1), Thbs1, Il-1β, and Cxcl10 from Qiagen. The
remaining primer sequences were designed using primer express
software, and the sequences are available. Genes were analyzed
using either TaqMan Express qPCR Supermix (Invitrogen) or
Quantifast SYBR Green PCR Kit (Qiagen) on an ABI 7500 Fast
Real-Time System according to the manufacturers’ instructions.
Immunohistochemistry and Immunofluorescence. After harvest, liver
tissue was fixed overnight in 10% neutral buffered formalin or
Methacarn solution followed by paraffin embedding. Human cir-
rhotic liver was fixed in formalin; 4-μm tissue sections were dew-
axed and rehydrated in decreasing concentrations of ethanol.
Where stated, antigen retrieval was performed by boiling for
15 min in 10 mM sodium citrate buffer, pH 6. Endogenous per-
oxidize activity was inhibited with 3% hydrogen peroxide, and
nonspecific binding was minimized using protein block solution
(Dako). All primary antibodies were incubated overnight at 4 °C.
Appropriate biotinylated secondary antibodies were used at 1/300
dilution at room temperature for 1 h. Immunostaining was de-
veloped using 3,3′-diaminobenzidine (Dako). The following pri-
mary antibodies and conditions were used: collagen 1 (1310–08; 1/
100 dilution; formalin-fixed; antigen retrieval; Southern Biotech),
collagen 3 (1310–01; 1/100 dilution; formalin-fixed; antigen re-
trieval; Southern Biotech), α-smooth muscle actin (α-SMA; clone
1A4; 1/4,000 dilution; formalin-fixed; antigen retrieval; Sigma-
Aldrich), F4/80 (ab6640; 1/200 dilution; formalin-fixed; no antigen
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retrieval; Abcam), Chi3l3 (01404; 1/100 dilution; formalin-fixed;
antigen retrieval; Stemcell Technologies), metalloproteinase en-
zyme 12 (MMP-12; sc-8839; 1/240 dilution; formalin-fixed; 20 min
antigen retrieval; Santa Cruz), murine and human Glycoprotein
(transmembrane) nmb (Gpnmb) (sc-47006; 1/200 dilution; for-
malin-fixed; 15 min antigen retrieval; Santa Cruz), and human
MMP-12 (AB52897; 1/400 dilution; 20 min antigen retrieval by
boiling in Tris·EDTA, pH 9; Abcam). Picrosirius red staining was
performed according to standard protocols. Where stated, mor-
phometric pixel analysis to quantify histological staining was per-
formed. Briefly, sections were blinded, and a minimum of 20
nonoverlapping fields per section were photographed at 100×
magnification using a Nikon Eclipse E600 microscope and NIS-
Elements D3.1 Software. Pixel counts of positive staining were
performed in Adobe Photoshop CS2 and expressed as a percent-
age of the total pixel count. Where stated, relative percent area
was calculated by normalizing to the mean the percent area of one
group, which was assigned a value of one. Where stated, cell
counts were performed at 200× magnification on blinded slides,
with a minimum of 20 fields counted per mouse.
Dual immunofluorescence for F4/80 and phospho-ERK was
performed on formalin-fixed paraffin-embedded sections, se-
quentially incubated with F4/80 (ab6640; Abcam) at 1:100 for 2 h,
and rinsed; then, rabbit anti-rat HRP (P0450; Dako) was added
followed by the TSAT Plus Cyanine 3 System (NEL744B001KT;
PerkinElmer). Sections were then antigen-retrieved for 10 min
with 10 mM sodium citrate buffer and blocked again. The second
primary antibody pERK (4370; Cell Signaling) was incubated at
1:100 overnight followed by donkey anti-rabbit Alexa 488 (A21206;
Invitrogen). Sections were mounted in DAPI hard-set mounting
medium (H1500; Vector Labs).
For dual immunofluorescence on human tissue for CD68 and
MMP-12, antigen retrieval (20 min; Tris·EDTA, pH 9) was fol-
lowed by protein block (X0909; Dako), sequential incubation
with anti–MMP-12 (ab52897; 1/100 dilution; overnight; Abcam)
and donkey anti-rabbit Alexa 488 (A21206; Invitrogen), protein
block, anti-CD68 (M0867; 1/50 dilution; 2 h; Dako), and donkey
anti-mouse Alexa 555 (A31570; Invitrogen). For CD68 and
GPNMB, antigen retrieval (15 min; Tris·EDTA, pH 9) was fol-
lowed by protein block (X0909; Dako), sequential incubation of
GPNMB (sc47006; 1/100 dilution; overnight; Santa Cruz), don-
key anti-goat Alexa 488 (A11055; Invitrogen), protein block,
anti-CD68 (M0867; 1/50 dilution; 2 h; Dako), and donkey anti-
mouse Alexa 555 (A31570; Invitrogen). For both, sections were
then blocked with 0.1% Sudan Black B (Sigma) and mounted
with DAPI hard-set mounting medium (H1500; Vector Labs).
Immunocytochemistry. TUNEL staining of FACS-sorted Ly-6Chi
and Ly-6Cint macrophage subsets was performed using TACS
TdT-Fluor in Situ Apoptosis Detection Kit—Fluorescein (R&D
Systems) according to the manufacturer’s protocol. The associ-
ation between apoptotic debris and macrophages was assessed
using a Leica SP5 Confocal microscope with z-stacks on each
field. Images were blinded and analyzed using ImageJ software
for the presence of cell surface or intracellular apoptotic debris.
A minimum of 25 macrophages was counted per slide. The per-
centage of macrophages associated with TUNEL-positive nuclei
was quantified followed by quantification of the localization of
the apoptotic debris.
Western Blotting, Zymography, and ELISA. For tissue inhibitor of
metalloproteinase 1 (TIMP-1) Western blotting, whole-tissue
protein extracts were made by homogenization of samples in lysis
buffer (50 mMHepes, 1mMDTT, 0.1 mM EDTA, 0.1% CHAPS,
pH 7.4). Protein concentration was determined by BradfordAssay,
and equal amounts (20 μg protein/well) were subjected to SDS/
PAGEon 12% gels. After electrophoresis, samples were transferred
onto nitrocellulose membranes and blocked for 2 h at room tem-
perature in 5% nonfat dry milk in Tris-buffered saline and 0.1%
Tween (TBST). Membranes were incubated overnight at 4 °C with
primary antibody in TBST containing 5% BSA (TIMP-1 at 1:500
dilution; 7–6C1; Calbiochem). Membranes were then washed
(three times for 15 min each) in TBST before the addition of an
HRP-conjugated secondary antibody (1:2,000 dilution) in TBST
containing 5% nonfat dry milk for 1 h at room temperature. After
incubation, membranes were washed again (three times) in TBST
for 15 min each followed by development using enhanced
chemiluminescence (ECLplus; Amersham) and visualization on
a VersaDoc.
For Western blotting and zymography on in vitro phagocytosis
assays, culture supernatants were harvested. Protein levels were
quantified using Bradford reagent (Sigma-Aldrich) and equalized
with PBS to ensure equal protein loading. Gelatin zymography
was performed as previously described (4). Briefly, samples were
subjected to electrophoresis on a 10% SDS/PAGE gel copoly-
merized with 1% gelatin substrate. After electrophoresis, gels
were renatured in 2.5% Triton X-100 for 30 min before in-
cubation in activity buffer [50 mM Tris, 200 mM NaCl, 5 mM
CaCl2 (anhydrous), 0.02% Brij-35, pH 7.5] at 37 °C for 16–24 h.
Gels were then stained with 0.5% Coomassie Brilliant Blue be-
fore destaining in 40% methanol and 10% acetic acid. MMP-9
gelatinolytic activity was detected as destained bands against a
background of Coomassie-stained gelatin. The active form of
MMP-9 was detected at 92 kDa. Casein zymography was per-
formed as previously described (5) with minor modifications.
Equalized culture supernatants were subjected to electrophoresis
on a 12% SDS/PAGE gel containing 0.25% skimmed milk pow-
der. After electrophoresis, gels were rinsed in deionized water
and renatured in 2.5% Triton X-100 for 1 h before incubation in
activity buffer (50 mM Tris, 200 mM NaCl, 5 mM CaCl2, 0.02%
Brij-35, pH 7.5) at 37 °C for 72 h. Subsequently, the gel was
stained with SimplyBlue Safe Stain (Life Technologies) before
destaining in water. Proteolytic activity was detected as destained
bands against a background of Coomassie-stained casein. For
MMP-12 Western blotting, media from the phagocytosis assay
were freeze-dried, and equalized resuspended samples were
subjected to SDS/PAGE on a 10% gels. After electrophoresis,
samples were transferred onto nitrocellulose membranes and
blocked for 2 h at room temperature in 3% BSA (Sigma-Aldrich)
in TBST. Membranes were incubated overnight at 4 °C with
primary antibody in TBST containing 3% BSA (MMP-12 at
1:1,000 dilution; SA453-0100; Biomol). Membranes were then
washed (three times for 10 min each) in TBST before the addition
of an HRP-conjugated secondary antibody (1:2,000 dilution) in
TBST containing 5% nonfat dry milk for 1 h at room tempera-
ture. After incubation, membranes were washed again (three
times) in TBST for 10 min each followed by development using
Immobilon Western Chemiluminescent HRP Substrate (Milli-
pore) and visualization on a VersaDoc Imaging system (BioRad).
For tissue cytokine ELISA, whole-tissue protein extracts were
made in Tissue Protein Extraction Reagent (T-PER; Thermo
Scientific), containing protease inhibitors aprotinin, leupeptin,
and PMSF. A Bradford assay was performed, and samples were
equalized to a total protein concentration of 50 μg/μL. These
samples were then assayed using Bio-plex mouse cytokine assay
(Bio-Rad) according to the manufacturer’s protocol.
Serum Analysis.At the time of harvest, whole blood was collected
from the inferior vena cava, and serum was isolated by centri-
fugation at 7,000 × g for 5 min and analyzed for alanine amino-
transferase and aspartate aminotransferase levels using a standard
bioanalyser.
In Vitro Phagocytosis Assay. Bone marrow-derived macrophages
(BMDMs) were prepared as described (6) from adult male
C57BL/6mice by differentiating whole bonemarrow for 7 d at 37 °C
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5% CO2 in DMEM/F12 Glutamax (Gibco) medium with 10%
FCS and 20% L929 conditioned medium under nonadherent
conditions using Ultra Low Adherence Flasks (Corning). This
process routinely yielded a macrophage population of>90% purity
as assessed by flow cytometry for CD11B and F4/80.
Primary murine hepatocytes were prepared using a modified
two-stage perfusion technique (http://tools.invitrogen.com/
content/sfs/manuals/3736.pdf). Briefly, adult male C57BL/6
mice were anesthetized with i.p. ketamine and medetomidine.
After cannulation of the portal vein, livers were perfused with
50 mL Liver Perfusion Medium (Gibco) followed by 50 mL
Liver Digestion Medium (Gibco). Livers were dissociated, and
hepatocytes were washed three times in hepatocyte wash me-
dium (Gibco) and cultured overnight at 37 °C 5% CO2 on
collagen-coated (10 μg/cm2 rat tail collagen; Sigma) tissue
culture flasks in Williams E medium (Gibco) supplemented
with 10% FCS and 1% Pen/Strep solution. For preparation of
hepatocyte debris, adherent viable hepatocytes were detached
using trypsin, washed, and cultured in suspension in serum-free
Williams E medium containing anti-mouse CD95 (1/500 di-
lution; Clone Jo-2; BD Pharmingen) at 37 °C for 8 h. This
preparation yielded a population of >95% trypan blue-positive
hepatocytes.
Apoptotic thymocytes were prepared as previously described
(7). Briefly, thymuses were removed from C57BL/6 mice, ages
3–5 wk, homogenized in RPMI medium, and incubated with
dexamethasone (1 μM; Mayne Pharma) and 1% FCS at 37 °C 5%
CO2 for 16 h. This process routinely yielded a population of dead
thymocytes with over 90% trypan blue-positive.
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Fig. S1. Fibrosis regression follows a reduction in hepatic TIMP-1. Whole-liver Timp-1 levels were measured at stated time points after the final CCl4 injection
after 4 wk of chronic injury. (A) Gene expression by quantitative PCR expressed relative to mean expression at the 24-h time point (n = 4–8 from two in-
dependent experiments). (B) TIMP-1 protein expression by Western blot (representative blot shown). All data shown as mean ± SEM. **P < 0.01.
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Fig. S2. Gating strategy for identification of hepatic macrophages. The hepatic nonparenchymal cell fraction was isolated as detailed in Materials and
Methods. (A) Viable cells were selected by propidium iodide (PI) exclusion. (B) CD45-positive viable cells were gated. (C) Neutrophils were identified as viable
CD45+ CD11b+ and Ly-6G+ cells, and they were excluded from subsequent macrophage gating. (D) Cells positive for CD3, B220, or NK1.1 were excluded from
subsequent macrophage gating. (E) Macrophages were selected as viable CD45+ Ly-6G− NK1.1− B220− CD3− and dual-positive CD11B+ F4/80+ cells. Repre-
sentative flow cytometry plots are shown.
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Fig. S3. Macrophage depletion in CD11B promoter–diphtheria toxin receptor (CD11B-DTR) transgenic mice is selective. (A, B, E, F, I, and J) Model of mac-
rophage depletion during fibrosis resolution in CD11B-DTR mice after 4 wk of injury by administration of diphtheria toxin (DT; or PBS control) 48. 72, and 96 h
after the final CCl4 injection with harvest at 120 h. (A) Analysis of circulating monocytes by flow cytometry. Ly-6C
hi and Ly-6Clo circulating monocytes were
identified in blood gating on CD11B+ Ly-6G− CD115+ Ly-6Chi and Ly-6Clo cells. (B) Ly-6Chi and Ly-6Clo circulating monocyte number per 1 ml blood in CD11B-
DTR mice given DT or PBS control (n = 11–13 from two independent experiments). (C) Macrophage depletion during inflammation/fibrogenesis phase. CD11B-
DTR mice were injured with CCl4 followed by administration of DT (or PBS control) 8 h after the final CCl4 injection with harvest at 24 h. Analysis of hepatic
macrophage subsets after DT or PBS administration (data shown as percentage of mean total hepatic macrophage number in PBS-treated animals; n = 2). (D)
CD11B expression of Ly-6Chi and Ly-6Clo hepatic macrophages in WT mice after 4 wk of CCl4 was assessed 24 and 72 h after the final CCl4 injection by flow
cytometry expressed as mean fluorescence intensity (MFI) of CD11B relative to mean CD11B MFI of Ly-6Chi macrophages at the stated time point (n = 14–15). (E)
Quantification of the number of hepatic neutrophils in DT- and PBS-treated mice expressed relative to total neutrophil number in PBS-treated livers (n = 11–13
from two independent experiments). (F) Quantification of the number of hepatic CD3-positive cells in DT- and PBS-treated mice expressed relative to total CD3
cell number in PBS-treated livers (n = 11–13 from two independent experiments). (G and H) Administration of DT or PBS to WT mice after 4 wk of injury at 48,
72, and 96 h after the final CCl4 injection with harvest at 120 h. (G) Analysis of hepatic macrophage subsets in WT mice receiving DT or PBS. (H) Quantification
of fibrosis in WT mice receiving DT or PBS by picrosirius red staining and morphometric pixel analysis expressed relative to mean percentage area for PBS-
treated liver (n = 2). (I) Correlation of the degree of fibrosis assessed by picrosirius red staining, collagen 1, and collagen 3 percent area with the relative
number of hepatic Ly-6Chi macrophages in CD11B-DTR mice (n = 22 from two independent experiments). (J) Correlation of degree of fibrosis assessed by
picrosirius red staining, collagen 1, and collagen 3 percent area with the relative number of resident hepatic macrophages in CD11B-DTR mice (n = 22 from two
independent experiments). All data shown as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001. NS, nonsignificant. Representative flow cytometry plots and
percentages are shown.
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Fig. S4. Minimal contribution of dendritic cells to macrophage subsets. (A) CD11c expression of each macrophage subset 72 h after the final CCl4 injection
after 4 wk of injury expressed as MFI of CD11c assessed by flow cytometry (n = 5). Data indicate intermediate CD11c expression of proresolution Ly-6Clo
macrophage subsets. (B and C) Adult male CD11c.DOG mice were administered two time per week i.p. CCl4 for 4 wk followed by 12 ng/g diphtheria toxin (or
PBS control) 48 and 72 h after the final CCl4 injection. Mice were harvested at 96 h. (B) Quantification of total hepatic macrophage number as a proportion of
CD45-positive hepatic nonparenchymal cells after DT or PBS control (n = 7). Data indicate no depletion of hepatic macrophages by administering DT to CD11c.
DOG mice. (C) Quantification of the number of each macrophage subset as a proportion of total hepatic macrophages after DT or PBS control (n = 7). Data
indicate no depletion of macrophage subsets after DT administration to CD11c.DOG mice. All data shown as mean ± SEM. ***P < 0.001.
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Fig. S5. Contribution of circulatingmonocytes to restorativemacrophage population. (A) Ly-6Chi and Ly-6Clo circulatingmonocytes were identified in blood gating
on CD11B+ Ly-6G− CD115+ Ly-6Chi and Ly-6Clo cells. (B) Ly-6Chimonocytes were quantified as a proportion of total circulatingmononuclear cells at stated time points
during injury and resolution after chronic CCl4 administration and normal (uninjured control) mice (n = 5). (C) Ly-6C
lo monocytes were quantified as a proportion of
total circulating mononuclear cells during injury and resolution after chronic CCl4 administration and normal (uninjured control) mice (n = 5). (D) Ly-6C
hi monocytes
for adoptive transfer were isolated by FACS sorting of whole bone marrow frommale CD45.1+ C57BL/6 mice gating on the cells [excluding the neutrophils (CD11B+
Ly-6G+) and selecting CD115+ CD11B+ Ly-6Chi cells]. (E and F) Administration of fluorescent latex beads through the tail vein 4 h after the final CCl4 injection after 4
wkof injury,with harvest of peripheral blood at 24, 72, and 168 h. (E) Flow cytometry analysis of Ly-6Chi and Ly-6Clomonocytes (monocyte populations identifiedas in
A) showed fluorescent latex beads predominantly in circulating Ly-6Clo monocytes. (F) Quantification of the proportion of circulating Ly-6Chi and Ly-6Clo monocytes
containing latex beads as assessed by flow cytometry at the stated time points after the final CCl4 injection. All data are expressed as mean ± SEM. *P < 0.05, **P <
0.01. Representative flow cytometry plots are shown.
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Fig. S6. Pathway analysis and specific markers of inflammatory and restorative macrophages. Microarray analysis of inflammatory Ly-6Chi and restorative Ly-
6Clo hepatic macrophage populations isolated by FACS sorting from livers 24 and 72 h after the final CCl4 injection, respectively. Pathway analysis of genes up-
regulated in each macrophage subset using the DAVID tool expressed as the number of up-regulated genes in the stated pathway. (A) Pathways enriched in
proinflammatory macrophage subset. (B) Pathways enriched in the restorative macrophage subset. All microarray data are based on n = 3 per group taken
from two independent experiments. (C and D) CD11B-DTR mice were injured for 4 wk with CCl4 followed by administration of DT or PBS 48, 72, and 96 h after
the final CCl4 injection with harvest at 120 h. Immunohistochemistry for MMP-12 and Chi3l3 was performed. (C) Average cell counts of MMP-12–positive cells
per 200× field expressed relative to the average count from PBS-treated mice (n = 5–6). (D) Average cell counts of Chi3l3-positive cells per 200× field expressed
relative to the average count from PBS-treated mice (n = 5–6). (E) Dual immunofluorescence for CD68 (red), MMP-12 (green), and DAPI (blue) in cirrhotic
human liver. (Scale bar: 10 μm.) Arrows indicate cells with colocalization. (F) Dual immunofluorescence for CD68 (red), GPNMB (green), and DAPI (blue) in
cirrhotic human liver (arrows indicate cells with colocalization). (Scale bar: 10 μm.) Representative images are shown. All data expressed as mean ± SEM. *P <
0.05, **P < 0.01, ***P < 0.001. NS, nonsignificant.
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Fig. S7. Inhibition of ERK or p38 signaling cascades during macrophage phagocytosis of hepatocyte debris . (A) Coculture of BMDMs ± mitogen-activated
protein kinase kinase 1 and 2 (MEK1/2) inhibitor (PD98059; 50 μM) ± hepatocyte debris. Changes in macrophage gene expression after coculture (data are
shown relative to mean expression of macrophages alone; n = 6). (B) Coculture of BMDMs ± MEK1/2 inhibitor (UO126; 20 μM) ± hepatocyte debris. Changes in
macrophage Mmp12 gene expression after coculture (data are shown relative to mean Mmp12 expression of macrophages alone; n = 3). (C) Coculture of
BMDMs ± p38 MAPK inhibitor (SB203580; 10 μM) ± hepatocyte debris. Changes in macrophage gene expression after coculture (data are shown relative to
mean expression of macrophages alone; n = 6). All data expressed as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001. NS, nonsignificant.
Table S1. Genes more highly expressed in inflammatory macrophages
Table S1
List of genes more highly expressed in inflammatory 24 h Ly-6Chi macrophages compared with restorative 72 h Ly-6Clo hepatic macrophages on microarray
analysis of FACS-sorted populations. Fold change shown is based on average expression level in restorative macrophages compared with average expression
level in inflammatory macrophages. Genes are shown with fold difference > 2 and P < 0.05. Based on n = 3 for each macrophage subset from two independent
experiments.
Table S2. Genes more highly expressed in restorative macrophages
Table S2
List of genes more highly expressed in restorative 72 h Ly-6Clo macrophages compared with inflammatory 24 h Ly-6Chi hepatic macrophages on microarray
analysis of FACS-sorted populations. Fold change shown is based on average expression level in restorative macrophages compared with average expression
level in inflammatory macrophages. Genes are shown with fold difference > 2 and P < 0.05. Based on n = 3 for each macrophage subset from two independent
experiments.
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